Document

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001600132-20-000059.txt : 20200511 0001600132-20-000059.hdr.sgml : 20200511 20200511160101 ACCESSION NUMBER: 0001600132-20-000059 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200511 DATE AS OF CHANGE: 20200511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bellerophon Therapeutics, Inc. CENTRAL INDEX KEY: 0001600132 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473116175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36845 FILM NUMBER: 20864639 BUSINESS ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-574-4770 MAIL ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: Bellerophon Therapeutics LLC DATE OF NAME CHANGE: 20140213 10-Q 1 blph03312010q.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-36845

Bellerophon Therapeutics, Inc.

(Exact name of registrant as specified in its charter)



Delaware		47-3116175
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)



184 Liberty Corner Road, Suite 302 Warren, New Jersey (Address of principal executive offices)		07059 (Zip Code)

(908) 574-4770

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	BLPH	The Nasdaq Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ý

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý

The number of shares outstanding of the registrant’s common stock as of May 8, 2020: 6,132,393

TABLE OF CONTENTS



		Page No.
PART I. FINANCIAL INFORMATION		6

Item 1.	Financial Statements	6

	Condensed Consolidated Balance Sheets as of March 31, 2020 (Unaudited) and December 31, 2019	6

	Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019 (Unaudited)	7

	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2020 and 2019 (Unaudited)	8

	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 (Unaudited)	9

	Notes to Condensed Consolidated Financial Statements (Unaudited)	10

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28

Item 4.	Controls and Procedures	29

PART II. OTHER INFORMATION		30

Item 1.	Legal Proceedings	30

Item 1A.	Risk Factors	30

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30

Item 3.	Defaults Upon Senior Securities	30

Item 4.	Mine Safety Disclosures	30

Item 5.	Other Information	30

Item 6.	Exhibits	30

	Signatures	31

REFERENCES TO BELLEROPHON

In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires references to the “Company,” “Bellerophon,” “we,” “us” and “our” refer to Bellerophon Therapeutics, Inc. and its consolidated subsidiaries.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:


•	the timing of the ongoing and expected clinical trials of our product candidates, including statements regarding the timing of completion of the trials and the respective periods during which the results of the trials will become available;


•	INOpulse® may prove not to be an effective treatment for COVID-19 or approved for marketing by the FDA;


•	our ability to obtain adequate financing to meet our future operational and capital needs;


•	the timing of and our ability to obtain marketing approval of our product candidates, and the ability of our product candidates to meet existing or future regulatory standards;


•	our ability to comply with government laws and regulations;


•	our commercialization, marketing and manufacturing capabilities and strategy;


•	our estimates regarding the potential market opportunity for our product candidates;


•	the timing of or our ability to enter into partnerships to market and commercialize our product candidates;


•	the rate and degree of market acceptance of any product candidate for which we receive marketing approval;


•	our intellectual property position;


•	our estimates regarding expenses, future revenues, capital requirements and needs for additional funding;


•	the success of competing treatments;


•	our competitive position; and


•	our expectations regarding the time during which we will be an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2019, particularly in the “Risk Factors” section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

This Quarterly Report on Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

BELLEROPHON THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands except share and per share data)



	As of			As of
	March 31, 2020			December 31, 2019
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	8,595		$	9,874
Restricted cash	103			103
Prepaid expenses and other current assets	349			405
Total current assets	9,047			10,382
Restricted cash, non-current	300			300
Right of use assets, net	1,961			2,110
Property and equipment, net	270			316
Total assets	$	11,578		$	13,108
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	2,220		$	3,106
Accrued research and development	1,785			2,117
Accrued expenses	2,101			1,703
Current portion of operating lease liabilities	669			658
Total current liabilities	6,775			7,584
Long term operating lease liabilities	$	1,489		$	1,659
Common stock warrant liability	1,168			274
Total liabilities	9,432			9,517
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value per share; 200,000,000 shares authorized and 4,857,393 and 4,580,127 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	49			46
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized, zero shares issued and outstanding at March 31, 2020 and December 31, 2019	—			—
Additional paid-in capital	196,830			193,308
Accumulated deficit	(194,733		)	(189,763		)
Total stockholders’ equity	2,146			3,591
Total liabilities and stockholders’ equity	$	11,578		$	13,108

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BELLEROPHON THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(in thousands except share and per share data)



	Three Months Ended March 31,
	2020			2019
Operating expenses:
Research and development	$	2,238		$	2,305
General and administrative	1,872			2,037
Total operating expenses	4,110			4,342
Loss from operations	(4,110		)	(4,342		)
Change in fair value of common stock warrant liability	(894		)	1,616
Interest and other income, net	34			130
Pre-tax loss	(4,970		)	(2,596		)
Income tax benefit	—			1,801
Net loss	$	(4,970	)	$	(795	)
Weighted average shares outstanding:
Basic	4,615,046			4,346,109
Diluted	4,615,046			4,346,109
Net loss per share:
Basic	$	(1.08	)	$	(0.18	)
Diluted	$	(1.08	)	$	(0.18	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BELLEROPHON THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

(in thousands except share data)

For the three months ended March 31, 2020:



	Common Stock				Additional		Accumulated			Total Stockholders’
	Shares		Amount		Paid in Capital		Deficit			Equity
December 31, 2019	4,580,127		$	46	$	193,308	$	(189,763	)	$	3,591
Net loss	—		—		—		(4,970		)	(4,970		)
Reverse stock split adjustment	(826	)	—		—		—			—
Warrant exercises	254,760		3		3,054		—			3,057
Stock-based compensation	23,332		—		468		—			468
March 31, 2020	4,857,393		$	49	$	196,830	$	(194,733	)	$	2,146

For the three months ended March 31, 2019:



	Common Stock			Additional		Accumulated			Total Stockholders’
	Shares	Amount		Paid in Capital		Deficit			Equity
December 31, 2018	3,911,857	$	39	$	180,313	$	(176,496	)	$	3,856
Net loss	—	—		—		(795		)	(795		)
Public offering	666,666	7		6,229		—			6,236
Stock-based compensation	15,151	—		1,008		—			1,008
March 31, 2019	4,593,674	$	46	$	187,550	$	(177,291	)	$	10,305

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BELLEROPHON THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in thousands)



	Three Months Ended March 31,
	2020			2019
Cash flows from operating activities:
Net loss	$	(4,970	)	$	(795	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of common stock warrant liability	894			(1,616		)
Stock based compensation	468			1,008
Depreciation	46			88
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	56			(298		)
Accounts payable, accrued research and development, and accrued expenses	(830		)	(727		)
Net cash used in operating activities	(4,336		)	(2,340		)
Cash flows from financing activities:
Proceeds received from exercise of warrants	3,057			—
Proceeds from issuance of common stock in Public Offering	—			6,374
Net cash provided by (used in) financing activities	3,057			6,374

Net change in cash, cash equivalents and restricted cash	(1,279		)	4,034
Cash, cash equivalents and restricted cash at beginning of period	10,277			17,046
Cash, cash equivalents and restricted cash at end of period	$	8,998		$	21,080

Non-cash financing activities:
Unpaid expenses related to offerings	$	—		$	138

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

BELLEROPHON THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(1) Organization and Nature of the Business

Bellerophon Therapeutics, Inc., or the Company, is a clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension, or PH, using its proprietary delivery system, INOpulse. The Company has three wholly-owned subsidiaries: Bellerophon BCM LLC, a Delaware limited liability company; Bellerophon Pulse Technologies LLC, a Delaware limited liability company; and Bellerophon Services, Inc., a Delaware corporation.

The Company’s business is subject to significant risks and uncertainties, including but not limited to:


•	The risk that the Company will not achieve success in its research and development efforts, including clinical trials conducted by it or its potential collaborative partners.


•	The expectation that the Company will experience operating losses for the next several years.


•	Decisions by regulatory authorities regarding whether and when to approve the Company’s regulatory applications as well as their decisions regarding labeling and other matters which could affect the commercial potential of the Company’s products or product candidates.


•	The risk that the Company will fail to obtain adequate financing to meet its future operational and capital needs.


•	The risk that the Company will be unable to obtain additional funds on a timely basis and hence there will be substantial doubt about its ability to continue as a going concern.


•	The risk that key personnel will leave the Company and/or that the Company will be unable to recruit and retain senior level officers to manage its business.

•

There are many uncertainties regarding the novel coronavirus (COVID-19) pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its clinical trials, employees and suppliers. While the pandemic did not materially affect the Company's financial results and business operations in the Company's first quarter ended March 31, 2020, the extent to which the coronavirus impacts the Company's results will depend on future developments, which are highly uncertain and cannot be predicted. Further, should the COVID-19 continue to spread, the Company's business operations could be delayed or interrupted. For instance, the Company's clinical trials may suffer from lower than anticipated patient recruitment or enrollment and it may be forced to temporarily delay ongoing trials.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission, or the SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America, or U.S. GAAP, can be condensed or omitted. The Company operates in one reportable segment and solely within the United States. Accordingly, no segment or geographic information has been presented.

The Company is responsible for the unaudited condensed consolidated financial statements. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive income (loss) and its cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three months ended March 31, 2020 for the Company are not necessarily indicative of the results expected for the full year.

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of costs and expenses during the reporting period, including right of use asset and operating lease liability, accrued expenses, accrued research and development expenses, stock-based compensation, common stock warrant liabilities and income taxes. Actual results could differ from those estimates.

On February 5, 2020, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of the Company's outstanding shares of common stock which became effective on February 7, 2020. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance under the Company’s equity incentive plans and employee stock purchase plan were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans and warrants were proportionately adjusted for the reverse stock split. There was no change to the Company’s authorized number of shares or to its par value per share. The reverse stock split reduced the number of shares of the Company’s common stock that were outstanding at February 10, 2020 from 69,053,548 to 4,603,460, after the cancellation of fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the reverse stock split received a de minimis cash payment in lieu of such fractional shares. These condensed consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly.

(b) Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity date of three months or less to be cash equivalents. All investments with maturities of greater than three months from date of purchase are classified as available-for-sale marketable securities.

The Company accounts for its stock-based compensation in accordance with applicable accounting guidance which establishes accounting for share-based awards, including stock options and restricted stock, exchanged for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company recognizes stock-based compensation expense in operations based on the fair value of the award on the date of the grant. The resulting compensation expense, less estimated forfeitures, is recognized on a straight-line basis over the requisite service period or sooner if the awards immediately vest. The Company determines the fair value of stock options issued using a Black-Scholes-Merton option pricing model. Certain assumptions used in the model include expected volatility, dividend yield, risk-free interest rate, estimated forfeitures and expected term. For restricted stock, the fair value is the closing market price per share on the grant date. See Note 7 - Stock-Based Compensation for a description of these assumptions.

(d) Common Stock Warrants and Warrant Liability

The Company accounts for common stock warrants issued as freestanding instruments in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company classifies warrant liabilities on the consolidated balance sheet based on the warrants' terms as long-term liabilities, which are revalued at each balance sheet date subsequent to the initial issuance. Changes in the fair value of the warrants are reflected in the consolidated statement of operations as “Change in fair value of common stock warrant liability.” The Company uses the Black-Scholes-Merton pricing model to value the related warrant liability. Certain assumptions used in the model include expected volatility, dividend yield and risk-free interest rate. See Note 6 - Fair Value Measurements for a description of these assumptions.

(e) Income Taxes

The Company uses the asset and liability approach to account for income taxes as required by applicable accounting guidance, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount expected to be realized, on a more likely than not basis. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the

taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.

(f) Research and Development Expense

Research and development costs are expensed as incurred. These expenses include the costs of the Company’s proprietary research and development efforts, as well as costs incurred in connection with certain licensing arrangements. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties upon or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. The Company also expenses the cost of purchased technology and equipment in the period of purchase if it believes that the technology or equipment has not demonstrated technological feasibility and it does not have an alternative future use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and are recognized as research and development expense as the related goods are delivered or the related services are performed.

(g) Leases

A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of operations in the same line item as expenses arising from fixed lease payments.

Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.

The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended March 31, 2020 and 2019 were de minimis.

(g) Recently Issued Accounting Pronouncements

Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which eliminates, adds and modifies certain disclosure requirements for fair value measurements. The standard requires the disclosure of the range and weighted average used to develop significant unobservable inputs and how weighted average is calculated for recurring and nonrecurring Level 3 fair value measurements. The amendment is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted ASU 2018-13’s during the quarter ended March 31, 2020 by including disclosure on the range of inputs used to calculate the Company's Level 3 fair value measurements.

(3) Liquidity

In the course of its development activities, the Company has sustained operating losses and expects such losses to continue over the next several years. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development and clinical trials of, and seeks regulatory approval for, its product candidates. The Company's primary uses of capital are, and it expects will continue to be, compensation and related expenses,

third-party clinical research and development services, contract manufacturing services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.

The Company had cash and cash equivalents of $8.6 million as of March 31, 2020. The Company's existing cash and cash equivalents as of March 31, 2020 will be used primarily to fund the Phase 3 trial of INOpulse for PH-ILD, to complete the dose escalation study for PH-Sarc. and to treat COVID-19 patients under the emergency expanded access.

On June 25, 2018, the Company filed a shelf registration statement on Form S-3 with the SEC, which became effective on July 6, 2018. The shelf registration allows the Company to issue, from time to time at prices and on terms to be determined prior to the time of any such offering, up to $100 million of any combination of common stock, preferred stock, debt securities, warrants and rights, either individually or in units.

On January 25, 2019, the Company completed the sale of 666,666 shares of its common stock at a public offering price of $10.50 per share, resulting in net proceeds of $6.2 million, after deducting placement fees of $0.5 million and other offering costs of $0.3 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3.

On April 1, 2020, the Company completed the sale of 1,275,000 shares of its common stock in a registered direct offering at an offering price of $12.00 per share, resulting in net proceeds of approximately $14.1 million, after deducting agent fees of $1.1 million and offering costs of $0.1 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3.

Taking into consideration the cash proceeds from the April 1, 2020 registered direct offering, the Company evaluated whether there are any remaining conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.

Based on such evaluation and the Company's current plans, which are subject to change as discussed below, management believes that the Company's existing cash and cash equivalents as of March 31, 2020, proceeds received from the April 1, 2020 registered direct offering and proceeds received in May 2020 and expected to become available upon the future sale of state net operating losses, or NOLs, and research and development (“R&D”) tax credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program, will be sufficient to satisfy its operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q.

In April 2020, the Company submitted an Investigational New Drug Application (“IND”) to study the iNO delivery system for the treatment of patients infected with COVID-19. The IND was accepted by the U.S. Food and Drug Administration (the "FDA") in May 2020, which allows the Company to initiate the Phase 3 study. The Company is currently reviewing its clinical plans for this program and, in parallel, the Company submitted an application for federal funding, through the Biomedical Advanced Research and Development Authority (“BARDA”) and the National Institutes of Health (“NIH”), to support the study. If the Company decides to incur additional costs related to the COVID-19 trial in the next 12 months in advance of receiving federal or other funding, its operating cash needs are likely to increase and its existing cash and cash equivalents as of March 31, 2020 may not be sufficient to satisfy its operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q.

The State of New Jersey's Technology Business Tax Certificate Transfer Program enables qualified, unprofitable New Jersey based technology or biotechnology companies to sell a percentage of NOL and R&D tax credits to unrelated profitable corporations, subject to meeting certain eligibility criteria. Based on consideration of various factors, including application processing time and past trend of benefits made available under the program, the Company believes that it is probable that its plans to sell its NOLs can be effectively implemented to address its short term financial needs. The Company has sold $21.2 million of state NOLs and $0.2 million of Research and Development credit under the State of New Jersey’s Technology Business Tax Certificate Transfer Program in May 2020 for net proceeds of $2.0 million and has sold $20.0 million of state NOLs for net proceeds of $1.7 million in January 2019. Subject to state approval and program availability, the Company plans to sell additional NOLs and credits under the same program in the future. The proceeds from such sales are recorded as income tax benefit when sales occur or proceeds are received.

The Company’s estimates and assumptions may prove to be wrong, and the Company may exhaust its capital resources sooner than expected. The process of testing product candidates in clinical trials is costly, and the timing of progress in clinical trials is uncertain. Because the Company’s product candidates are in clinical development and the outcome of these efforts is uncertain, the Company may not be able to accurately estimate the actual amounts that will be necessary to

successfully complete the development and commercialization, if approved, of its product candidates or whether, or when, the Company may achieve profitability.

Until such time, if ever, as the Company can generate substantial product revenues, it expects to finance its cash needs through a combination of equity and debt offerings, sales of state NOLs and R&D credits subject to program availability and approval, existing working capital, funding from federal programs subject to approval, and funding from potential future collaboration arrangements. To the extent that the Company raises additional capital through the future sale of equity or debt, the ownership interest of its existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences or rights such as anti-dilution rights that adversely affect the rights of its existing stockholders. If the Company raises additional funds through strategic partnerships in the future, it may have to relinquish valuable rights to its technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to it. If the Company is unable to raise additional funds through equity or debt financings when needed, is unable to sell its state NOLs and R&D credits or obtain federal funding for the IND to study the iNO delivery system for the treatment of patients infected with COVID-19, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself.

(4) Right of Use Assets and Leases

The Company has two operating leases in Warren, NJ, one for the use of an office and research facility and a second for the use of a laboratory. The office and research facility lease is for a term of four years with a term date of March 31, 2023, with the Company's right to extend the original term for one period of five years. The laboratory lease is for a term of three years and nine months with a term date of April 30, 2023, with the Company's right to extend the original term for one period of 90 days. Operating lease expense is recognized on a straight-line basis over the respective lease term.

Information related to the Company's right-of-use asset and related lease liability were as follows ($ amounts in thousands):



	Three months ended March 31,
	2020			2019
Cash paid for operating lease liability	$	187		$	161
Operating lease expenses	177			153
Weighted average remaining lease term	3 years			4 years
Weighted average discount rate	4.94		%	4.98		%

Maturities of the lease liability as of March 31, 2020 were as follows :
2020	$	570
2021	770
2022	783
2023	205
	2,328
Less imputed interest	(170		)
Total operating lease liability	2,158

(5) Common Stock Warrants and Warrant Liability

On November 29, 2016, the Company issued 1,142,838 warrants that were immediately exercisable and will expire 5 years from issuance at an exercise price of $12.00 per share (the “2016 Warrants”). On June 28, 2019, the Company entered into a warrant amendment (the “Warrant Amendment”) with certain holders (the “Holders”) of 839,899 of the 2016 Warrants to purchase shares. Pursuant to the Warrant Amendment, the Company and the Holders agreed to eliminate provisions that had previously precluded equity classification treatment on the Company’s consolidated balance sheets. In consideration of such amendment, the 2016 Warrants were extended by two (2) additional years (until November 29, 2023). The difference in fair market value of the warrants before and after the amendment, of $0.7 million, was recorded in the consolidated statement of operations as a warrant amendment charge. The fair market value of the amended warrants was reclassified from common stock warrant liability to stockholders' equity. The balance of the 2016 Warrants that were not amended could require cash settlement under certain circumstances, and therefore continue to be classified as liabilities and to be recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of March 31, 2020, 661,310 of the 2016 Warrants were outstanding, of which 585,139 were equity classified and 76,171 were liability classified. During the three months ended March 31, 2020, 254,760 of the 2016 warrants were exercised for net proceeds of $3.1 million.

On May 15, 2017, the Company issued to an investor a warrant to purchase 66,666 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $22.50 per share. In addition, the Company issued to the placement agent warrants to purchase 4,000 shares that were immediately exercisable and will expire five years from issuance at an exercise price of $28.125 per share. As the warrants, under certain situations, could require cash settlement, the warrants were classified as liabilities and recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of March 31, 2020, all of these warrants were outstanding.

On September 29, 2017, the Company issued warrants to purchase 1,296,650 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $18.63 per share. As the warrants could not require cash settlement, the warrants were classified as equity. As of March 31, 2020, all of these warrants were outstanding.

The following table summarizes warrant activity for the three months ended March 31, 2020 (fair value amount in thousands):



	Equity Classified		Liability Classified
	Warrants		Warrants	Estimated Fair Value
Warrants outstanding as of December 31, 2019	2,136,549		146,837	$	274
Exercises	(254,760	)	—
Change in fair value of common stock warrant liability recognized in consolidated statement of operations	—		—	894
Warrants outstanding as of March 31, 2020	1,881,789		146,837	$	1,168

The following table summarizes warrant activity for the three months ended March 31, 2019 (fair value amount in thousands):



	Equity Classified	Liability Classified
	Warrants	Warrants	Estimated Fair Value
Warrants outstanding as of December 31, 2018	1,296,650	986,736	$	6,965
Change in fair value of common stock warrant liability recognized in consolidated statement of operations	—	—	(1,616		)
Warrants outstanding as of March 31, 2019	1,296,650	986,736	$	5,349

See Note 6 for determination of the fair value of the common stock warrant liability.

(6) Fair Value Measurements

Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows:


•	Level 1 — Values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date.


•	Level 2 — Values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.


•	Level 3 — Values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.

The following table summarizes fair value measurements by level at March 31, 2020 for liabilities measured at fair value on a recurring basis (in thousands):



	Level 1	Level 2	Level 3	Total
Common stock warrant liability	—	—	1,168	1,168

The following table summarizes fair value measurements by level at December 31, 2019 for liabilities measured at fair value on a recurring basis (in thousands):



	Level 1	Level 2	Level 3	Total
Common stock warrant liabilities	—	—	274	274

The Company uses a Black-Scholes-Merton option pricing model to value its liability classified common stock warrants. The significant unobservable inputs used in calculating the fair value of common stock warrants represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. Any significant changes in the inputs may result in significantly higher or lower fair value measurements.

The following are the weighted average and the range of assumptions used in estimating the fair value of warrants outstanding (weighted average calculated based on the number of outstanding warrants on each issuance) as of March 31, 2020 and December 31, 2019:



	March 31, 2020							December 31, 2019
Valuation assumptions:	Range					Weighted Average		Range					Weighted Average
Risk-free interest rate	0.21	%	-	0.27	%	0.24	%	1.57	%	-	1.61	%	1.59	%
Expected volatility	149.76	%	-	187.49	%	169.86	%	104.74	%	-	109.05	%	107.00	%
Expected term (in years)	1.7		-	2.6		2.1		1.9		-	2.9		2.4
Dividend yield	—	%	-	—	%	—	%	—	%	-	—	%	—	%

(7) Stock-Based Compensation

Bellerophon 2015 and 2014 Equity Incentive Plans

During 2014, the Company adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which provided for the grant of options. Following the effectiveness of the Company's registration statement filed in connection with its IPO, no options may be granted under the 2014 Plan. The awards granted under the 2014 Plan generally have a vesting period of between one to four years.

During 2015, the Company adopted the 2015 Equity Incentive Plan, or the 2015 Plan, which provides for the grant of options, restricted stock and other forms of equity compensation. On May 4, 2017, the Company’s stockholders approved an amendment to the 2015 Plan to increase the aggregate number of shares available for the grant of awards to 333,333 and to increase the maximum number of shares available under the annual increase to 200,000 shares. On May 14, 2019, the Company's stockholders approved an additional amendment to the 2015 Plan to increase the aggregate number of shares reserved for issuance under the 2015 Plan from 333,333 to 833,333. As of March 31, 2020, the Company had 454,362 shares available for grant under the 2015 Plan.

As of March 31, 2020, there was approximately $2.7 million of total unrecognized compensation expense related to unvested stock awards. This expense is expected to be recognized over a weighted-average period of 2.4 years.

No tax benefit was recognized during the three months ended March 31, 2020 and 2019 related to stock-based compensation expense since the Company incurred operating losses and has established a full valuation allowance to offset all the potential tax benefits associated with its deferred tax assets.

Options

The weighted average grant-date fair value of options issued during the three months ended March 31, 2019 was $9.30. No options were granted in the three months ended March 31, 2020. The following are the weighted average assumptions used in estimating the fair values of options issued during the three months ended March 31, 2019:



	Three Months Ended March 31, 2019
Valuation assumptions:
Risk-free rate	2.51	%
Expected volatility	82.95	%
Expected term (years)	6.0
Dividend yield	—

A summary of option activity under the 2015 and 2014 Plans for the three months ended March 31, 2020 is presented below:



	Bellerophon 2015 and 2014 Equity Incentive Plans
	Options		Range of Exercise Price				Weighted Average Price		Weighted Average Remaining Contractual Life (in years)
Options outstanding as of December 31, 2019	663,501		$	7.35	-	199.20	$	24.15	8.3
Forfeited	(325	)	7.35		-	199.20	32.41		—
Options outstanding as of March 31, 2020	663,176		$	7.35	-	199.20	$	24.15	8.0
Options vested and exercisable as of March 31, 2020	295,768		$	7.35	-	199.20	$	39.48	7.1

The intrinsic value of options outstanding, vested and exercisable as of March 31, 2020 was $0.4 million.

Restricted Stock

All restricted stock awards granted under the 2015 Plan during the three months ended March 31, 2020 were in relation to director compensation and vested in full by December 31, 2020 subject to certain terms and conditions.

A summary of restricted stock activity under the 2015 Plan for the three months ended March 31, 2020 is presented below:



	Bellerophon 2015 Equity Incentive Plan
	Shares		Weighted Average Fair Value		Aggregate Grant Date Fair Value (in millions)		Weighted Average Remaining Contractual Life (in years)
Restricted stock outstanding as of December 31, 2019	—		$	—	$	—	—
Granted	23,332		6.00		0.1
Vested	(16,666	)	6.00		—
Restricted stock outstanding as of March 31, 2020	6,666		$	6.00	$	—	0.7

Ikaria Equity Incentive Plans prior to February 12, 2014

Options

A summary of option activity under Ikaria incentive plans assumed in 2014 for the three months ended March 31, 2020, is presented below:



	Ikaria Equity Incentive Plans
	Options		Range of Exercise Price				Weighted Average Price		Weighted Average Remaining Contractual Life (in years)
Options outstanding as of December 31, 2019	3,463		$	116.55	-	223.65	$	124.21	2.3
Forfeited	(195	)	116.55		-	124.05	118.55		—
Options outstanding as of March 31, 2020	3,268		$	116.55	-	223.65	$	124.54	2.1
Options vested and exercisable as of March 31, 2020	3,268		$	116.55	-	223.65	$	124.54	2.1

The intrinsic value of options outstanding, vested and exercisable as of March 31, 2020 was zero.

Stock-Based Compensation Expense, Net of Estimated Forfeitures

The following table summarizes the stock-based compensation expense by the unaudited condensed consolidated statement of operations line items for the three months ended March 31, 2020 and 2019 (in thousands):



	Three Months Ended March 31,
	2020		2019
Research and development	$	79	$	311
General and administrative	389		697
Total expense	$	468	$	1,008

(8) Income Taxes

Excluding the impact of the sale of state net operating losses and research and development credits during the first quarter of 2019, the effective tax rate for each of the three months ended March 31, 2020 and 2019 was 0.0% which was lower than the federal statutory rate primarily due to the losses incurred and the full valuation allowance on deferred tax assets.

The Company’s estimated tax rate for 2020 excluding any benefits from any sales of net operating losses or research and development, or R&D, tax credits is expected to be zero because the Company expects to generate additional losses and currently has a full valuation allowance. The valuation allowance is required until the Company has sufficient positive evidence of taxable income necessary to support realization of its deferred tax assets. In addition, the Company may be subject to certain limitations in its annual utilization of NOL carry forwards to offset future taxable income (and of tax credit carry forwards to

offset future tax expense) pursuant to Section 382 of the Internal Revenue Code, which could result in tax attributes expiring unused.

In May 2020, the Company has sold $21.2 million of state NOLs and $0.2 million of Research and Development credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program for net proceeds of $2.0 million. In January 2019, the Company sold $20.0 million of state NOLs for net proceeds of $1.7 million under the State of New Jersey's Technology Business Tax Certificate Transfer Program, which resulted in the reversal of the valuation allowance and a tax benefit of $1.8 million for the three months ended March 31, 2019. Subject to state approval, the Company plans to sell additional NOLs and credits under the same program in the future. The proceeds from such sales are recorded as Income tax benefit when sales occur or proceeds are received.

As of March 31, 2020, there were no material uncertain tax positions. There are no tax positions for which a material change in any unrecognized tax benefit liability is reasonably possible in the next 12 months.

(9) Net Loss Per Share

Basic net loss per share is calculated by dividing net (loss) income by the weighted average number of shares outstanding during the period, as applicable. Diluted net loss per share is calculated by dividing net (loss) income, adjusted to reflect the impact of dilutive warrants, by the weighted average number of shares outstanding, adjusted to reflect potentially dilutive securities using the treasury stock method, except when the effect would be anti-dilutive.

The Company reported a net loss for the three months ended March 31, 2020 and 2019, therefore diluted net loss per share is the same as the basic net loss per share.

As of March 31, 2020, the Company had 666,444 options to purchase shares, 6,666 restricted shares and 2,028,626 warrants to purchase shares outstanding that have been excluded from the computation of diluted weighted average shares outstanding, because such securities had an anti-dilutive impact due to the loss reported.

(10) Commitments and Contingencies

Legal Proceedings

The Company periodically becomes subject to legal proceedings and claims arising in connection with its business. The ultimate legal and financial liability of the Company in respect to all proceedings, claims and lawsuits, pending or threatened, cannot be estimated with any certainty.

As of the date of this report, the Company is not aware of any proceeding, claim or litigation, pending or threatened, that could, individually or in the aggregate, have a material adverse effect on the Company’s business, operating results, financial condition and/or liquidity.

(11) Subsequent Events

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read the “Risk Factors” section in Part II—Item 1A. of this Quarterly Report on Form 10-Q and in Part I—Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

Business

We are a clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Our focus is the continued development of our nitric oxide therapy for patients with pulmonary hypertension, or PH, using our proprietary pulsatile nitric oxide delivery platform, INOpulse.

In 2016, we began developing INOpulse for the treatment of pulmonary hypertension associated with interstitial lung disease (“PH-ILD”), which includes PH associated with idiopathic pulmonary fibrosis (“PH-IPF”) as well as other pulmonary fibrosing diseases. During August 2017, we announced acceptance by the U.S. Food and Drug Administration (the “FDA”) of our Investigational New Drug (“IND”) application for our Phase 2b (“iNO-PF”) clinical trial using INOpulse therapy in a broad population of patients with pulmonary fibrosis, or PF, at both low and intermediate/high risk of PH. In January 2018, we announced the first patient enrollment in our iNO-PF Phase 2b trial. In October 2018, we announced the enrollment completion of the planned 40 subjects, or cohort 1, in our iNO-PF trial. In addition, we announced the expansion of the trial with the addition of cohort 2 and cohort 3, to evaluate a higher iNO 45 and iNO 75 dose as well as a longer 16 week evaluation period.

In January 2019, we announced top-line results from cohort 1 of our iNO-PF trial. The results showed statistically significant improvements in multiple clinically meaningful activity parameters as measured by a wearable medical-grade activity monitor. In addition, iNO was well-tolerated with no safety concerns, supporting the continuation into cohort 2. In April 2019, we announced that we reached an agreement with the FDA on modifying the ongoing Phase 2b trial into a seamless Phase 2/3 trial, with cohort 3 serving as the pivotal study, as well as an agreement on the primary endpoint of change in moderate to vigorous activity (“MVPA”) from baseline to week 16, measured by Actigraphy. Actigraphy (medical wearable continuous activity monitoring) provides highly sensitive objective real-world physical activity data that correlates to clinically meaningful patient functional abilities and health outcomes. In addition to the primary endpoint, we are currently utilizing Actigraphy to evaluate multiple clinically meaningful activity parameters in the iNO-PF study. Actigraphy is currently being utilized as the primary endpoint in multiple late-stage clinical programs in various cardiopulmonary diseases such as heart failure and COPD. In December 2019, we announced top-line results from cohort 2 of the iNO-PF trial. Cohort 2 of iNO-PF demonstrated statistically significant placebo corrected improvement in MVPA, in subjects treated with iNO45 (45 mcg/kg IBW/hr) versus placebo. The improvements in MVPA were underscored by benefits in other actigraphy parameters, as well as multiple patient reported outcomes. In March 2020, we announced that in consultation with the FDA, we had finalized the key elements of our planned pivotal Phase 3 study for PH-PF, including the use of MVPA as the primary endpoint for approval, the patient population of pulmonary fibrosis subjects at risk of PH, as well as the dose of iNO45.

In 2018, we initiated an ancillary Phase 2 intra-patient dose escalation study that utilizes right heart catheterization to assess the hemodynamic effect of INOpulse from a dose of iNO 30 to iNO 125 in PH-ILD subjects. In February 2020, we announced the completion of the study and that the top-line results demonstrated that INOpulse achieved clinically and statistically significant improvements in pulmonary vascular resistance and mean pulmonary arterial pressure. Inhaled nitric oxide was well-tolerated with no safety concerns across doses.

In July 2014, we completed a randomized, placebo-controlled, double-blind, dose-confirmation Phase 2 clinical trial of INOpulse for pulmonary hypertension associated with chronic obstructive pulmonary disease, or PH-COPD. The results from this trial showed that iNO 30 was a potentially safe and effective dose for treatment of PH-COPD. Based on the results of this trial, we completed further Phase 2 testing to assess the targeted vasodilation provided by INOpulse in this patient population. We presented the results of this trial in September 2015 at the European Respiratory Society International Congress 2015 in Amsterdam. The data showed that INOpulse improved vasodilation in patients with PH-COPD. In July 2016, the results were published in the International Journal of COPD in an article entitled “Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension.” During September 2017, we shared the results of our Phase 2a

PH-COPD study designed to evaluate the acute effects of pulsed inhaled nitric oxide, or iNO, on vasodilation as well as the chronic effect on hemodynamics and exercise tolerance. The trial showed a statistically significant increase (average 4.2%) in blood vessel volume on iNO compared to baseline (p=0.03), and a statistically significant correlation in Ventilation-Vasodilation (p=0.01). The chronic results demonstrated a statistically significant and clinically meaningful increase in 6MWD of 50.7m (p=0.04) as well as a decrease of 19.9% in systolic pulmonary arterial pressure (p=0.02), as compared to baseline. The therapy was well tolerated with no related safety concerns. In May 2018, we announced that the FDA concurred with the design of our planned Phase 2b study of INOpulse for treatment of PH-COPD. The study will assess the effect of INOpulse on various parameters including exercise capacity, right ventricular function and oxygen saturation, as well as other composite endpoints. We continue to evaluate alternatives for the funding and timing of this program.

In 2018, we initiated development of INOpulse for the treatment of PH associated with Sarcoidosis (“PH-Sarc”). Sarcoidosis is a multi-system disease which is characterized by the growth of granulomas (inflammatory cells) in one or more organs. The most frequent organs involved are the lungs and lymph nodes within the chest. Pulmonary hypertension may be present in as many as 74% of patients depending on how the pulmonary hypertension (“PH”) is defined. The presence of PH in sarcoidosis is associated with a poor prognosis. There are a number of different mechanisms linking PH with sarcoidosis. The primary treatment for sarcoidosis is corticosteroids; however, the outcome of this treatment on the PH is unclear. There is no approved therapy for PH associated with sarcoidosis. Various PAH treatments have been tried including iNO and IV prostacyclin with some clinical and functional improvement. The study is a Phase 2a dose escalation design that will utilize right heart catheterization to assess the hemodynamic effect of INOpulse from a dose of iNO 30 to iNO 125 in PH-Sarc subjects. We have completed the process of initiating sites and enrolled our first subject in 2019, with results expected in 2020.

On March 19, 2020, the FDA granted emergency expanded access to allow for our proprietary inhaled nitric oxide (“iNO”) delivery system, INOpulse®, to immediately be used as supportive treatment for a patient with COVID-19 under the care and supervision of the patient’s physician. The clinical goal of this experimental treatment is to avert the hospitalized patient’s disease progression and avoid the need to perform intubation. This emergency expanded access from the FDA was granted on a named patient basis and we have treated over 50 patients with COVID-19. In April 2020, we submitted an IND to the FDA to study the iNO delivery system for the treatment of patients infected with COVID-19. The proposed randomized, open-label study will evaluate the efficacy and safety of INOpulse in patients with COVID-19 who require supplemental oxygen. The protocol utilizes an adaptive design and aims to enroll up to 500 patients who will be treated with either INOpulse or placebo. The IND was accepted by the FDA in May 2020, which allows us to initiate the Phase 3 study. In parallel, we have submitted for federal funding, through Biomedical Advanced Research and Development Authority (“BARDA”) and National Institutes of Health (“NIH”), to support the study.

We initiated a Phase 3 clinical trial of INOpulse for PAH in June 2016. As agreed upon with the FDA, a pre-specified interim analysis was conducted by the Data Monitoring Committee, or DMC, in August 2018, after half of the planned subjects completed 16 weeks of blinded treatment. The data showed INOpulse provided clinically meaningful improvements in pulmonary vascular resistance (18%), cardiac output (0.7 L/min) and NT Pro-BNP. In addition, subjects on PAH background mono-therapy showed a 23 meter improvement in 6MWD, while subjects that were not on prostanoid background therapy showed a 17 meter improvement in 6MWD. However, the DMC determined that the overall change in 6MWD, the primary endpoint of the trial, was insufficient to support the continuation of the study. Accordingly, based on the DMC's recommendation, we have discontinued the trial. The trial results showed 6MWD was improved when subjects were on less background therapies and more patients deteriorated in 6MWD on placebo as compared to iNO. In addition, INOpulse was well tolerated and there were no safety concerns.

In addition, other potential indications for our INOpulse platform include: chronic thromboembolic PH, or CTEPH and PH associated with pulmonary edema from high altitude sickness.

We have devoted all of our resources to our therapeutic discovery and development efforts, including conducting clinical trials for our product candidates, protecting our intellectual property and the general and administrative support of these operations. We have devoted significant time and resources to developing and optimizing our drug delivery system, INOpulse, which operates through the administration of nitric oxide as brief, controlled pulses that are timed to occur at the beginning of a breath.

To date, we have generated no revenue from product sales. We expect that it may be several years before we commercialize a product candidate, if ever.

Financial Operations Overview

Revenue

To date, we have not generated any revenue from product sales and may not generate any revenue from product sales for the next several years, if ever. In the future, we may generate revenue from a combination of product sales, license fees and milestone payments in connection with strategic partnerships, and royalties from the sale of products developed under licenses of our intellectual property. Our ability to generate revenue and become profitable depends primarily on our ability to successfully develop and commercialize or partner our product candidates as well as any product candidates we may advance in the future. We expect that any revenue we may generate will fluctuate from quarter to quarter as a result of the timing and amount of any payments we may receive under future partnerships, if any, and from sales of any products we successfully develop and commercialize, if any. If we fail to complete the development of any of our product candidates currently in clinical development or any future product candidates in a timely manner, or to obtain regulatory approval for such product candidates, our ability to generate future revenue, and our business, results of operations, financial condition and cash flows and future prospects would be materially adversely affected.

Research and Development Expenses

Research and development expenses consist of costs incurred in connection with the development of our product candidates, including upfront and development milestone payments, related to in-licensed product candidates and technologies.

Research and development expenses primarily consist of:

•employee-related expenses, including salary, benefits and stock-based compensation expense;


•	expenses incurred under agreements with contract research organizations, investigative sites that conduct our clinical trials and consultants that conduct a portion of our pre-clinical studies;

•expenses relating to vendors in connection with research and development activities;

•the cost of acquiring and manufacturing clinical trial materials;

•facilities, depreciation and allocated expenses;


•	lab supplies, reagents, active pharmaceutical ingredients and other direct and indirect costs in support of our pre-clinical and clinical activities;

•device development and drug manufacturing engineering;

•license fees related to in-licensed products and technology; and

•costs associated with non-clinical activities and regulatory approvals.

We expense research and development costs as incurred.

Conducting a significant amount of research and development is central to our business model. Product candidates in late stages of clinical development generally have higher development costs than those in earlier stages of clinical development primarily due to the increased size and duration of late-stage clinical trials. Subject to the availability of requisite financing, we plan to increase our research and development expenses for ongoing clinical programs for the foreseeable future as we seek to continue multiple clinical trials for our product candidates, including Phase 3 trial for PH-ILD, potentially advance INOpulse for PH-COPD, and seek to identify additional early-stage product candidates.

We track external research and development expenses and personnel expenses on a program-by-program basis. We use our employee and infrastructure resources, including regulatory, quality, clinical development and clinical operations, across our clinical development programs and have included these expenses in research and development infrastructure. Research and development laboratory expenses are also not allocated to a specific program and are included in research and development infrastructure. Engineering activities related to INOpulse and the manufacture of cylinders related to INOpulse are included in INOpulse engineering.

INOpulse for PH-ILD

We initiated our clinical program in PH-ILD in 2016. During May 2017, we announced completion of our Phase 2 study using INOpulse therapy to treat PH-IPF. After reaching agreement with the FDA, we initiated and are currently

conducting our Phase 2b trial in PH-ILD. In January 2018, we announced the first patient enrollment in our iNO-PF Phase 2b trial. In October 2018, we announced the enrollment completion of the planned 40 subjects, or cohort 1, in our iNO-PF study. In addition, we announced the expansion of the trial with the addition of cohort 2 and cohort 3, to evaluate higher doses of iNO as well as a longer 16 week evaluation period. In January 2019, we announced top-line results from cohort 1 of our iNO-PF study. The results showed statistically significant improvements in multiple clinically meaningful activity parameters as measured by a wearable medical-grade activity monitor. In December 2019, we announced top-line results from cohort 2 of the iNO-PF trial. Cohort 2 of iNO-PF demonstrated statistically significant placebo corrected improvement in MVPA, in subjects treated with iNO45 (45 mcg/kg IBW/hr) versus placebo. The improvements in MVPA were underscored by benefits in other actigraphy parameters, as well as patient reported outcomes. In March 2020, we announced that in consultation with the FDA, we had finalized the key elements of our planned pivotal Phase 3 study for PH-PF, including the use of MVPA as the primary endpoint for approval, the patient population of pulmonary fibrosis subjects at risk of PH, as well as the dose of iNO45.

INOpulse for PH-Sarcoidosis

In 2018, we initiated development of INOpulse for the treatment of PH associated with Sarcoidosis (PH-Sarc). The study is a Phase 2a dose escalation design that will utilize right heart catheterization to assess the hemodynamic effect of INOpulse from a dose of iNO 30 to iNO 125 in PH-Sarc subjects. We have completed the process of initiating sites and enrolled our first subject in 2019, with results expected in 2020.

INOpulse for PH-COPD

We completed and received results from a randomized, placebo-controlled, double-blind, dose-confirmation Phase 2a clinical trial of INOpulse for PH-COPD in July 2014. During September 2017, we shared results of our Phase 2a PH-COPD study designed to evaluate the acute effects of pulsed inhaled nitric oxide, or iNO, on vasodilation as well as the chronic effect on hemodynamics and exercise tolerance. In May 2018, we announced that we reached agreement with the FDA on the design of our planned Phase 2b study of INOpulse for treatment of PH-COPD. We continue to evaluate alternatives for the funding and timing of this program.

INOpulse for PAH

We initiated a Phase 3 clinical trial of INOpulse for PAH in June 2016. As agreed upon with the FDA, a pre-specified interim analysis was conducted by the Data Monitoring Committee, or DMC, in August 2018, after half of the planned subjects completed 16 weeks of blinded treatment. The data showed INOpulse provided clinically meaningful improvements in pulmonary vascular resistance (18%), cardiac output (0.7 L/min) and NT Pro-BNP. In addition, subjects on PAH background mono-therapy showed a 23 meter improvement in 6MWD, while subjects that were not on prostanoid background therapy showed a 17 meter improvement in 6MWD. However, the DMC determined that the overall change in 6MWD, the primary endpoint of the trial, was insufficient to support the continuation of the study. Accordingly, based on the DMC's recommendation, we discontinued the trial in August 2018. The trial results showed 6MWD was improved when subjects were on less background therapies and more patients deteriorated in 6MWD on placebo as compared to iNO. In addition, INOpulse was well tolerated and there were no safety concerns.

Drug and Delivery System Costs

Drug and delivery system costs include cartridge procurement, cartridge filling, delivery system manufacturing and delivery system servicing. These costs relate to all indications that utilize the INOpulse delivery system. During the three months ended September 2017, we began to incur drug and delivery system costs for our Phase 2b study using INOpulse therapy in a broad population of patients with PF. Historically, drug and deliver system costs were primarily for our studies of INOpulse for PAH.

Research and Development Infrastructure

We invest in regulatory, quality, clinical development and clinical operations activities, which are expensed as incurred. These activities primarily support our clinical development programs.

INOpulse Engineering

We have invested a significant amount of funds in INOpulse, which is configured to be highly portable and compatible with available modes of LTOT via nasal cannula delivery. Our Phase 2 clinical trials of INOpulse for PAH and INOpulse for PH-COPD utilized the first generation INOpulse DS/DS-C device. We believe our second generation INOpulse device, as well as a custom triple-lumen cannula, have significantly improved several characteristics of our INOpulse delivery system. We have also invested in design and engineering technology, through Ikaria, for the manufacture of our drug cartridges. We manufacture and service the INOpulse devices that we are using in our ongoing clinical trials of INOpulse for PH-ILD and PH-COPD by third party turnkey manufacturers.

General and Administrative Expenses

General and administrative expenses include salaries and costs related to executive, finance, and administrative support functions, patent filing, patent prosecution, professional fees for legal, insurance, consulting, investor relations, human resources, information technology and auditing and tax services not otherwise included in research and development expenses.

Results of Operations

Comparison of Three Months Ended March 31, 2020 and 2019

The following table summarizes our results of operations for the three months ended March 31, 2020 and 2019.



	Three Months Ended March 31,
(Dollar amounts in thousands)	2020			2019			$ Change			% Change
Research and development expenses:
PH-ILD, PH-Sarc and PH-COPD	$	644		$	609		$	35		6	%
PAH	23			94			(71		)	(76	)%
Other clinical trials	42			—			42			N/A
Drug and delivery system costs	183			125			58			46	%
Clinical programs	892			828			64			8	%
Research and development infrastructure	1,105			1,185			(80		)	(7	)%
INOpulse engineering	241			292			(51		)	(17	)%
Total research and development expenses	2,238			2,305			(67		)	(3	)%
General and administrative expenses	1,872			2,037			(165		)	(8	)%
Total operating expenses	4,110			4,342			(232		)	(5	)%
Loss from operations	(4,110		)	(4,342		)	232			(5	)%
Change in fair value of common stock warrant liability	(894		)	1,616			(2,510		)	(155	)%
Interest and other income, net	34			130			(96		)	(74	)%
Pre-tax loss	(4,970		)	(2,596		)	(2,374		)	91	%
Income tax benefit	—			1,801			(1,801		)	(100	)%
Net loss	$	(4,970	)	$	(795	)	$	(4,175	)	525	%

Total Operating Expenses. Total operating expenses for the three months ended March 31, 2020 were $4.1 million compared to $4.3 million for the three months ended March 31, 2019, a decrease of $0.2 million, or (5)%. This decrease was primarily due to decreased research and development infrastructure cost as well as general and administrative expenses.

Research and Development Expenses. Total research and development expenses for the three months ended March 31, 2020 were $2.2 million compared to $2.3 million for the three months ended March 31, 2019, a decrease of $0.1 million, or (3)%. Total research and development expenses consisted of the following:

• PH-ILD, PH-Sarc and PH-COPD expenses for the three months ended March 31, 2020 were $0.6 million, essentially flat as compared to the three months ended March 31, 2019.

• Drug and delivery system costs for the three months ended March 31, 2020 were $0.2 million, compared to $0.1 million for the three months ended March 31, 2019, an increase of $0.1 million, or 46%. Drug and delivery system costs are recorded at the time of procurement from our suppliers.

•Research and development infrastructure expenses for the three months ended March 31, 2020 were $1.1 million, compared to $1.2 million for the three months ended March 31, 2019, a decrease of $0.1 million, or (7)%. The decrease was primarily due to lower stock based compensation.

General and Administrative Expenses. General and administrative expenses for the three months ended March 31, 2020 were $1.9 million, compared to $2.0 million for the three months ended March 31, 2019, a decrease of $0.1 million, or (8)%. The decrease was primarily due to lower stock based compensation.

Income Tax Benefit. Income tax benefit was $0.0 million for the three months ended March 31, 2020, compared to $1.8 million for the three months ended March 31, 2019, a decrease of $1.8 million, or (100)%. The benefit in the first quarter of 2019 was from the sale of $20.0 million of state NOLs under the State of New Jersey's Technology Business Tax Certificate

Transfer Program for net proceeds of $1.7 million. In May 2020, we sold $21.2 million of state NOLs and $0.2 million of Research and Development credit under the same program for net proceeds of $2.0 million. The proceeds from such sales are recorded as income tax benefit when sales occur or proceeds are received.

Change in fair value of common stock warrant liability. Change in fair value of common stock warrant liability for the three months ended March 31, 2020 was an expense of $0.9 million, compared to an income of $1.6 million for the three months ended March 31, 2019. The warrants were issued in November 2016 and May 2017 and the change in the liability fair value was primarily due to a change in our stock price and volatility.

Liquidity and Capital Resources

In the course of our development activities, we have sustained operating losses and expect such losses to continue over the next several years. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue to develop, conduct clinical trials and seek regulatory approval for our product candidates. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, contract manufacturing services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.

If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses. We do not have a sales, marketing, manufacture or distribution infrastructure for a pharmaceutical product. To develop a commercial infrastructure, we will have to invest financial and management resources, some of which would have to be deployed prior to having any certainty of marketing approval.

We had cash and cash equivalents of $8.6 million as of March 31, 2020. Our existing cash and cash equivalents as of March 31, 2020 will be used primarily to fund the Phase 3 trial of INOpulse for PH-ILD, to complete the dose escalation study for PH-Sarc. and to treat COVID-19 patients under the emergency expanded access.

On June 25, 2018, we filed a shelf registration statement on Form S-3 with the SEC, which became effective on July 6, 2018. The shelf registration allows us to issue, from time to time at prices and on terms to be determined prior to the time of any such offering, up to $100 million of any combination of common stock, preferred stock, debt securities, warrants and rights, either individually or in units.

On January 25, 2019, we completed the sale of 666,666 shares of our common stock at a public offering price of $10.50 per share, resulting in net proceeds of $6.2 million, after deducting placement fees of $0.5 million and other offering costs of $0.3 million. Such shares were sold pursuant to our effective shelf registration statement on Form S-3.

On April 1, 2020, we completed the sale of 1,275,000 shares of our common stock in a registered direct offering at an offering price of $12.00 per share, resulting in net proceeds of approximately $14.1 million, after deducting agent fees of $1.1 million and offering costs of $0.1 million. Such shares were sold pursuant our effective shelf registration statement on Form S-3.

Taking into consideration the cash proceeds from the April 1, 2020 registered direct offering, we evaluated whether there are any remaining conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.

Based on such evaluation and our current plans, which are subject to change as discussed below, we believe that our existing cash and cash equivalents as of March 31, 2020, proceeds received from the April 1, 2020 direct offering

and proceeds received in May 2020 and expected to become available upon future sale of our state net operating losses, or NOLs, and research and development (R&D) tax credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program will be sufficient to satisfy our operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q.

In April 2020, we submitted an IND to study the iNO delivery system for the treatment of patients infected with COVID-19. The IND was accepted by the FDA in May 2020, which allows us to initiate the Phase 3 study. We are currently reviewing our clinical plans for this program and in parallel, we have submitted for federal funding, through BARDA and NIH, to support the study. If we decide to incur additional costs related to the COVID-19 trial in the next 12 months in advance of receiving federal or other funding, our operating cash needs are likely to increase and our existing cash and cash equivalents as of March 31, 2020 may not be sufficient to satisfy our operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q.

The State of New Jersey's Technology Business Tax Certificate Transfer Program enables qualified, unprofitable New Jersey based technology or biotechnology companies to sell a percentage of NOL and R&D tax credits to unrelated profitable corporations, subject to meeting certain eligibility criteria. Based on consideration of various factors, including application processing time and past trend of benefits made available under the program, we believe that it is probable that our plans to sell our NOLs can be effectively implemented to address our short term financial needs. We have sold $21.2 million of state NOLs and $0.2 million of Research and Development credit under the State of New Jersey’s Technology Business Tax Certificate Transfer Program in May 2020 for net proceeds of $2.0 million and have sold $20.0 million of state NOLs for net proceeds of $1.7 million in January 2019. Subject to state approval and program availability, we plan to sell additional NOLs and credits under the same program in the future. The proceeds from such sales are recorded as income tax benefit when sales occur or proceeds are received.

We have based our estimates on assumptions that may prove to be wrong, and we may exhaust our capital resources sooner than we expect. In addition, the process of testing product candidates in clinical trials is costly, and the timing of progress in clinical trials is uncertain. Because our product candidates are in clinical development and the outcome of these efforts is uncertain, we may not be able to accurately estimate the actual amounts that will be necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Our future capital requirements will depend on many factors, including:


•	progress and cost of our clinical trials and other research and development activities;


•	our ability to manufacture sufficient supply of our product candidates and the costs thereof;


•	the cost and timing of seeking regulatory approvals;


•	the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution for any of our product candidates for which we receive marketing approval;


•	the number and development requirements of any other product candidates we pursue;


•	our ability to enter into collaborative agreements and achieve milestones under those agreements;


•	the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;


•	the cost of filing, prosecuting, defending and enforcing patent applications, claims, patents and other intellectual property rights; and


•	the extent to which we acquire or in-license other products and technologies.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and debt offerings, sales of state NOL and R&D credits, existing working capital, funding from federal programs subject to approvals, and funding from potential future collaboration arrangements. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences or rights such as anti-dilution rights that adversely affect the rights of our existing stockholders. If we raise additional funds through strategic partnerships in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, are unable to sell our state NOLs and R&D credits or obtain federal funding for the IND to study the iNO delivery system for the treatment of patients infected with COVID-19, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Cash Flows

The following table summarizes our cash flows for the three months ended March 31, 2020 and 2019:



	Three Months Ended March 31,
(Dollar amounts in thousands)	2020			2019
Operating activities	$	(4,336	)	$	(2,340	)
Financing activities	3,057			6,374
Net change in cash, cash equivalents and restricted cash	$	(1,279	)	$	4,034

Net Cash Used in Operating Activities

Cash used in operating activities for the three months ended March 31, 2020 was $4.3 million as compared to $2.3 million for the three months ended March 31, 2019. The change in cash used in operating activities was primarily due to the net proceeds received in 2019 from selling the 2018 New Jersey state NOLs and R&D tax credits of $1.7 million.

Net Cash Provided by Financing Activities

Cash provided by financing activities for the three months ended March 31, 2020 was $3.1 million, which included proceeds from warrant exercises. Cash provided by financing activities for the three months ended March 31, 2019 was $6.4 million, which included the proceeds from the January 2019 Public Offering.

Contractual Obligations and Commitments

There were no material changes in our outstanding contractual obligations from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

In the course of our normal business operations, we also enter into agreements with contract service providers and others to assist in the performance of our research and development and manufacturing activities. We can elect to discontinue the work under these contracts and purchase orders at any time with notice, and such contracts and purchase orders do not contain minimum purchase obligations.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to research and development expense, stock-based compensation and fair value of liability classified warrants. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

During the three months ended March 31, 2020, there were no material changes to our critical accounting policies. Our critical accounting policies are described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risk related to changes in interest rates. As of March 31, 2020, we had cash and cash equivalents of $8.6 million, consisting primarily of demand deposits with U.S. banking institutions. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in cash and cash equivalents. Due to the nature of our deposits and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our deposits.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2020. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2020, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the

Exchange Act) occurred during the fiscal quarter ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

We are currently not a party to any material legal proceedings.

Item 1A. Risk Factors.

Except as set forth below, here have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2019. For a further discussion of our Risk Factors, refer to the “Risk Factors” discussion contained in our Annual Report on Form 10-K for the year ended December 31, 2019.

Our business may be adversely affected by the COVID-19 pandemic.

The COVID-19 pandemic has affected our operations, and may materially affect our business. In response to the pandemic, we have limited operations, including implemented work from home and social distancing policies. For instance, our clinical trials may suffer from lower than anticipated patient recruitment or enrollment and we may be forced to temporarily delay ongoing trials in PH. In addition, we risk a delay, default and/or nonperformance under our existing agreements arising from force majeure. The extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.

In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, social distancing and business shutdowns. We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily requiring all employees to work remotely. We have already suspended non-essential travel worldwide for our employees and are discouraging employee attendance at other gatherings. These measures could negatively affect our business. For instance, temporarily requiring all employees to work remotely may induce absenteeism, disrupt our operations or increase the risk of a cybersecurity incident. COVID-19 has also caused volatility in the global financial markets and threatened a slowdown in the global economy, which may negatively affect our ability to raise additional capital on attractive terms or at all.

The extent to which COVID-19 may impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the severity of COVID-19 or the effectiveness of actions to contain and treat COVID-19, particularly in the geographies where we or our third party suppliers , contract manufacturers, or contract research organizations operate. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions. If we or any of the third parties with whom we engage, however, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial condition.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

The exhibits listed in the Exhibit Index to this Quarterly Report on Form 10-Q are incorporated herein by reference.

Exhibit Index



Exhibit Number		Description
31.1		Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2		Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended
32		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	BELLEROPHON THERAPEUTICS, INC.

Date: May 11, 2020	By:	/s/ Fabian Tenenbaum
		Fabian Tenenbaum
		Chief Executive Officer (Principal Executive Officer)


Date: May 11, 2020	By:	/s/ Assaf Korner
		Assaf Korner
		Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 blph03312010qexhibit311.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION

I, Fabian Tenenbaum, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Bellerophon Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: May 11, 2020	By:	/s/ Fabian Tenenbaum
		Fabian Tenenbaum
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 blph03312010qexhibit312.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION

I, Assaf Korner, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Bellerophon Therapeutics, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: May 11, 2020	By:	/s/ Assaf Korner
		Assaf Korner
		Chief Financial Officer
		(Principal Financial Officer)

EX-32 4 blph03312010qexhibit32.htm EXHIBIT 32 Exhibit

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer's knowledge, that:

(1) the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





Date: May 11, 2020	By:	/s/ Fabian Tenenbaum
		Fabian Tenenbaum Chief Executive Officer (Principal Executive Officer)





Date: May 11, 2020	By:	/s/ Assaf Korner
		Assaf Korner Chief Financial Officer (Principal Financial Officer)

EX-101.INS 5 blph-20200331.xml XBRL INSTANCE DOCUMENT 0001600132 2020-01-01 2020-03-31 0001600132 2020-05-08 0001600132 2019-12-31 0001600132 2020-03-31 0001600132 2019-01-01 2019-03-31 0001600132 us-gaap:CommonStockMember us-gaap:WarrantMember 2020-01-01 2020-03-31 0001600132 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001600132 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001600132 us-gaap:RetainedEarningsMember 2019-12-31 0001600132 us-gaap:CommonStockMember 2020-03-31 0001600132 us-gaap:RetainedEarningsMember 2020-03-31 0001600132 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001600132 us-gaap:CommonStockMember 2019-12-31 0001600132 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001600132 us-gaap:AdditionalPaidInCapitalMember us-gaap:WarrantMember 2020-01-01 2020-03-31 0001600132 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001600132 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001600132 us-gaap:RetainedEarningsMember 2018-12-31 0001600132 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001600132 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001600132 us-gaap:CommonStockMember 2018-12-31 0001600132 us-gaap:CommonStockMember 2019-03-31 0001600132 2019-03-31 0001600132 us-gaap:RetainedEarningsMember 2019-03-31 0001600132 2018-12-31 0001600132 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001600132 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001600132 2020-02-10 0001600132 2020-02-09 0001600132 2020-02-07 2020-02-07 0001600132 us-gaap:StateAndLocalJurisdictionMember 2019-01-01 2019-01-31 0001600132 2019-01-25 2019-01-25 0001600132 2018-07-06 0001600132 us-gaap:StateAndLocalJurisdictionMember 2018-02-01 2018-02-28 0001600132 us-gaap:SubsequentEventMember 2020-04-01 0001600132 us-gaap:SubsequentEventMember 2020-04-01 2020-04-01 0001600132 2019-01-25 0001600132 us-gaap:BuildingMember 2020-03-31 0001600132 us-gaap:PropertyPlantAndEquipmentMember 2020-01-01 2020-03-31 0001600132 us-gaap:PropertyPlantAndEquipmentMember 2020-03-31 0001600132 us-gaap:BuildingMember 2020-01-01 2020-03-31 0001600132 us-gaap:EquityMember 2019-03-31 0001600132 us-gaap:EquityMember 2018-12-31 0001600132 us-gaap:LiabilityMember 2019-03-31 0001600132 us-gaap:LiabilityMember 2018-12-31 0001600132 us-gaap:LiabilityMember 2020-03-31 0001600132 us-gaap:LiabilityMember 2019-12-31 0001600132 us-gaap:EquityMember 2018-01-01 2018-12-31 0001600132 us-gaap:LiabilityMember 2018-01-01 2018-12-31 0001600132 us-gaap:EquityMember 2019-12-31 0001600132 us-gaap:EquityMember 2020-03-31 0001600132 2017-05-15 0001600132 2017-05-15 2017-05-15 0001600132 2019-01-01 2019-12-31 0001600132 blph:PlacementAgentMember 2017-05-15 0001600132 2016-11-29 2016-11-29 0001600132 blph:PlacementAgentMember 2017-05-15 2017-05-15 0001600132 blph:Equity2016WarrantMember 2020-03-31 0001600132 2016-11-29 0001600132 2017-09-29 0001600132 2017-09-29 2017-09-29 0001600132 us-gaap:InvestorMember 2017-09-29 2017-09-29 0001600132 us-gaap:EquityMember 2019-06-28 2019-06-28 0001600132 2019-06-28 2019-06-28 0001600132 blph:Liability2016WarrantMember 2020-03-31 0001600132 us-gaap:InvestorMember 2017-05-15 2017-05-15 0001600132 us-gaap:FairValueInputsLevel2Member 2020-03-31 0001600132 us-gaap:FairValueInputsLevel3Member 2020-03-31 0001600132 us-gaap:FairValueInputsLevel1Member 2020-03-31 0001600132 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001600132 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001600132 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001600132 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001600132 srt:MaximumMember 2020-03-31 0001600132 srt:WeightedAverageMember 2020-03-31 0001600132 srt:MinimumMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001600132 srt:MaximumMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-03-31 0001600132 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001600132 srt:WeightedAverageMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001600132 srt:MaximumMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001600132 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001600132 srt:WeightedAverageMember 2019-12-31 0001600132 srt:MinimumMember 2020-03-31 0001600132 srt:MinimumMember 2019-12-31 0001600132 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001600132 srt:WeightedAverageMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-03-31 0001600132 srt:WeightedAverageMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001600132 srt:MaximumMember 2019-12-31 0001600132 srt:WeightedAverageMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001600132 srt:MinimumMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-03-31 0001600132 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001600132 srt:WeightedAverageMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001600132 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001600132 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001600132 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001600132 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001600132 blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2020-03-31 0001600132 srt:MaximumMember blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2019-12-31 0001600132 blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2019-12-31 0001600132 srt:MinimumMember blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2020-01-01 2020-03-31 0001600132 blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2020-01-01 2020-03-31 0001600132 srt:MaximumMember blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2020-01-01 2020-03-31 0001600132 srt:MaximumMember blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2020-03-31 0001600132 srt:MinimumMember blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2020-03-31 0001600132 srt:MinimumMember blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2019-12-31 0001600132 blph:IkariaEquityIncentivePlansPriorTo12February2014Member 2019-01-01 2019-12-31 0001600132 blph:Bellerophon2015EquityIncentivePlanMember 2019-12-31 0001600132 blph:Bellerophon2015EquityIncentivePlanMember 2020-01-01 2020-03-31 0001600132 blph:Bellerophon2015EquityIncentivePlanMember 2020-03-31 0001600132 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001600132 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001600132 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001600132 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001600132 blph:BellerophonEquityIncentivePlansMember 2019-01-01 2019-03-31 0001600132 srt:MaximumMember blph:Bellerophon2015And2014EquityIncentivePlanMember 2020-03-31 0001600132 blph:Bellerophon2015And2014EquityIncentivePlanMember 2019-01-01 2019-12-31 0001600132 srt:MaximumMember blph:Bellerophon2015And2014EquityIncentivePlanMember 2020-01-01 2020-03-31 0001600132 blph:Bellerophon2015And2014EquityIncentivePlanMember 2020-01-01 2020-03-31 0001600132 srt:MaximumMember blph:Bellerophon2015And2014EquityIncentivePlanMember 2019-12-31 0001600132 blph:Bellerophon2015And2014EquityIncentivePlanMember 2019-12-31 0001600132 srt:MinimumMember blph:Bellerophon2015And2014EquityIncentivePlanMember 2019-12-31 0001600132 srt:MinimumMember blph:Bellerophon2015And2014EquityIncentivePlanMember 2020-03-31 0001600132 blph:Bellerophon2015And2014EquityIncentivePlanMember 2020-03-31 0001600132 srt:MinimumMember blph:Bellerophon2015And2014EquityIncentivePlanMember 2020-01-01 2020-03-31 0001600132 2019-05-14 0001600132 2017-05-04 0001600132 blph:BellerophonEquityIncentivePlansMember 2020-01-01 2020-03-31 0001600132 srt:MinimumMember 2020-01-01 2020-03-31 0001600132 srt:MaximumMember 2020-01-01 2020-03-31 0001600132 blph:BellerophonEquityIncentivePlansMember 2020-03-31 0001600132 us-gaap:StateAndLocalJurisdictionMember us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 0001600132 us-gaap:ScenarioForecastMember 2020-01-01 2020-12-31 0001600132 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001600132 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001600132 us-gaap:WarrantMember 2020-01-01 2020-03-31 xbrli:shares blph:integer iso4217:USD blph:lease xbrli:pure blph:period blph:subsidiary iso4217:USD xbrli:shares 2117000 1785000 P6M P6M 21200000 20000000 21200000 200000 200000 1 1 100000000 2 3 6200000 14100000 2000000 1700000 2000000 333333 200000 199.20 223.65 7.35 116.55 199.20 124.05 7.35 116.55 199.20 223.65 7.35 116.55 199.20 223.65 7.35 116.55 100000 0 0 0.00 6.00 0 16666 138000 0 500000 1100000 700000 274000 0 0 274000 1168000 0 0 1168000 254760 0 254760 P5Y P5Y P5Y P2Y 1142838 4000 66666 1296650 839899 false --12-31 Q1 2020 2020-03-31 10-Q 0001600132 6132393 Yes true true Non-accelerated Filer Yes Bellerophon Therapeutics, Inc. false true

3106000

2220000

1703000

2101000

193308000

196830000

1008000

468000

1008000

697000

311000

468000

389000

79000

666444

6666

2028626

13108000

11578000

10382000

9047000

9874000

8595000

17046000

21080000

10277000

8998000

4034000

-1279000

12.00

28.125

1296650

986736

1296650

986736

2136549

146837

661310

585139

76171

1881789

146837

0.01

125000000

200000000

3911857

4593674

4580127

4857393

4580127

4857393

69053548

4603460

46000

49000

88000

46000

-0.18

-1.08

-0.18

-1.08

0.000

2700000

P2Y4M24D

-1616000

894000

2037000

1872000

-2596000

-4970000

-1800000

-1801000

-727000

-830000

298000

-56000

130000

34000

2328000

205000

783000

770000

570000

170000

P5Y

P90D

P4Y

9517000

9432000

13108000

11578000

7584000

6775000

6374000

3057000

-2340000

-4336000

-795000

-4970000

4342000

4110000

-4342000

-4110000

153000

177000

2158000

658000

669000

1659000

1489000

161000

187000

2110000

1961000

0.0498

0.0494

P4Y

P3Y

300000

100000

0.01

5000000

405000

349000

6374000

3057000

3100000

316000

270000

2305000

2238000

103000

300000

-189763000

-194733000

1008000

468000

P4Y

P1Y

6.00

P8M12D

6.00

0.8295

0.0251

23332

6666

454362

333333

833333

295768

3268

39.48

124.54

325

195

9.30

400000

663501

3463

663176

3268

24.15

124.21

24.15

124.54

32.41

118.55

P6Y

P2Y3M18D

P7Y1M6D

P2Y1M6D

P8Y3M18D

P8Y

22.50

18.63

10.5

12.00

666666

1275000

666666

254760

15151

23332

826

6236000

6229000

7000

3054000

3000

3057000

3856000

180313000

39000

-176496000

10305000

187550000

46000

-177291000

3591000

193308000

46000

-189763000

2146000

196830000

49000

-194733000

0.0667

6965000

5349000

274000

1168000

1.0905

0.0161

1.0474

0.0157

1.0700

0.0159

1.8749

0.0027

1.4976

0.0021

1.6986

0.0024

P2Y10M24D

P1Y10M24D

P2Y4M24D

P2Y7M6D

P1Y8M12D

P2Y1M6D

4346109

4615046

4346109

4615046

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Warrants and Warrant Liability</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for common stock warrants issued as freestanding instruments in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of the warrant agreement.  The Company classifies warrant liabilities on the consolidated balance sheet based on the warrants' terms as long-term liabilities, which are revalued at each balance sheet date subsequent to the initial issuance. Changes in the fair value of the warrants are reflected in the consolidated statement of operations as “Change in fair value of common stock warrant liability.” The Company uses the Black-Scholes-Merton pricing model to value the related warrant liability. Certain assumptions used in the model include expected volatility, dividend yield and risk-free interest rate. See Note 6 - </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;"> for a description of these assumptions.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bellerophon 2015 and 2014 Equity Incentive Plans</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2014, the Company adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which provided for the grant of options. Following the effectiveness of the Company's registration statement filed in connection with its IPO, no options may be granted under the 2014 Plan. The awards granted under the 2014 Plan generally have a vesting period of between </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2015, the Company adopted the 2015 Equity Incentive Plan, or the 2015 Plan, which provides for the grant of options, restricted stock and other forms of equity compensation. On May 4, 2017, the Company’s stockholders approved an amendment to the 2015 Plan to increase</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">the aggregate number of shares available for the grant of awards to </font><font style="font-family:inherit;font-size:10pt;">333,333</font><font style="font-family:inherit;font-size:10pt;"> and to increase the maximum number of shares available under the annual increase to </font><font style="font-family:inherit;font-size:10pt;">200,000</font><font style="font-family:inherit;font-size:10pt;"> shares. On May 14, 2019, the Company's stockholders approved an additional amendment to the 2015 Plan to increase the aggregate number of shares reserved for issuance under the 2015 Plan from </font><font style="font-family:inherit;font-size:10pt;">333,333</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">833,333</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">454,362</font><font style="font-family:inherit;font-size:10pt;"> shares available for grant under the 2015 Plan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation expense related to unvested stock awards. This expense is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.4</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> tax benefit was recognized during the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> related to stock-based compensation expense since the Company incurred operating losses and has established a full valuation allowance to offset all the potential tax benefits associated with its deferred tax assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant-date fair value of options issued during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$9.30</font><font style="font-family:inherit;font-size:10pt;">. No options were granted in the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">. The following are the weighted average assumptions used in estimating the fair values of options issued during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:42.1875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation assumptions:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.95</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of option activity under the 2015 and 2014 Plans for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> is presented below: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Bellerophon 2015 and 2014 Equity Incentive Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">663,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of March 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">663,176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and exercisable as of March 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of options outstanding, vested and exercisable as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All restricted stock awards granted under the 2015 Plan during the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> were in relation to director compensation and vested in full by December 31, 2020 subject to certain terms and conditions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of restricted stock activity under the 2015 Plan for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> is presented below: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Bellerophon 2015 Equity Incentive Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding as of March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Ikaria Equity Incentive Plans prior to February 12, 2014</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Options</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of option activity under Ikaria incentive plans assumed in 2014 for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, is presented below:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ikaria Equity Incentive Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.05</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of March 31, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and exercisable as of March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223.65</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of options outstanding, vested and exercisable as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense, Net of Estimated Forfeitures</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the stock-based compensation expense by the unaudited condensed consolidated statement of operations line items for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">468</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the weighted average and the range of assumptions used in estimating the fair value of warrants outstanding (weighted average calculated based on the number of outstanding warrants on each issuance) as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation assumptions:</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149.76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187.49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169.86</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of operations in the same line item as expenses arising from fixed lease payments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and 2019 were de minimis.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information related to the Company's right-of-use asset and related lease liability were as follows ($ amounts in thousands):</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three months ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for operating lease liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.94</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of the lease liability as of March 31, 2020 were as follows :</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less imputed interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Adopted</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which eliminates, adds and modifies certain disclosure requirements for fair value measurements. The standard requires the disclosure of the range and weighted average used to develop significant unobservable inputs and how weighted average is calculated for recurring and nonrecurring Level 3 fair value measurements. The amendment is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted ASU 2018-13’s during the quarter ended March 31, 2020 by including disclosure on the range of inputs used to calculate the Company's Level 3 fair value measurements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of option activity under Ikaria incentive plans assumed in 2014 for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, is presented below:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ikaria Equity Incentive Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.05</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of March 31, 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and exercisable as of March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223.65</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes fair value measurements by level at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> for liabilities measured at fair value on a recurring basis (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The following table summarizes fair value measurements by level at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> for liabilities measured at fair value on a recurring basis (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the stock-based compensation expense by the unaudited condensed consolidated statement of operations line items for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">468</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of option activity under the 2015 and 2014 Plans for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> is presented below: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Bellerophon 2015 and 2014 Equity Incentive Plans</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">663,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(325</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of March 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">663,176</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and exercisable as of March 31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the weighted average assumptions used in estimating the fair values of options issued during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:42.1875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation assumptions:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.95</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of restricted stock activity under the 2015 Plan for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> is presented below: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Bellerophon 2015 Equity Incentive Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,332</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding as of March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes warrant activity for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;"> (fair value amount in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Classified</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability Classified</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,136,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(254,760</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of common stock warrant liability recognized in consolidated statement of operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding as of March 31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,881,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:174%;padding-bottom:6px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes warrant activity for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> (fair value amount in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Classified </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability Classified</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding as of December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,296,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">986,736</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of common stock warrant liability recognized in consolidated statement of operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants outstanding as of March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,296,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">986,736</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 6 blph-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2111100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Common Stock Warrants and Warrant Liability link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Common Stock Warrants and Warrant Liability - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Common Stock Warrants and Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Common Stock Warrants and Warrant Liability - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Fair Value Measurements - Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Net (Loss) Income Per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Nature of the Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization and Nature of the Business (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Right of Use Assets and Leases link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Right of Use Assets and Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Right of Use Assets and Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Right of Use Assets and Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Stock-Based Compensation - Allocation of Recognized Period Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Options Issued (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 blph-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 blph-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 blph-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Nature of the Business Nature of Operations [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Option Employee Stock Option [Member] Restricted Stock Restricted Stock [Member] Warrant Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Income Statement [Abstract] Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense (Excluding Acquired in Process Cost) General and administrative General and Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Change in fair value of common stock warrant liability Fair Value Adjustment of Warrants Interest and other income, net Investment Income, Interest Pre-tax loss Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Net loss Net Income (Loss) Attributable to Parent Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Net loss per share: Earnings Per Share, Basic and Diluted [Abstract] Basic (in usd per share) Earnings Per Share, Basic Diluted (in usd per share) Earnings Per Share, Diluted Common Stock Warrant Liability [Abstract] Common Stock Warrant Liability [Abstract] Schedule of warrant activity Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Bellerophon 2015 and 2014 Equity Incentive Plans Bellerophon 2015 And 2014 Equity Incentive Plan [Member] Represents information pertaining to the Bellerophon 2015 and 2014 equity incentive plan. Ikaria Equity Incentive Plans Ikaria Equity Incentive Plans Prior To12 February2014 [Member] Represents information pertaining to the Ikaria Equity Incentive Plans which existed prior to February 12, 2014. Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options outstanding as of beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options outstanding as of end of period (in shares) Options vested and exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Range of Exercise Price Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price [Abstract] No definition available. Options outstanding as of beginning of period, Exercise Price (in dollars per share) Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price The exercise price for purposes of disclosing shares potentially issuable under outstanding stock option awards. Options forfeited, Exercise Price, (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Exercise Price Exercise price underlying shares with respect to stock options that were terminated. Options outstanding as of end of period, Exercise Price (in dollars per share) Options vested and exercisable, Exercise Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Exercise Price Exercise price at which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Weighted Average Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options outstanding as of beginning of period, Weighted Average Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Forfeited, Weighted Average Price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options outstanding as of end of period, Weighted Average Price (in dollars per share) Options vested and exercisable, Weighted Average Price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options vested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Bellerophon 2015 Equity Incentive Plan Bellerophon2015 Equity Incentive Plan [Member] Represents information pertaining to the Bellerophon 2015 Equity Incentive Plan. Shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Restricted stock outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Restricted stock granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Restricted stock forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested Restricted stock outstanding, end of period (in shares) Weighted Average Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract] Beginning of period, weighted average fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Outstanding in Period, Weighted Average Fair Value The weighted average fair value of vested and nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Restricted stock granted, weighted average fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted stock forfeited, weighted average fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value End of period, weighted average fair value (in usd per share) Aggregate Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Restricted stock beginning of period, aggregate grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Outstanding in Period, Aggregate Grant Date Fair Value Aggregate grant date fair value of outstanding restricted shares. Restricted stock granted, aggregate grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Granted in Period, Aggregate Grant Date Fair Value Aggregate grant date fair value of restricted shares granted Restricted stock forfeited, aggregate grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested in Period, Aggregate Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested in Period, Aggregate Grant Date Fair Value Restricted stock end of period, aggregate grant date fair value Weighted Average Remaining Contractual Life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Restricted stock, weighted average remaining contractual life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Statement of Financial Position [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred tock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Bellerophon Equity Incentive Plans Bellerophon Equity Incentive Plans [Member] Represents information pertaining to the Bellerophon Equity Incentive Plans. Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted stock outstanding Stock-Based Compensation Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Number of shares available for grant (in shares) ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateNumberOfSharesAvailableForGrant ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateNumberOfSharesAvailableForGrant Maximum annual increase number of shares available for grant (in shares) Share Based Compensation Arrangement By Share Based Payment Award Maximum Annual Increase Number Of Shares Available For Grant Share Based Compensation Arrangement By Share Based Payment Award Maximum Annual Increase Number Of Shares Available For Grant Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted-average period unrecognized compensation expense is to be recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Tax benefit recognized related to stock-based compensation expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Weighted average grant-date fair value of options issued (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Options, outstanding, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options, exercisable, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative General and Administrative Expense [Member] Stock-based compensation expense by condensed consolidated statement of operations and comprehensive loss line item Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Allocated share-based compensation expense Allocated Share-based Compensation Expense Leases [Abstract] Right of Use Assets and Leases Lessee, Operating Leases [Text Block] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Public offering (in shares) Stock Issued During Period, Shares, New Issues Shares Issued, Price Per Share Shares Issued, Price Per Share Proceeds from issuance of common stock, net Proceeds From Issuance Of Common Stock, Net Proceeds From Issuance Of Common Stock, Net Underwriting discounts And commissions Underwriting Discounts And Commissions Underwriting discounts and commissions that were deducted from the gross proceeds of the offering. Payments of stock issuance costs Payments of Stock Issuance Costs Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Assumptions used in estimating the fair value of options issued Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of option activity Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of restricted stock activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Summary of stock-based compensation expense by the condensed consolidated statement of operations line item Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Document and Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Interactive Data Current Entity Interactive Data Current Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Class of Warrant or Right [Table] Class of Warrant or Right [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Investor Investor [Member] Placement Agent Placement Agent [Member] Placement Agent [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Equity Classified Equity [Member] Equity, 2016 Warrant Equity, 2016 Warrant [Member] Equity, 2016 Warrant [Member] Liability, 2016 Warrant Liability, 2016 Warrant [Member] Liability, 2016 Warrant [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Warrants issued (in shares) Warrants Issued Warrants Issued Warrants expiration Warrants Expiration Warrants Expiration Exercise price of warrants (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of warrant, outstanding (in shares) Class of Warrant or Right, Outstanding Period of time after issuance date before exercisable Class Of Warrant Or Right, Period Of Time After Issuance Date Before Exercisable Class of Warrant or Right, Period of Time after Issuance Date before Exercisable Price to the public (in dollars per share) Extension term Warrants Expiration, Extension Term Warrants Expiration, Extension Term Warrant amendment charge Warrant Amendment Charge Warrant Amendment Charge Warrants exercised (in shares) Warrants Exercised Warrants Exercised Proceeds received from exercise of warrants Proceeds from Warrant Exercises Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Building Building [Member] Property, Plant and Equipment Property, Plant and Equipment [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Number of operating leases Number Of Operating Leases Number Of Operating Leases Term of contract Lessee, Operating Lease, Term of Contract Number of renewal periods Lessee, Operating Lease, Term of Contract, Number Of Renewal Periods Lessee, Operating Lease, Term of Contract, Number Of Renewal Periods Renewal term Lessee, Operating Lease, Renewal Term Cash paid for operating lease liability Operating Lease, Payments Operating lease expenses Operating Lease, Cost Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Operating leases Operating Lease Liabilities, Payments Due [Abstract] 2020 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four EX-101.PRE 10 blph-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R27.htm IDEA: XBRL DOCUMENT

Common Stock Warrants and Warrant Liability - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		12 Months Ended
	Jun. 28, 2019	Sep. 29, 2017	May 15, 2017	Nov. 29, 2016	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jan. 25, 2019
Class of Warrant or Right [Line Items]
Warrants issued (in shares)				1,142,838
Warrants expiration		5 years	5 years	5 years
Exercise price of warrants (in usd per share)				$ 12.00
Class of warrant, outstanding (in shares)					661,310
Period of time after issuance date before exercisable		6 months	6 months
Price to the public (in dollars per share)		$ 18.63	$ 22.50						$ 10.5
Extension term	2 years
Warrant amendment charge							$ 700
Warrants exercised (in shares)					254,760
Proceeds received from exercise of warrants					$ 3,057	$ 0
Equity Classified
Class of Warrant or Right [Line Items]
Warrants issued (in shares)	839,899
Class of warrant, outstanding (in shares)					1,881,789	1,296,650	2,136,549	1,296,650
Warrants exercised (in shares)								254,760
Equity, 2016 Warrant
Class of Warrant or Right [Line Items]
Class of warrant, outstanding (in shares)					585,139
Liability, 2016 Warrant
Class of Warrant or Right [Line Items]
Class of warrant, outstanding (in shares)					76,171
Investor
Class of Warrant or Right [Line Items]
Warrants issued (in shares)		1,296,650	66,666
Placement Agent
Class of Warrant or Right [Line Items]
Warrants issued (in shares)			4,000
Exercise price of warrants (in usd per share)			$ 28.125

XML 12 R23.htm IDEA: XBRL DOCUMENT

Organization and Nature of the Business (Details)	Mar. 31, 2020 subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of subsidiaries	3

XML 13 R7.htm IDEA: XBRL DOCUMENT

Organization and Nature of the Business

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of the Business

The Company’s business is subject to significant risks and uncertainties, including but not limited to:


•	The risk that the Company will not achieve success in its research and development efforts, including clinical trials conducted by it or its potential collaborative partners.


•	The expectation that the Company will experience operating losses for the next several years.


•	Decisions by regulatory authorities regarding whether and when to approve the Company’s regulatory applications as well as their decisions regarding labeling and other matters which could affect the commercial potential of the Company’s products or product candidates.


•	The risk that the Company will fail to obtain adequate financing to meet its future operational and capital needs.


•	The risk that the Company will be unable to obtain additional funds on a timely basis and hence there will be substantial doubt about its ability to continue as a going concern.


•	The risk that key personnel will leave the Company and/or that the Company will be unable to recruit and retain senior level officers to manage its business.

•

XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	125,000,000
Common stock, shares issued (in shares)	4,857,393	4,580,127
Common stock, shares outstanding (in shares)	4,857,393	4,580,127
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred tock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

ZIP 16 0001600132-20-000059-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001600132-20-000059-xbrl.zip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
Z+!9_>560J>!"[P+/-W^VV!;Y$KV0.FMZ M>G=3M7_NDD)B(8QQS6&X[(@WK?8%)^EJR/VR)8'H#'3TITD_O_LO4$L#!!0 M ( !V JU#64D!/1P\ .B< 5 8FQP:"TR,#(P,#,S,5]C86PN>&UL M[5U;<]LXLGZ?7^'C?<88=Q!3D]ER8N<<5V635#)S9O>)!0*-F&=DT4-*B;V_ M_C0EV4EL76B1@N2IS8,L*KAT?_B 1J,!\.>_WUR-CCY#W935^,4Q^Y$>'\'8 M5Z$'G_R+DGR\_O#DZJ_ST"L:3HUQKJZ.?J_J/\K/CI!YIJ/9EU$Y_N.G]J-P#1S=-.5/C;^$*_>F M\FXRJ_MR,KG^Z>3DRYC'JOYTPBD5)_>Y5J9HG\A=,M+^1!@G@OUX MTX3C(]1PW,SJ[E#)7?*;1^F_B%EJ9JT]F?WO?=*F7)80BV4G__S'FX\S/4DY M;B9N[.'XEQ^.CN9PU-4(/D \:O_^]N'BNT(*&(V@KJXOJ_&/OKHZ:=.5E#?'%H0PG/24LQI_G%3^C]]=7;MYI8NO;TI7E*-RK4 -N7FEJ[7UTQZD:JIY:56I/%\ZE'5/%QT-9:7_:0FHX#C!MH^VU3 MC DPZZ-.UA)12OW^B4^G9H#2NN7P]JKYLQ[JU)274XMTU MU+.I1W\U'AX21][RG3;-].IZUFZ_8>MV- U;%+5C/>Y__)\2>5C[RZY6;KO2 M=JQ-MZE'AZS#R7F!'M$5_.IN-LNU).E.Y.C8PJMS#"?5FQ(-4>A@Y1XEW($, M'7%9E7XXB=["9 [^FZIIWD/]\1)G)YO$6IMI4-G:"N95W55S&A /',#S MYQVS#R?OS)-ZZ6:S^JMKG-YWFE&OS[5KZ4Y'H\5RZ;OX 7SU";L^!!QORPK3 M-9.NS!ZF]%UK^]05MJ>5LFOI/TZOKEQ]^R[>SU1;/W'F(5R@L]#9W1BF]&3: MSH5XXFI;GS*3:?8!FDE=^IGKCPF'5;%;X;O6M=M0W27O@)).BP;^G*)[=_ZY MRX+"JO2[DZ@K ]9G&U*^!:D^ECB$Q]+/EJA]-9W%?-Y7H[)+P.AII:26OC/F M6Q266I=A6Z1SRWB>Q)J&7#])Y$Z1(]VX%H3PN$W0O05G\G ,Z3O^NKBTIG.PJB:XI9_'_:D$_. M79]PRK(3&$V:NU](^PNA;+%!X6^+G_.YXW-7_BJO](\9\ MOR5DD>*D:[1R\5 MH][7<.W*<'[3.J& FKR;7$+=U0!UR)U[L)1)YPEU7A(-@9-"B4@"IU$$7 M2IGLAN2T4DT(%8K*"$DU=("I@#Q)2>*/!%2+8 MYS'J])K2[!2Q5-Q9;/ 9?YK%)![$*M;096V^7/&HM&% E "-^BKLAE8!T460 M3,:0Z8>!FD,=77HQ9&B0TIF?"B6?W+X?N?D6*R3U=;LF\G8M)]9ERZ,P+M", M$F^,(VA<%?%6:"(R6S#M"B\YW9X2\KE08F",4C'B;FFCA':]8_5>S26LV)0U MUR)C)DA*HE&61&<]DG"46"64++2DP [>>]LI$?J!M8>&W^R;/4Z<\^"+(@ GEDF-[D3AB(G:HQ%@ MA!I+;6ZQ;>')U7#+T)4S7MWV\8>?JU=@ [+PZMSY0H-O=8B M$#!.$X[C&0E12=35"B.,,9X_)RILU80/%XX'A6LS-1Y')]M?6C'J*03T^:#= M.8YCW1E\AE$UF[LM:>W-F7(AO75 '2F<](0:_$:Q@Y BBX&QR*RG[AD-_WT: M>R=H)1P&6KF?9 96YLDSR7GD./.7-$/G@G%!"BL4B8(Q!90+V\<:I'&=AQ\" M!@-K/^LJ]Y'AS(SVW/\[+<5OS)L;X%F(D9/@M"",SXL'P*PB#8)9L M[\G7S64;MYD\2)H[B" B15T*D$05F2#6:8F4-R9DP)4(X= ]Q[Z-M609L2=& MR5R(^P.%[UT9+L:OW'4Y^7K3PS('8GF.7*-)S 1W)-,,^XG) BD8CJ3":B4$ M BAI#QZDF34,S(/AH$H7T)^X<@SAW-5C-&P-.D#3J[8UVM,OL?3E^D#^ILRY MPYFP5PZ(%JBOQP#0$>!%L%/C)]:&;C8%)LA/4'O-EGV[7#H;7741I?CYY MB-0;?$ZU1WK-33MI=FQO/-N1\_\,W*>='/R_& MOFY]AC.8_\7GT;2]'_#\QL^@_X *G\<(?MUXFU:0W!HI@L*I2XCM4.0 I\1, M".RW( 0+T5CN]QY M3$66^U7'T_!_TV8R-\QW1[_6$&9MOIP'I44TGEBO-9'>%\1:Y8FR^$-&G9*B MQ^[K-%Y:(M(,#62RI;WVHJ"5]VDL6]Y;FB&WU!<>.P")2BFB)36D$(4D!2^B MRZ2WD?4X/Y;&5TM$E<$03,61QV9[<1 !74ZH:UA^(&$-A[8K,*<@F?XD2P;Q_DCX8,L-:O(X O\D$G8I,+?,"R4# M(X%ED5#%@&38<]O)J:<,YP6%[;%RJ?Y* UTRA%-Q\+O; ==[AE_3Y8Y1 ,0",O@>%V.W=CW7#]84D@>,LL, M<$FH#@$_T 5QW%("DFMO,JM '?Q$_/FO'PS3,@E/1WF T+S&EFBO)&L7C]_% M;Z*-:ZBY,6^NP6>%SX 4/EB<'KA 0H9 <\^C0WB#[7-.:J_K";V;^?%9JL'! MW >)%M[L^0W4OFS6#FWKLN7<1D^]CR1H5%E8STB&(SSA.-%D,O*B8#W">GM= M5=@E=0; <8_1JRZW]2<,R^QW)K:1SBES\"O=+B%4-WUQ)?GXS MJ1UV'*1M?7N!#30[#8XYL2%1OD\7XPG4:)/7NU&[JC67(2MT8!;-MVK[CW.H MNS'$,RHRG&1R&@X^;-*#08_=J0-".OD.U4[]=4GJ7/G,4F4H499*8JS)T,0& M_%"%U<%'J?KL14_#HH-I^U6[6GOAG9Q+B\6O3DRZ2YL['J6/B).23A!OO2*V M:.VM*(S&G@R\S_(C2[/\V+O!5A&@!TP)+Z!9!-)!"8SG F).1 E$K!J.T8\/BV MFH1HIF+>?\,801JUZYWAJAR7S61^,>E"KS7LVI S=]IF6G-/%'H!"'-FB,TB M$,IEIGQP*HL]XFYIG*EA&30\8O\)XG=BR"[-UJ'.?YYKV/]B_!GFXLX1Z^3H M+<^2JXB]ABH@JJ"!F,@I88P%_% !O#0 1:>M?OL,_1\JOP8$/6&@=@[18L!] MB>-Q7'L48$6.W*)3[$ 95"^31 9GB?.N(!J=:*4YE98/BH9(U0&23(1<'(B>.98I_UM>T3B URY$INF M?A=?EPTRXE_@ZK[8+"TT1TP0IMF%7A;1XEX3830C'C@$&GE4]/ OR=P)-1[> MF)<2XU2N3E?D6C5^_5(-T#T7)>6 >E-F='L2!0AP&XDKJ"4JDPZ[+_H'%P(13,FC'IY?F9Q !"G4IR=L7-VSLTI/Q7/>9+^VSC@ MU*X]!=*>06ICMZ=7[=.VN*TJ;S.(H7!2<# $ $$$&CPQ+ LD2AV!:Q%!_G7F M[L-2ZBE#4,H&VO.UB5VV$WV?HT.[,)-)KR.1[;%0%RTGF ?;)6:&,F],U#VV MB!S83'^G+$W8!'LVF$F6UY>_A7POE9Z.9IS';^V+W'WU:5S^&\+\S%"[,RC1 MNN5RX1*_A7C#>^[OPS'M-OQ97*H]DI(J,K5!N+E$:=]'O$&DKR?29@D/0;8T MO7M:-/#GM-U[]SE!\/1A=8GP[?1"]X,0XI Z0#,PNRU'P7R]Y9X]QOTQ,SP:NN][P6 [;W;/GJ8(F2Q)/4Z2ZBO1E M?OT!BBQ:DGDIUHU%=4_TR!)9*&1^F0 2B43FW__SZ]WLQ>+^<\_P;^" MGUZD\_%B,IW?_/S3+Q]>J@_F]>N?_O,??_G[_WGY\G_U^S?KB:S[]6SZ^3>]&;Q;CT;+H^W:YO/_;JU=?OGSYZ]=/V>ROB^SF%0( O]JV MVOM$_.ME^=C+^-%+B%YB^->O^>2G%X'#>5[T7:&3\O'X[62Y;?#P8?IJ_>7V MT1]>_047ST(IY:OBV^VC^737@^&E\-7__O/-AP*2E]-YOAS-Q^E/__C+BQ=K MY++%+'V?7K^(__[R_O6CEWQ*9[,T6]S?+N9_'2_N7L5G7IG%W=UT&>64J_G$ M+.;+(-$@V6F:!V**=]YFZ?7//WV:W=\&R"((:\#^HT+3Y;?[].>?\NG=_2P@ M]JHAG8OYA^5B_-N_1EDV6G>Z^?7-=/1I.ILNOU4AN?I;^J;^;?Q[.?VKTCK\[C8YG4_2>9[&<9LO M9M-)G*+U:!;GDP^W:;JLP$_5-_1)];M1%B:DVW0Y'8]FS5G8^;J.^?FP##_C MM'IU;6Y'84K-7Z_5YG8QFX05V/V^JC35-7YU7WSF@9I1?NMGBR_UM.[@FWKD MXNH^S0HKI3D;/[ZJ/3Y*RRQ,/RXLVLMOK^?7B^RNZ.X8X57:MD>I'TVS7T>S M5?K/=)2OLC4XQT@\V*ACVE2>K^[N"[G]$J1;<6FH\:J.^=A^^-_3H(?9^+;J M*E?O;1US4\WTJ-"T/3I?A\W37?IQ]/4X73L>[82.BA+>WZ(]JMY,PT(TJ;#* M_?!@!S14Q&7?\^U1]#9=KL%_L\CS=VGVX398)\?(.MBH5=IB!^NNRF[4). 1 M)K#1[,$J41'.VB]LCZ>K[&8TG_Z[Z"2L=V]'RS K7%WK53Z=I_E1#BHV[XW> MBL"?]I;VJ'\_O;D-=FE8Z\+*EQ:;HS=A(CX^/QYMV .-%;&MVKX'BJNMB16; MMT=OL1O1H\(ROKL/)G(EJ_1PJZZI4[/9QCMY=?T^'2]NPO!))V'.FB["<_FR MJG:T\_:NN3W52W7:6[JF_L/J[FZ4?;NZWEI[<:]56-FO@\%=V61OY^V]<;LF MXD2/59-W]L;9^S1?9M-QL7T.#[;+8K67=\UKM:FZ2ML6*5U]RM/?5V&+Y#Y7 MV93O>[X[BJIJP.%F;=*W4:H/TS"%7T_'A9MWO%@5YR;O%K-IE4.7T][2-_65 M,:_QLKYY:5O)M.[5YMG7HUF3[S=>TXPRT/) M>/I)"_H?M&R;J/![F(?"+/1RDEZ/5K-E31+WOJ=#@A=WH^F\.;V/7M,ZN<7; M7]ZE=Y_2K"ZMN][1-J&WX7W9>/4I?;F%IB:Y!]ZTE^B@---YX3=X$_[C_%,A_E7^ M\F8TN@]J ,6K=+;,RT]>QD]> K@)W/B/S<>)F8WR_.IZ0]]55NQ= ]/IZV5Z MMR5K-@J\_OQ3("&IUC#15"@G!:-8(68EI) K*:2 #C$*-7G,<+%96V0;&9R! MX\+B.Y7;HE%B%-1.6,2TM]QKC+"'&TZ)9!Y7X?2[OJEL_&*13=+LYY]@V7(S M(9RTGL5@H6X$MN@(F[!L2^1Q.J$-:$*0R0 M1<)B3CTIV5?$]:D8!Q: BHIRHD07K6)3J$9'4GZ?WJ^R\6W8 JJ;+"U4ZRG% M]I$]\D3TE=LGRBNM* )6>P DE%+AK%7AOQNU8T%^&B/[#^ M&(IR'@5YQ-O@]:,5O3C9MG@]_YSF01C_?+0QV&%//'XP@5 'L#1R3E(5V'*$ MF0TWE#.+^I3XKJW-8W%W(*5%B_ <%_:/_HCX2?)N-AH7W*BP6UGNE>'>9Q,- M.;4*.F,\A*/A6D8)A& M7XORJZ(1C;!ZOKHQ*#MOF"IQ'E581WP?-?(>/I8X;!$45OE@NP0[1L=5L/2O MA&FUOFW0NHG7JEP6K4%2VZQ;]QE$R3:L'+;L]CR> .:50(I1QIU5S!JMM@XR M(*0:CG'7A0!;A*:V(+?>\\JRW-\BD=H023!SQ'(K3:!<\Y)F0V%]<>*+$6=K MZ-26:'E"LH[SV2?%QT\E4KKHJL: 8< 9X.'7DE>N%>07,I/6=[TW!Z6QP-S7 M^VGV*%YPG]"^/YEX8+TS'F)%J-:,2B!E22/WT%W(#-J2X&H#/5_)@=X50M>M TP0[!,)8T@)@2YPS O-R&<.Q@_6,W\AP4ICY2 MM=>,G72L0[&OKC^&C:>Z7J997,?B%6([6J8ZO5YDZ4:W]YS,M_7J.$( 5Y@A M@P@@ !&LREV(8-S47Y7HA>C+F9#L:ZXI[D!MS*1BFGQZGVO')+.W38(] 8HP M;!03E /!B-0EC\9S75M;V(5H2]L0M6B*NA@V%9U8']/LKKI=^JA9@@S0!@&I M/!%6*(2Y$R7U@2M86\#\0@3< 4I-9:SNTOFD.)\*"G:S=S78_70"D6(:6LVC M.F)JM)/E,B>G2OOWTP$58R80'Q86,4UA$O)"HI ME-+@^@-27J#X:N/2UVK[+EN,TW22^X#*AN:2Y$.GJ8>:)6%&TNVU7FBLJODD7H&L=G. M<(J8"BNXT5 );YW.*\8$XJC@6S)%A:9FMDA;'!:HOX+/$]=47<#)5F9T2+DI7%#V=5[Q>SF5]D M7T;97L_1":](+,$*2^N1U]199FW0I@U7G/ &9X3G"B$Y=8?0,6+/X1S966LD MI$8+RU2 UECO2XX=H'UN!([H2'?"//5$^33,SN%-ALAPK0&'BCF .6%>X@V% MPB!6_Z95Z[-\YU)M!:'V9+C-_E59F-L6B1!AL3.$.P8TQ!!ZS&A)LT:POBW> M>I#0F:1:%ZK&X@T,K4.1'K"W):;"JG[J>P)>F@'C'= <*&TDP&4L'10,.CN< M =[ETMXQ;'VM[P]\]3^P<6!M/]0L<4H%GK@-^J^@(%P#MCDW@]($+1[8NMZ= M)!>=@=:7>FSY5Y/_M\J7ZQH-)1\'].-@NP2'L69I8(O1L @2Y+YO>62 H'Y\ M>30W''%# MAG.>V4083^,,FR PZ'/+F$1U.IF.LF\?1K/TZGJ=+??PN>7>-HDV GKMJ4 J M[+F110J0$IB ^6"S3=65[U,U:0F8WJ*2OU,9$VU<77\,RV@^&A>U&8X=2QUO MG%!!M.5.02*1D$0+@/"&:X$ ,\,^N6Q!FD_UHRO(_B@*,\CCS$'JR5FWRD>/ MO1[?\W7,4:R"V0$"U;_.T-E!2)L"VKT#K@5-;]- N5RN;?.8 MM7XQ+S+M'C$<#K5+#)97@)W/)\CHF*T!0TJIM\9PX2B2%8Z)$36*"!Y2RLAOIMXE. M7YKP/MY+F:<3-\KFT_E-?E0%=C=(C,>8&@< 5)@JP105IG3)^;!A&LZI>3>R M;P66OH3^>C[.8A%!FZ[_W>6I/WR>7O--"44F[)J@11 $: T+P+ 2#\)[]2Q6 MW2.VYW[N%JPS6 @/[^U7LQ,>MDB((QQ3CZ@,P\,P"!S4)7^&H0$&0G/IP$M/,*>$=,0I*0XUAHK21M)4-3J(ZLQOZTH/&8/6E M H^*7!^0_J/G$NP\)"ALI*1#0"*OD;,E+QSJ 87:]2WX)CCU.NPW555762RU M5Z3X64]8[]// 9!T/87=SZ8'8VA.?%-"I(:$&V]B53(J.60D6%5( N88)JC^ M^4)G:;EZG3 Z0W(0FO4V_5)\55NAMB](E.=28*'"C$J\Q8AJ",MQ%8RZ^M%9 MG:7K&H0>U07PS.I3Q)LUT)['[1-&/ .4 \CC+\PS*\I=@([;^]K*TUGVKC,K M3R/\!C'U/*U&'5$**_75=4#L.ITN5UG]6:G*NQ/HA9>&*P^(5E88";;>Q# $ M;?U[A9TE%!O$A-4!MOUY:LOXV/SC8H^#L6#RT]/"X^_3 &X^7:8?TNSS.J=> M .1].E[]W%O(\+>ZVE!?< MIVF^H7MR%4;@>)7%%2@\\'8QS\H_]2B?YK%](<&/Z?AV/OT]&$)O*@2D=]UU M@L-:1X(-!GRLT@"9YK_Y(F$426)(IHXHREA M&A37]"/=\8R)D&'&[M7$_JGD&F%P.3(<5,1=OZ+K3V3_#/#=K>X."NW1,XG$ MEA!@@?6:2R@I,X)$VBU!2C#4:^7&"H5^ZZ"^:(?W3N4V^GI<;@^?2:#F5FH, M@(4408T0QS+0;H"*7B0RH%/K5N36@/L"':2RW)[P*VM (J>>J%X,RP(>H#L-0@_?3_#>?I>GK^3+- MTGSY?K3<;U><_I)@/&FOXN)JO%*..X3I%EC!2)_>OXK'7FV(](B6M(;7N;2F MJ%OVZV(6%MI**8,KM4^0Q9YX*Z7V6G@D+'(EO(AX,,!$PCWH2AM0G4M-W-?[ M- 8BV.GGZ22=3VI-+OM?DKB @-,48..-MA0R&4U2:RTB#D.@#M$)8$(>+I! A//!G@U9[#'4QWB/@0-W%,2 MLVK3Q%-K@%<(!IN2A,6<$54.ZY@DH_Z]G\X6M8O4M!I8]Q'HLS/48_OA?T_3 M+%!Q>_:":6V(_$U/H1W?]<@)'QTZ@&G(($!(Q#R:@E(G$4585+J /UP\^PC: M6'O&O&6Q#B;37G+OB74,V V.R-)>$QET'J%10WLZ",>H@WN?L1?U%5Y_^W%V M>Y-^3F='?-G57I!H9JP@%C"'G;"2(,'E!C+,D>O3Z]2[9_M$I=FGMFT"W)>! M5G49/>;//.D]B7**4"XQ92K>0-24Z"T6+-BMPW9]MRWP??K4(91_;/4:I ?] MHK3JS-I4;'GS A1XU.UUH%4BM(846.,^ M;6F,V3EU ]72#53Z]" @EGA@'"9,&VJA(26?U(D!%5TXOV[4P^R=S4!99W MR/I(B[#:"L3#+A:)H+[($2X%*K>R+*R_ UX?SK*5;Q?/L_D1BPUAQW?5UHE9 M/HZ^]MC1N;VA6^>UFLT67V+5F2J^S0.M$@D1LUQ!J[6VPG# Y3IUA(6"N6IA MEWWQ>LSON*=%(C#G80@RS!FG@C*.J=KP2+'E]1>;EKV(K^KF"[X<\P;?CP\=4^+1.)X!JT=EYQCPQ16P2"W,=$34HSUNILYR8?76,@[ M*J\TQZ>W7"$_4GN\>L:^-@F!D$OMM(-$:Z&A91)M> R(*3=LUUICR1W7A$8X M/4^=&*0_;#BJ, @5.+I=W?E\0C'VV$DA+7#<.B@UT)$W*[RA"O4:3%PQ4VYS M.1V6?"UD^I+ZUEA7J^7M(ILNOQVQ!78W2 )CP:SBB#I@4=QL ^\V2R=K%,#7 M\465MDV!5N YG_"/3OK[FB0TH 01IU8Q$.QK%]2:EQS&%*_#M@.:BNVH%C1" MZ3GJPR!M@*&HP9DL@)@N*CKP@C!F_[/*IOED6A05.VX+'&Z9:$TPP I00""# M3!DLRMUXF&)1KW?\*Z=,:RBZ706V6H.H5Y6(GHD/XW0^RJ:+JC76'CZ?2*Z! M,])+27BL*<'T)D>A#8-*T?I^@M-/+\[K)V@!G=XDOR'QEWE^GXZGU]-T:D'+*#U/C1BD?3 413BO OA% MEHY'>047PQQ@)0XAE%AI2^>8=(KZ*OZ"-H+JD]LF\$35^"=]?7 M:;!5/J=;JRA>13.+^7(Z7TWG-S_F%MU5;['R2Q(%C"<<,X:H!=1A[.#V\,8K M-\"2O%T<174&6.U0!YM>IUF63J)97)SV;TB8W\1Z'V:49=^NURF$QOB?&FI2]84)$]HR:(1G7@6 F65*E!Q+(^O/(IW%3'6O*AV!5UM= MWF6+<9I.60 )9YRX/BEUP@S^O['3JKN-.Z M"K0/4^_>R'@/?IZG.IT'41RZ.+ZG14)T "@L@TA('!3:,X?+_;KD@-:?"3HK MF-.%/=$..KUM-J8W\V!HCT?SI;F-V>->SW^)88.Q(,"_"^7=T)^_#O/7*%_, M1Y]FW]Z%%7#Z:9:N9[*KZW63(*S)<>WIJ,<$LF#0.\60==([(3V2>(.O"@*K M[PGOK.).%]HW#'3[B/!\,_U]-9T\*"?939CEMIOZ099[%N7MF]\<");<\V0" M.2!2(RR%Q5@KI#7USECJM/(& %1%VT^EO> MFCX'K*M_4-U2<&-C7!=M\?X'"6(4ACB+0R_A_R9 @[04)2A$J_K5/#L*8FPD MV(J!BZ=A&>2@Q M&%48A K4#%PD#(7=#]),4$"(-!B*+6^(L0&FMVQ!3I4"%T]#YM("%R5% 2+# MPJ:&>@Z9EH&STJ["N/Z-NXX"%]M<_EN!Y!*#TX301 .LJ7764>68D'C+H5)@ MV&M_4[%5C5*KA])SU(=!KOM#48/G%JS(*7 >48X5%M1KZ(#C);^.R@%F%&TN MNA.#%4^#J"^5B*56 ]'QGUC3]O-H5I3C7)]U3>$?5HRY74)3ZU3PXWE7T^Q$0"1:Z!#[?I[/KJ^CJ-:07V M.0,/MTJ0D9HSK[& X5>*-9>VI!UI7-]5WWIT0:MNPE91Z6\!.% Z_6WZI?BJ M=EW[[0N2.*$1)H5PC@+(F'0:E=Q+WL GT'H80=OCO1. >E./@LHU]47F_4!\ M\=DAC=C7)I%< 2Z1THAP)!7#&*B21P= ?2=QZX$$K2M!2YBT$B(2R8C'D5?7 M9G%WMUB7L7^;[CK5K=PV(8HA+BEAW O.!/?0X>V"Y73] =YZ=$"KDWX'V-26 M\2_S -B7N/;,;V+VGGC8&U,)16JF>;XGLK1JTP0S#D-_1C,1-D#*!%Q$R85V M#7+-MGX"WZJ$VX>FK\G[W>A;D1?IZGJ[!D7U-(M\9SQ8E68)]0 [A6#H$AAI M19BMRF4*(D&\- I81"QW):G0$V&!#A"6#T$"#;-C)6D&- M(%LN8)@.Z[MSP*#EWCXV?<36!9MT[>R,<]?3'5TW<7:AR]C9NMNR2S69%&\; MS5[/PQ"Y*Z(ESYWM4,V703-FJWAGZ+LOQWT=SU:!@"CH8/G=KY8%L5?7;I3- MPRJPA?%-A=2(;7610.@(0EY22!BSSGNH1%'@1SD9/8=UP@3;NN5XFTY6<4 T M9/98^L5V.TJ,XT9I8;2T#CF/@ )P@RC3S/49P' P:V/_*O3#U.AONU]P)#"CPUX3A"A G$).PCI(),%,\XUP8NVZP6:H/)>.+H8JFKX\#[L) M?CNZ.QY6>*QI0E3XGU&20^(#VT(1;4J.A15JV%$G@]"%2OK9&/(_@K(-,J3E M6>K8>73+W=W/%M_2M'#Y7=U7BHS9VR9!S!HLF&*(>(T=I%Z"#8_"$3W E!WM MB>UI6H:60.I+$=ZG^3*;QCK2!<5'E6#G\XF71$$&G.70:@J8%=26O%E/!A09 MT;D"M %07\+?E,8X*O1'SR78.0>].2:2>4JA]=OM.@!D@*7/SNZI. ?P?7AQ MK[*;T7SZ[_45\_GD[6BYRL)65Z_R %G><7F:(YT?=N*V1$-1]/SJ^I?\0=6D M=)1W79EG;[?G]ER_"<"G:4&+3?-Q-KW?\'?4(7VD9:*8$-()I1USA!) #5^G M!W"8(H(JI?[HD^=C3N,#K1(>!C@Q3D*L'(6!3<'\AM>8$:S/W/L'/<"MR6S1 M%3:#]M*^"\,ZS9;?WLV"81*&<(S%OH^]ZV\5KL%7:)UXZU18I(3Q G")8.; M?$ !+*I@GT<))WE-6U& I\$SK>/56Q#5/LHK79*NT#IA2A*G8VHPK@1B#&HF M-WP3Q8T>MD.S50'LJA*\UYE$6OIK-)V'H<]3,\?C QR,BP MA88(>VP4#(O^)BEE+.>+W0#+G;8JHT6+X)Q]7C@J^R,M$VJKZ^]!HX_VJ4\C[O8\GECG%?*0 M<" 4\0H@KTQ)+0&RSR1+%67;]B:E17CZ&NIK"![3^C'-[N(MD?DR&XT/.0V/ M-TZ (LY"%F\.,6-1+*M#MBHL1?U#I]U&RV%)2ZO#[=)Y^ M&4#>&1 MJQ/GDPL-X.O06[\7%Q,C%R< Y^HS9=L>;LYSWV\RXZP%=7-8ZMYM^&_J09I^G MXW0=)LQ7,)BP+BP\:WR=YX#UF4#IX-'#V?1J;PSZ^:0PZ$..]76; M;;VM-QOV*^7XV]DJD8YCB;VP'" BF*7G70(EH!)J@ T)X$$@'>:;@0\ A0,O:-B*%*MI1B.\GK>.#/* M8WBJ<;:PV?6%Y_G$II_3V:)POFY*IU0)HCW6.@$".<6DBT:#Q#AL[X@M^=:F M02FSCO,,-I;CC_&T+6/5EX[\5]A59Z-9(%Q-[H(<\F7<^ZT9,NT.HM1'=ME:63W4;;AH5#,;B57I 0)JR7 MRCG"J#/08T5QR;UB:H!!MD/9D74"X,:]I$P:#@DG$M.71@CR@BL-C@2Y,Q@@D_[5)F]3I]^P>[3T9-GRP<: M'OYZJMWAH^1]9'./*^?1]PF)!0FI]U9@[$&8=:UG):/:]KJ>U73:]";J17/\ M:EI#U66^UR)^\D0BL0D&OS1$(BL1P9R+DFNJJ<+#=*_4Q/ZIY!IA<#DR')3[ MHU_1]2>R?P;X[E9W!X7VZ)G$01*V9A#PL*@A9J&06]Z#84WJ!UZTOH6HC?JB M'=X[E=LZ)?MAN3U\)F$&4B4)=C@PSH'GC. M]\K4O[3;NIN@%;DUX+VW4-G9 M:!ZO(!^[D?/@L<0KP0Q1B&I)C2:4<2U+3N+/'J5X(09/"S#VK1#'KT\\>C! MXA%EC#@'E>% (@E+;IB&2 S3&FHFF#W2;83(I?._B6[UQ IE$@C@IA+*(&."0I24GCNL!50MJ*HI%Q]C4 MEO+KWT;9=+2+CG?9=)%]7$#DTT_9:I1]"^.9')9ZK94VAELQM MOTW_Z+F@NAXJJ2E!1CJKN6+>EKQ@:NHGR3I= MU!=FO#?!L2^=J(_-=^[FD\JV81?=)8(0 Y4SE.FPT88\&F4ELLZ"@8>MU=22 M716MA@'LGZK;'L*#W!Q=L,:>+>RNA6R55'-L@CG!B:+4RUCXN#19!!9^@->- MSROB2ADN3P-U^(9Y,%0D$]02$2P3Z0 RM!R-PDL\P'P#@U"2+D$>S'IX$,=? MP_#85D.%3=;!$[I)J #*8B@9P2* R!#>Y/#73'J)!G0N-X10F_,A7WOBJT_S MS4V6WHR6:7D5?%VS57T>36=Q5^87V7_%)+;[9LS..T["-(*HD#J>I#LO'%5 M;Q!45)OZE[//-]6VK[N#E$7_VKPYV57S^2I6UQIG\29XWYI=AXA$ X6@)YC% M8II2"4*5*Y&UVMS,TW=Q6MZ#7 9O@YP^%KKN,B$N0,MBZ5@@*>("<":V M".,&Y2$Z2[YQB;9)NU+H2\\K7?!XNYA_#D97NK:_\H^+Y6CV\/MXR>/M8OE_ MT^7WZQ\'%+VS/A,A/:<8("60MUQSCGBY"=94-+BTUWJQ^ %H^E#$6&BY:_GZU'ZKS2F/ O#^W.:C6[2XDL;-N]^-,U^'K9;X?-)7/[BD>O' M1?S(?4VS\32/^_NM9[>WH5";IH0(1X@T2BDL#.=" %#*R) @M_J'5.#/L7(V M.9TOC<6'U=W=*/MV=;U=\6+R](+YUWF^2B=_IK^VAA!8PP*T3KN1&0T:'';E=3S"'+PG60^32Y3S(,.=SB+?]<-.N[H * MC!#U@%-FI">! B)]N:#BP-[P(O?JBN+T.Z"G83/X3?UVFZ+"[N1NO5%Y/\U_ M\UD:MV!I%K9G[\-VK NCOVK?"=5*4V<901)Q)ZWUHC3PM!6V_C6U(4>2UK9J M!R:.BQP"I7_BU\4LO&86)H,^!\'NWA,7)C)O*;?*:T E#CL(L)B]:?9P^'%0\&*5+/"*.6(A"$K=DF](Q@S&BE!*!_ MGCVD"5':>\*$E%H#02U28),BA805I->F:X->YS"L7 MX#"0(4(%HA(PXZPVO$S<2; @8J#)_FIBOZ<21ST,+D>&@S+)^A5=?R([O8@* MU,980KDGU 6+E$*C;4F[14X-Q\2JC?K>(BJG\=ZIW$XNHF**&R8:6TD DPA; M85!).T5@0+566Y%; ]X'?R#UXWVB]XO9S"^R^&47CN^#'2:88*2UA1QJ'R04 M;UELDG,0XK 'PYD1AN#.'8(,+E##UQEB^E'N=5^))1@(ZXP .DST'"NR];@0 MY6#]S>/P]+HEY>I.UVN)Y%+4/.!\G4Z7JRS=7H_N4-%W])90 L,BRP%FBH@P MDP'/-WD@2?BJ0>Z?X06,#5/5FPOE4I3]P17.SN?T'_I*O F+,X\E$"&$PCO, M8"E?JG"UFM@7HNCGMU6:PM]RAL[BTURMEK>++&85^F4>)%>$Q:SI+3RD&YK3 M=]ETG*I/^3(;C4],PEF_GP1!YSU$6ED/#'-(2%=N=9B&HOXQU9 C&$]5SR% M?W;5[%HE$VUB)0>OO!5Q_4'2L2T>1L->:QP?5L4SZT,76GDB^BUK8Y73A_UV M2P,U;;'CQ$@JJ/*4"8@4TMQA6AZ,Q)2*]?6W]95^\/I[/K%TI]C539=V]+EF M?TG@2F-NF #48L^$HEOG)X_U Y]E7'>+%D'O(KB4?=B##?"37&R/N(^;X^L^ M/V:@Y_U!)H(UU M9@70/I9U401(7 9Y"0/M@.SW2U#2\XRG$X4XF$%4PTKL:C2U3$JB.2'!>C68 MDGBQG5@FRA" 8!2HY^TI/_NP.J\T!S.^JENR9UJD*E*00,6L$- X9AUC@'#' MRMV@C%40:H^F(:?7'X [OD6A7,J@4)-)H22CF9WF\4);G"0../A[Z3?&=R-E MB.+,>^4=0@)ODER'SQRK'\ \Y"S\YQH ;8IB\#DZCJ[>[],H[_"Y6^9-UNY&-L@;]]@=S'#'%/=RVX J46>U%S_ M,\=(-2M):B>HH)P XZD%S *Q.79 "GM;:8QVA-Q%Y1A1R%/L.=!8,R@=L'R+ MHQ"*UC>QAY=CI++*=)9CY#2PGU^.$6@-0-)Z :7F1@OMX)9]9_N\TW:F^ZB5 M%>!@CI&38!QZ[@G@ AK0>F^L49!:B.PFZ!%)0] EY3>O+)C#22CJ(7+I%N*\7F2]J)IIF^-S]R;7-WH&)Y'D.CNUL])W2?*!=F'X8D1-0@;+0+$UV)O-8-,L,,;T!T MIY6]CIM:@KO@(5.4O$U[7CXVG29*AEU:F".Y$@AYAJ'TY=2IB0#U+QH-SP%\ MR<.CGKB:1/*M1UO*5H@*T$<44B" M\MB@/6'VH-K84E*"JOH>CN&M&F?<9?0OJ?X7C*,\/IBZIKLC.;>U&%I?7-HD M+K&<&V6-M(H")K4-Z..-)(QRML^2IUV/F5X5MY6UZ8R2OOQUK#!.]\59%U_: MT?+@,!T8CVCO=[S'+3="GSP8:5'\5$W-UEZ$R!X M+-2JMQ?.05.BJ8.(ZK!?8LX:B)QCY5FRY<34S[0UO$'9TE[Q L1T&1O%+<^5 MUK-!T9=0K;E"QL@X%VNF.47E\8<5V _UML.P=?=L>\7V)#W D;(ZUK* QQM:QMYD(.M,FF)D!@#+X77 M%"MK@_ZH,A#-FK -&:A1^.=8ZT[(E^]2Z?UF>3.*$JB9PY(JQSPPE&)NR>;Z M-7)0/M-2X<,[Q6M32)<_B$Z_7=S)];LNZ$R<#3J&@28VB X+"0PI;0\G!']. M!5+ZTOK>1FGW\C[?#=WBQM:^"[@;DAKWO/J4I[^O K3N<\2WW][.?L?X,3UO MJMP[,4?J3UZJW)OFX18#Q"F0EK! M+(+<<"C"H-0@;W7= \^GVCF M-398 Q68"0!!KG#!&R,(&SG$.X_-Y718\K60Z4WJ<1/R.L]7Z<2NLK!Q6KL2 MBXU9_C;]4GQUT#"H](*$64JAI1(&3IU'F$BDUE@:;42O"5_JZ44+1F472/7J M9,K7U!<920/QQ6?''#Z[VB3"0! VXA@(C9&V6$KNUCPZHBVJ?^30W?%>Z]K0 M$CBU3\7>98MQFDYR'WB-9(SFX_3JVBSN[A;S0E7?IGMKK%5IFV@#O.06 FHE MTTP+QLV:#Z\5-?7/<+L[5VI+R%V!5%O818VB+UE ( M3R^NZ#(MY(?IS7QZ/1V/YDLU+M0XVBF+V70\[=XI786&P\[C7DFI ,M&8O%' M/-S_QU_^/U!+ P04 " =@*M0<&.O&9=^ 8U@8 %0 &)L<&@M,C R M,# S,S%?;&%B+GAM;.R]:Y/;.I8E^GU^!6_-AZF*2-?A"R#9T=T3 'V>*Z/ M[;!]JJ;CQ T%4V(Z.4Q??P$^).5#$@ ")-+=$SUUTOD0UEX;6'L# MV #^^7_^N%L[WXJZ*:O-O_S)^ZO[)Z?8+*M5N?GZ+W_Z[?,;]#E]^_9/__-? M_]L__S]OWOP?_.F=0ZKE[J[8;)VT+O)ML7*^E]M;Y^^KHOG#N:FK.^?O5?U' M^2U_\Z;[(Z?]8EUN_O@G_C_7>5,X/YKRGYKE;7&7OZN6^;9M^W:[O?^G7W[Y M_OW[7W]C/\VAO^K3>>_R;P_OJC6?W)819N MFK9M@4:&7__Q[/>_!^UO>TF2_-+^=/^K3?G2+[*/]7[Y/[^^^]S:^:;<--M\ MLRS^]*__S7$Z.NIJ77PJ;AS^W]\^O3V)+OF%_\8OF^(KY_MC49?5ZO,VK[?O M\NMBS6"TGW9;%S>Q+SFO_6.?=7_(O_T,_+;-MZ+ZM$'%S^VQ695K%K1 M?/313KGZES^QKQ:[YLW7/+]??*B_YIOR/]I@DE:;IEJ7J_8?:+/Z6!<-BUCM M/S_<9.6&"7&9KYG4;0L>RAITW6SK?+E=!$E,TBA+PX"Z+H9Q&+E>$@- $Q"'K."1_S.L'\]QG_E/++ MR3DZ9+5[\ M2['>-L-WWO#OO'&]/M#_=ZWD/W5NM9S)N9VOUCQ-JNI^B#T:":A>.E6]*FJ6 MO@U_E-?+"YVB_XU?EA7+2>ZW;Q[U#Y[&S6IS->=PZAAG!+W$]C/=>9]O=W7Q MX>;#?5&W()H%Q8E'$$%Q"CV4$@_3A P-09>FB^T^PEY4$H6/EY&%[8E8+Z@- MK1AT$+D,;&\+!^^:S<<.& M*VPKL(L4)A[&413[(: )SH 7N7U[!$-"96*S>BN&0_2S(207C$>PIZ8Z9H@; M+3NSQ>63_$@HCSRG=DJ/@AT7M$>5&5'Q2:N[NW+;S3TV*S9?V9:;KP6;E10- M*9OENFI8[K 70.+!P,M"'(5^DB+7C3R0MGE#XA*,LD1P2.EMU-PP.\+93AX> M(74.4&<+^E)$GAF/9AQBQQ@U9%LU19+E$8IPG&*$T)] MFODN:K= 6I 84KG5CVFAF5XRZ:WA:_/']C@'@YS!HJ[,Z<@F_D&?QL9HU(JT?.+2S-XWH[XL=#Z$?"BT'7], D#B*,><11X>G>_KAZ*XO.V6O[QX9XK[:_%W751+WQ( MTB"&"/IAA@/J@2QQ^_9B&N),1LK46S&]6L,!.1TB.:4:09S@2O0DG$DN1?>8 MG&/>G-\[7%.O19_BY]QB]&A.[5 A#78\78[6Q(RH[GPJFFU=+K?%JFVQ;RM+ M0N1!EY+((QBXD,2 #&V1+$P6WXKZNA)5';4V9$;/,1SA072 U0TC.=U1)$Y, M<\PS)JI.6,S(RCT0Z)&6E#I;-CR4G+W_.ZSC?;OHV 4NI2%+@P MBMP(I, 'PQ)EG$8 R*0QAQS"02CU@X(PYJ M;-DA"HK8*QW]9=(]A'?EIGB[+>Z:A>?1T/>S!'@AA(1FF8?B'EZ2(M^?<,- M'-1,NP/2^YW<(JG8+C#C5QCV&O1/,;2C(^]D.W9_> M;+U;!:J\3Q1MT%VUVVP7"+D92!B0($Q@!H!'LCTVUPVGW)L61#1EG&D.DE0\ MDJ3E8TDJ!DFZ9Y+4M)+TYW+3?=7\9=(P(^K726*, 9?.$F"NG,Z25Q5;.LCF M HND " LJB>K'F].&#M'ATI_9*MQ/4'-FY(XETXZQ.-J*2F\7DQLO_?49FZ_T MQWVQ:8K#M0 9(*X?>@"[U/5X'4B6[MN+ @+E=A34VS&^J["'QK*C#ML_R>4Z M(S@44YUIR)/3G0-K ZCY;AL[1<\9[1E/J1WJH\&.IS=]:6)&8C^333R6MVBS M(L6W8EW=<]GK&^^2"@8&+?^Q*^MB]7;SL:Z61=.D5;-=^%E @)O *,HH]'SL MQ@CUB'PO@K'TKJ[.J1)_?P37N/CND=Q)+G^\&3\2NJ'S_6[%A M\6+- *'57;DI>:S@$\,>TR*+$<441KY/* L?U,5!,+3*OAG)+,V-;3:F8T$[)IIR8'A/Y&-L@I],JY06FSJBA+H[M4#QMUE1F>N+( MJ>_"C\,89R AO@?2+",9!%[?3A F*%YL][=OR\_9+GZZE#J=N ;\S*!J;PYW MJF>3W9%SW%6CU?W=- M>S_4AYN^Q*]9T##P8X13&-+, T$4$IH.;?IA&BV>O15S<:2,:U!HS%QZ&N?R MW6JW[%\%7QJY86B=;QPNW\YFOKBK-D[3%K-_[^M5UV5^7:[+[8.<&(TD7DR6 M)B!;2: X+J<%YAR0<88';--*U5F:SHB6'GKMD"]-ME0F.J#L]ONWHFNJ4\^W MFVW!^N)VD05IE,$ T0A$B,0H@Q#WS0'/QT1F&4BY$N'MM+U M/>.*_27C;=UF@3UB&$0D3CR6"28)P(B$(!HFDR )TT1FBCP#1+,Z3U0U7X??9(7W:*(ZU)(.IAT_DW3=&C=,;%OSKIS'YLPFV<8< M<[& ;=[N8$O@L(")%POI;/".7/AB2/H53%QLBIMRNPBC.($Q"B#*7#?V2 AC M?VB-D#!06 I0;6J:18!>87@Z J802!2)EPH A\L9(.(-T*#CI44V\]'B" MFXLJJLZF30HXPHH7U6LL*\)/:!;;H^5.]O%I1#%-H\ C?I*PAD#?!O0Q\&12 M7;E/-IR<,C *B:DD.6(:8HX7.>7@E#Q. -%V6Y?7NRV_I];95L['O#Y71VCF M6YJG M^;#;-MM\T]:=#97";DH!Q@AAZH9AX&9I@/P]C,B+Y.IRM3=OO!AW0.SD'>3^ M#*53'SDEVY/>8W4ZL'QKHX/K'.&]<@@_P<9^>ZY3"[+, MGE%!8TZR0RC-F??T>A6S/.J66YPWY7)!W2P./(@@#'R/[TK[^U,94>9&L=0U M35I;-KS=TH)0/Z&NF66]M@'$X")P#$- (NCN(@ M#J /,WQH'4CEG+K:-"R;P]+AX7(DR1F\-F[%Y'(.6N5D\J4+BKJ\-P 9B'"(=.D5&F$(UF3'!WGBAF67*>((: M";&1)=-.N9&VXH+@J+%R27*NU_>WB[0]--4^'-$?_'@WG)C:)U(Q22/?\P," MVLM! "4NZ9H-4N!E[H6!HZT=_@S(\=; '*#+#,,3LJEKN>&U\6XUH M%\./H$W(]!/EXK8S/>*X>C429>,%6=).Y+SZI-^K_X72X'0[\ M:G_8ELF#TX%W?F]?AG>X$4YKQ<0K7LILG\D S7O0CAQQ CNKJ<>&Y$,.RR6_ MUILEMA^K=;DLC^X-)4GD)DF4!#@AF+JI&T;=Q7,H9EQ[PK?XJ[=@;K@?0#D# MJMF6K$\3=&:$:F#5CB&HPY"G%]WKXD8X]2F_;LJ; M^^\# B(4)D/CV,52+_-I:M)T4K.[N\OKAS:H'@ [+XP^R11'$^&"^Y92G*;,F)$'7G,A&]W-NA>;J->IICF.!,5 M)V2S75;.K68K#WQ,I-DV[ M&/&I6/-3A?Q*VZ9=/[O.FV+U,7_@RQ4'@0XPBF$401"B*(@RFF8^WQ],?!RZ MJ>^'@D/6, IS0_D G(OF,72GQ][>.=U<=6O*;UK\SF# ;#G,.+[/C/^)'&F' M+DQE;#7+8%%>3NJW]SB2 SC$YTE?V[=6&OQP^)T>'OJ>UZMV9KX($@=!ZH,-ZS_'XG P+&5D<"256XXB,?$U MQHZ 2/485H6M<0!,D&;-+%63! MG] %)0Z$2K-PL5X7=75_6VV8PP#:K-A_PF[_[BTS=<,?0.$P?BWX4:"%Y\>9 M%Y"44C]!+$F):9CV$'RF5D)K_D8:-JPJ1W =CK<]',(1#_OI>\P.!RVX_F_& M!><5:7;VY?3J&?'H+/'.[QUBF2(Z[0Z0**B;TQ%JQ76?BGOVTW:F76YNJOJN MFX+?%_66:13?I]E6SO:V<$X/F:+S7+GWW#UKX:\CB_$DF3Q5F&?*(184Z1DS MK9J@0TO$M+=_Y'69O]!D\[$NJ_I+Y?E9<5WO\OJ!8^N!)(E+$IR1P$N"!)&, M @&( CYOG!D,].\X?C6@1X?S QQ+Q#2YJ==+K"=9=QI,3LW3L'F]GR[\[[U+/O#P63'\Z_:N#@V BK1?"H.FO69 M!='0L('59/U?+#(V]7;QB:]#MVM,/OM$/_5]2"B.W3#STYCN/SL0*U&7^T3# M\:L%(K7V*TG(^0ADC@NYH")$@\BZ#C/H:$V'_>OI>LXCBU\0$35&YM4%1TG]Z$(=Q)C5^!3]SFA$LM68K38O@*#; MB-(XUK%"*SZ23R8$JKQ8,IIE43\=STI6BXSH7UD2>;>[&V;".$WY"PY9"&B" M7."EF R?3WR*1,>TW*<:'M4]&/'A+,G)Y0%MC@ZY(=WCN#R#TS:H'UE^8EBK ML3/_P%;$78WM%Q*#._]Q]/EIXFJO8Z5>SU MKMP4[:M."P^F,CF$Y$2GOO%#=R6UQ6F-D M:WIU5-?_A(@@#'V/B11[.V-0T#=DLM0<;TB!S)XDBXR :CBP]N(E" MPDAO&0X3TSEJXM!QY?2F71U?;.[\SLUS>OM>2T@YZR03849/KWCEH4<3";K" MD4Z?S!"BNLOC%R0,W)C0-':QE^(H0.&^G#U$U/,7]T5=5JO/V[S>3AZC!#'* MJ-Y3\'-OU\77/*(9<*L5P>RJ?\/C MU4:Q#OXT 4RR$_QTL4O6?G-A2\D34T4L%D]OBG*[8Z/Y[>9C*ZX+$'H>]",W M@"B,V=3/S=IWU3E2]B,_&EXZGR9>J2 4DK;'#Z3+1:L>U)@7G&;QW#2QR)C+ M9H]&1Y8YS/&=;:\K'KW@'(,1:4Q7^#EBTB@&-$>E\=Z8;R9% 3__B_P4$A1G MQ,\"-,SX ';#M)])TH?P\:C!&PRRJV*PDYT]6JM>\V;2HAW\.Y1IA MO_%L6LX34ZD6_5'4R[+AUYGT.+,T@/PM+!]ZGA=G-(#>'B<*0#CE[H0\NFDV M)IQO17LVA)^0+ X8YTNM%=PX36)MUH/SI=5'=KW.19YGCC$8EM0[P<\1ED;8 MKSDLC?6$T'G>ET&VWVW0;GM;U>5_%*O?-LQK[27T';;V?%6/K_A8E\MB?\.C M[]$L\WR,2.:FD/IQ0H=*;HB]6.CRFWF037(&@R7) SJGA2=QV'1Z7YV/._:[ M22'F./AYS.FL<0[F.*T]_2-(G47]>=3'SE5[>&IZ/TN<-[;:WVI'D=]7SJJX M*3=EZ\?\6UZNN>B./3*LFZD7@OZ\'K'@H/%\MEMU7C?2CZ=.[.0),P.MGIT[([#2 MF3.$?ZU.50O[7VZ+84&HX#>'L %X4]7._:Z^KYJB';2K[K9[/FJ[I2+GOMKR M*R;R]?K!*9MFURXE[5K?'X_YINT'5=_8G2!W&;3:0- MDHR/2!=$KML^O1GX&'2:@!B@#,#8\Y&/(QJ X4+NR(\2H?-9ED"=:"'[9B@+ M>9HX7)G*'";UMW)*8:NK]:]XGW^ X5(ER=-N\[JZQ^@DQ=9NHI:]T,>92YN" MK!^.,I7OY?;685_<%\LMOQ+M."5IG.UMOG6^%RR[98)T5VYXD9J9#$4C[7*I MRQS^MC:GF86,R\G.?#Z:>-&$1(3Z(,PB@"",0^3OW[V*8NQYHN5%TZ*RIZ1H M[%+)SS;%$G20((,Q OO+M")( ML=!]./,BG+4R:*IEV2D\K6-.98.3+2D>,C=_,M8#=$Z;;.@)6F9+?.[37AQ] ML^,+N7S5-Z_[5=U>%!Y/EYZG)_QJZNN<-<(^KKDMBJVS8G,H9YEOG&OVGUU= M,Y#LXUB,_%;4_!.[56+^=_VZL(Z7&4SY3'FJ9;J/6)O23,F!U,1J&H_,<'3C M[T7Y]9:-+,0&6/[U,7I^FO^F/\T?NQX-HR *O"SU"8XB&J/>D!BR_\YTAXLN M^(:3I0&FT^.4B7T6LS;]P?DY_#U?WO3H9/VS/B1?)F=E8;:\=Z,,3Z>Q0OC5G_)V\2V@*Q#;W!OLJO5Y7 M<-;LVS%1>JYN]DK"]6STR,;M>?UHV_0:13# .,J2),SI2Y>,;K MC4;AMJE"24]0_Z_9T20=YI7([=2LS#0[DO/:#/EUS(#U^-!B"=?>DGR,$ M:V?%W"U2&KTV50A&JU5[*TN^)MU1;#Y?VU^305FJ@-*090]9AC+J^W$0]I@1 MPX^G#+SCD$Y=P_.IX(]?\ZE,6FU:B+M\[;PK;[H8^U"P"#MQ7!WIZFFBZ71> MGB^&'FQTCHQ\M34Z9UUF,%SJZ2H_1Y#4Q(7FT*C30U(!\?HRYFOI&?5>TH\4 M_4M1W_F+F(*00#<*4>(G'@I!B(?0CF 0>])ATC+\$\U5CQ8 %2*C99S)Q$O+ MH+^.*'J^5.;E_(O;/T-PG=:_ET*NI;W-HD!L*T,OA6=;L4X:M$_/P4]9XBVB MQ,W\-$,!#9@-60:S=&])2I))@[8)_+,N,$\;OXVX?YKX/;?G;5U)_EGBMX)_ M#<9OD[WMYXC?1AG2'+_->U/HF@U==_82P_Q.^-D-;BX9CY!%.AP-U.J3. M'FI[@ZW$+0?ZJ#X?W>9C62X>/8'X,K_.[QU.F1<"]!$M<3W$+(2K7??PJ;AG M/VW+:,O-357?=6G ?5%O^["]K=J;&,2&P-A+&D29.W7I@G;F+;A$0;]-E?\#%KW_3W]>^U?V_PHV5,03W@%@4[8D]P_\*E@",OET<5IQ]M?+]Q!,,/SJUK[@@TQV$ 'L#C\OK*G M6R4\.%O(E>Q _QFBK2PEDP9:)7_-&&/_C?TM"PD+E( @"S(2H=CW,QAX239, MLG$8NT)OPEH T_"L]%D,_=KALBI4"KMTM@!IPINVA<7>QEW,TVC_UA:7+.*8A"@)O1CY(<78]T(*!K ! M">%B4WSE[^M\D;EV?Q:D0IJ8=)KXS"CU0+=_V$P^U,WM6H&-2LO=:6F(ZTQ\ M'9U ]HY]ZSN#VJ[K[)U"XLI\$RXXM7T[O\\MV.^U@(1GM^9;X!.K5L"I1U%& MPA0G)$H0R-QD. /L8Q"@;+);@G2"EE__EKXBZ/SJ]Z-K@H0RG-_Z8#U?YMQLVX#=-N?Q;OMX5 MQQN@?N0#+X1)1'P?L-P#X)0,)L4 @4G6.J^QIN'+V1'2=[!']D=M0Z_O M)@0-OG]:W8A^*(]1PE.^?*=LCR(M38N2!2EB*0) M0<"%"2;,F* W+$640/%JHU=DU"2U2/BE%T^^#^E$WJ<3-SR=^,91MU.R7;,: M\;:K]<0;7:>VM@O9DVU\>91M'!<5G[NS73;E?45NG&3-W-J.J;:^_N6V.*MC M3.Z.CKMOAN#JY)R+QF$]N6@)Z?LN?WZV<8H?R_6N[8E5M^[>??O/-U7-?I;? MW?/SS_>,LFUU-ZQNUE_KRZ^%1N.LG;N MZ^J&_^[RMF3?; =0]RDMTO;W_\(W!?M'>OE!K8(!J1[82"H;_J3NE@$NVO=U MJ^MUV6Y$\B-=9=.P%CHKV<@ZC$+V62QCWS0W[!/RIBG8M]BOLS'9?RXC]K9R M;O.&T;9U'@H&B)G0W)1\2:^HO_'+9SGPHFY/D_%'?Y=UR::U9>YLBF71-'G] MP#_R:\X&]+;>.ZAHWU?9)9Q_9KW4.8A3,M^RXR^GG^]L2V'.?4^1?M#PJ3O8!^%00C2 MP$.8L$D3\3#UAM,7*<$1M&/Q4;=5,]5EFIE4O#[Z9U_#G+,_V3/%>+R@V7%R M=G;1_HK#J1&9:+RR%4W)/C'+\J:I?ONSKW4:XVVRA4^SGI\_;_E;OZHK:E]( M(4#8C0(/0AC3) O)4#.31BF>YH#(Y%9-G;?<'!Z@?)V9B_9N-7?F,F>/LC5S MZ3CYSYNY2/:)63(74_WV9\]9BUO.O:/\VR\(P#J$;^6[@><#WD)\- MAL4@-6&)Y3[N%)YN"O MK2](3 RM-.!GF @>^MJ3DMQY"W#G\/>E29[5?="B29W=/.FZ?WUBS]HW:=O; M]\*$%& <(3]-$UX_C"&.@#].H7F5;_>U47Y$*H!%=+?ONZO&EM)>Y4752M&!>=%S&N M=T>GP)WZ2!G;$L]75=EYQA56+%CIZ"K_V=:LM' VV[*5/H_/G+[V-YZ)V(4C M9D=(71]D'LAB-XR@/]@%T]@7?J#H55@S6U7G:TA/=?::65/3F3J,K6EI3\=K M2TEU=D\ZLB>?$7<;RO/-YT>UK2#LU]D4KLLYY^N1LE_U.WC?GSFF%_3M]2JN_Z_W4 M&:T!NJ9):$WY^745 ;A^Y&4)39(@C*(@ :ZW?UZ"$NH#>XNWQU@U0?WVL^RV M>%S0K9KASJWF&A/^:DUW!1G5NZ)R7E\_A/$:+4J^1?YFI3- F1K^6VT ;#^U_/#E5^*N[RLBW52JM-"W&7 MKYUWY4UWU.:AR.O)WI\SW3WF/O<[7<^P9\'A27'WG@'GB(*?\&KELZZ>Y?"N MGLYG456WS2Q-=C!7IU?G#_]'V3:D128L&SB4ID7SN76^^1A>90\K.U,'HQTKKE3BKG[E:V)QJ,7 MY 63WI:=GR4!4>@8LZ0E)COPSYZL&.5NLA3&? \03FRV^;:UY<--5F[RS;+, MUQ^KIDVP]CF5BS,7XA!$+HA0X@<$I;S,&- (@3C(D&A(T-&60:4>X/%EW#U M9T XWXQ-@+9S.J:3=4OD1:M)3T>]?KY$!R.3F;MJ\YEGGA_S^D/=0EFURYH? MB[K5F@5Q(S^"4>(C'T.&(HNB9-\R1)Y,[J^C/<,9>0=QR,;O\^,[<5;5>LVR M;>7K^[30+29]4S,MIWP]R9\[DAE ?BM_![&_AV#_)-BTTB= VQGETTFZ'<*G MU:+*7!=5EKVVF0;MMK=57?X'?V,89&X0( Q<-TU8CM(HP3;FT*?V#2*=VB3*IZ(N M&:!RO"9=.1VLF06I R$C1I)L6BI$LE9<$B$E5I0%Z&@=:4&03ST7>T&"<1(@ M D%"AB99F^DH%9)I: XI.KZ 0I\>2=&K*$JFF-6A3$?89I:G(R0R&J5"KJ5" MI63*);52YT=4LCZR7E'4=;$Z/['$$?3"-*0 H11%$4Y)"H;&O8@@&?'2U*1A M&=NC-+.VI8MW,56;@7(Y?3NP;=\BEQAY9V1/,_MV"*!NHRJC/7:,*#Z;O:;8 MBX(PC"+*LL8,!EX0X;[1* FPT.TWFIJ:3 2U+WR-Y5A%^(S2.U+P9EX!.T^4 ML+@I,VRCJ*D;K4IM39:E?\NMUL8!>&GDL&4PB0&%, M4!H'J*LCA:%/TVCQK:BO*^'C(Y/ADAG"QR:(UW_VIO#R3Y&J_>9LV;[S>VO6 MU+6BNMQQKJ!TEW4U?UMM1GJWY>LT?);\9$- ML^;7XNZZJ!<>3/R8)W@Q(GZ8NM0?7LF$D$88"-_LK*IM/B ME+A=3!/!YQ.NF;B5R[DNT^K\WH$\+;_&^)6X7VUZGM5N0/M4W+.?MB&OW-Q4 M]5T7"^^+>MN?*=M6SO:V<"X[9NQC$$*4O1"\#/!MP94QF@VJC/5-N62W"U3L M3]"/LED$4>:A!(/03Q-*<(1@1OHVH@"D4E-UN4\V'!VZ/)&C<7[G> 3%2I$E ML8FV.8+D)%Z<&R-Y]",:SN3":G39D<\J8J]T=!C-MR^6(>9TH!T*/B\%LJ?ES?M#-)X;Z/*K=^6F>+LM[IH%2PL]2!% (0:^FX4(NND +$M!*+GI8!Z0^=T&[K8W M^-D.@V4Q^R*38R*T/C?9,<2G-%C7736J7!L7C_9_^"7N+#IUM_YZ"Q"[B 1> M L,@3@&!?N#VS[7#)$M\.,G%=RK #$?V'DU_^?A$M\\I.4C3Y&PNW\A-RD1V MD2_<_=9-Z ;_?CSO7[M"Q N^,!$LQKC\E8>-4:;K"B#C^1=_44,)WW!7_/L= MSY'[O?,&?- (X%3K&;PE4P^&F M@\?K9(8#&P-"_L9;_^"%=$FA)=P)/];V:CRL$+1,VO:Z>H/L,> QM MEMXA\3".27RG:@OL<;X%=0D6D?'LC1H[8$V0^/R:_RCO=G=HL]GEZ[>;95VP MW[AD ':1[V5A #TV'4A0' )$!P,(SB+S29 1V(83HAZSD[>@G;)'[6PL3)3, M= N32=/L/4(A@7*>K^P^FO7C?M;?_][CTO&A.W46.X/)3I]W?[C9G^;==R=F MMS-9=F6F"TV1:E49D7?9U*<,IF8JSM*=G1GO,:T[5S!*C)6V;P'?&MT$N MP0TIPPD#!MI-@!_%;@3C/=P ZRUC,P7R5:Y7SW:^KAZ+X7-3?RF7Q,OKWU>9; M^R1["[3Y4FWS]?'/TZK9OJ^V_UYL/Q7+ZNNFN\@YR2(0N#Z*_8Q$.(K\:"AH MPB#VA98CYD=I.+S]MJGW6)SEL1P6/_C7I^^SL\V;8@'M=3A2+J(--CF]42=/ MH+/(-5C6A;+FZG$(Y(:QW]DZ#\76.=@V;2PSYJ(SP6S^;F%'-+. A\JV 6M) M/.OJ(U@T[K_%?\];4)"DE&8^3%P4!B%-/##,.'$:(*DIG&70#4>^X?&\-\/K MK%T!G+.[%!&=LN%GEJ_Y>ZX7%?)5])&90Z?Y[F%9/+WJB_':V>*1T3])G'W1 MGW,$WW$=ZR>/R"/)F2I,Z_"AUMC])?^!BTUQ4VXSYJSCG] N/BS"+$80!DE( MP\#U @2"*!C Q3B3>M-G(DB&8RT#R.)EB_ H:+(OU^T5ZBR:MH?*>HF=:!JJ MP9$: ^>T/C06$+FG>SL<+F:/XR&]X,SYXMQ%^L?&+WW^?45Q2:/1*O%&-^?& M-^SZ)[[;]=;F[::+?4]>^6Y_2)AN9GE9MR\.+$"<((1I&O@)"XH)\%P<#E:P MV2V99!_/$/:)9H'., ML-_3>K!A&YX:![)]5J6Z[WO3N5QQNO,.M[YZ5>26;B&J^-;&W M:+B7V1%ZK65'UT[D)%Z<*I@?W>_\=K.MRTU3+CN\R,T2/X,1"$'D1=B-,=PO M0$/!^TSG1VDX0.\U].C"D2NFI#W&+CY/&WI'>'2:(#N-,^<+IQ^.N\+>PM<8 M,D]ZRF!P'-\[?HXPJ($'S0%/EV>F"FU_ZQ9S-RL^G>;W"7VI^+?HCZ)>E@TO M'MH??GIB3QC3,$Q2A% 0IU$4QZX[V).&S,8I0Y\Y*Z8*C<4!ZLRAT6"/F"9T MVM$9Y@NMG?T.$R%G8( OS_-O7SGTN)_M>7C=$5C9X08CM/E.^'-$\ EXTASA MI_*L_-- 0@OJ:-UV&?;5AYNG6[1\\[;I7@AAF#PW\S"D,?)0F%'05@H#FM L M%(%_^-:FD^AE!X4&4GK*)4RP*@VG9KEO8^S/,EKE22_5JN5K"UB>J7$D,2; M& 7[W5NT69'B6[&N[GG3?8U=_[R &_L4P82F@.(D"$ :A61H&:>^Y-/!.EJ4 M&6U*U_0/(-O5U-4!IIQN:2%73+VF9E5.PQ[1>81OJ"J^_&ZGJ?=(+I%V1M!T M4FZ'K&FUZ/G+)9K9$I6X?RLV19VO6<-H=5=NRF9;Y_Q!R\=M)X0$(4T#%%$* M(QJ0T -]VQ[!2%+D]+1I7.9ZF.VPS!\!E1,Z312+2=WTW,J)W3&ICQ'.+'=" MQ)T1/+W$VR%YFFVJ3'95 R?B+J[EO=N_$Y/1!(0T!CABF@P3KM'^@-(%H53) MX]383.\)73@!QW?P67]<\:_Y;VR::EVN\NY%MF%:UYY3*.J\.ZK Q8-_5%W< MLK_BVK&NFL9A> JG9']AX%"=SKX@IN0V=X/)ZSB>GS[_G5OFM*9-'"DT.V;L M 3P#7<".Z#.;]2I'\HQY0?A]^ Y L7H9W_Y@((Q)EB!*0PAHZF7\:.#0.((H ME7HX7D^3AN//'F5WG$W;66Q=A(M%@QFXEA/Y \TGY7Z64])BQ)T188E84II2N+$0UV!6>:".$T$!Z#D MIYH;:!T0Y_SHP;1<+L&!^JX"LMG4:VOS=-47SHID>;KUV;7XH? M6\PL^F,!J!\E&(1^C%+@)0$.W&#?:$BD(O[(I@Q'^D_$"6?*O[&9I6((=UV M4\4.IEQT'TNJJ*A,QJ>LR'!@O'Z^A^8,LL/1.2V\R87G'%=GA4@+R;8(DQYC MG@F51HZ$B[1WUTWQCQW?Z?C&_J>KC(M!2G&*$R_)HB! B9]Z/B%^1 !*7!?( MW=VOTH#IY; ])J<%I5C6K$2=F"@99TUR]4B6,#.%P"^0 M5M&.YT-55=@?MT5M(;_=/>"7XT8^@B%*/!SUK>$D";PQPB+:QM3:PH$I%;XJ MDZ@F,2;X&ZDR(M1-HC0]-Q)B(\NFG7HC;<4%R5%C983J]*5I(A(*V+1CZ09J,F58)MC"Q HW2'%'2 ME/3& %]C9U2S5%R]2(NXQ$C2:*6\R-IP7EJ4&%&4E7?[[6PO##!!<9"ED&1) MC('K#K,XD@8D&*$LXHU,OFCS3J#Z1#./2F)CAL*Q>B/"WA2:\TZ@"&%EA&_;.XK)KBXW7[O:FNY1O_?%]_9'S0(2 #P"$H$'XC0&6$J-]#1I6)L^[J[7)>M -S<%QSCBS59-# OJU/3D2JH6!^AT M")T.XOZ6XP[EE<-P=K]Q>G?1C(P)D7=.U/2R;XG$:3;JJ>"9X$SJ2L.F:_UC M72X+UGC[O46<>FY(:.#&./ Q"9(DHEU[-,1$X9)\I59,)V ML'XT7CDM-CX: MNY&H@&I6"TC8)BY)JID:@N:OM7N+GG&"-YM02C1IOQTM7MVE@YI(27:_O M;QHS=JT!ECY)7(2U;G-T+4%?.IA!$]36F.$8<0S160T8'=0=8QQ02@B8 M%H(%HL/4W,H%AT>TDD>TIO/1*A$6IJ97+2J6/C_'SN?=#>&')$?_NL&3UUY'!1(#&4[%$IPFQ\Y+3SB<-$8\GQR2V C*-4; UD,C8EYQ-'1!X6>%LBT[-$&ED(.4?2F;40 M+=S:L1RBQY3*0-^34ZG]8VU<'-=5LZN/CGVY"?OP! % (*%1$)'$[2_[]3P7 M>TAP2(UJP]R0.KSJZ!P!F^U\XCF6SHPI+>3:,:;TF%(9Z'SCQ]3A2!)U88Q3 MD(8D]>*4S5M# O9MHE J](]KR7#L/QI?OQ8YQ]:*FUS('\FEND"9H5&/0LUV ME/$L49(B)4^PO2JE8(N 3*DR)/_6S,M/Y+1)R/!.#L/6W1?#DI*[[GOM8:@# MR,PC68Q)&/@ACOGC>!2B%F2,LSB,Y)Z0FQ::824\ N;L^.TBY<8IFFUYUYU0 MYDL*YYXV5WTX9AJO"FXMV^M0R?WHHZ=BSMS[UIUR;A-\'N_;$3#F,O[D>S S^&!,2#J^@.<8)%INRV_E]N$),!=#D" O"X(P M"A#&6>9V=_/$*1L%+AP;AC3#,5U_M+N[R^N'0U!Q\A[G^*BBVS'JD61>A& MCY-OB3T)& -R*V.$'-V2<<&0+^V-!:8,%M!_HUPK:O[U4V"?6*IC>N8HCR/.P90^^/"-\6??;"VT-AQI]9AXH)JGHU@9PF:BXGQP MF],_L[WTO,?K@QB0E*9QDF8PK6@>H0I0!(,T!@'V48B 2SS835I1%(3L'S+1T#06TS&O M#73XF9#)!2CC#A$+0S;Y0B[8')#SJ/'HI8$>?!O9E6I3BA+7E>JRM((Q ME(7M+AB5. PR.;-*IT&>]$2Q M QHBIITZH:&5%@N.:.BUIS+5@<2T9U64BZZM3\77]@''S?9]?E6V>A"LY*9:DZ85, MJQE2K:98_O5K]>T79B7/LA+^!4^NDJ/DZA0#+^C*:++FE9'Q\"M-G496)%*F M3G6^?KM9%3_^W^)AD070AS&-,NI3-_)B-TKV[5"8")T!5O_T:62B1^6TL!R& M2U8HI$D350J3?"E)A3A5^L3B"0EGU4*5,%OD0AG_,[T8QX2(8 S)#+\N>0$R MWP_<%"(*80"2*/7\[MVL-'$A3H2S":D/-2P/^YD*!R.N"7*\7)8"8Y0HSMO. MLJ%CV!\;?&*T*W$R_R!7@UV-[ OR0[I;]*:;%R&"R'XY(?[Y*DB0]\##-* ^\A")VQWPMC7^'[EU ;4VIED= M&+ Y'3BG1R>[1J!(H^A*@7D&E=8+9,G3MVKP(B%GUP[&43B_H&BQXMDZ@@Y6 MQ,7F\UV^7N-=4VZ*IEF0,/5)F/AN%L6QYX8!AG0_P?%8*AS("X(;S=L>+4'@ N2;_-T5]?%9KM($" XC6 (4.)C ME'A)UQP-":1!*+SY,:J1:43B"!Q?U\^='IZL7J@R*:H<$Y"HI"'2_.F3DYY/6P31/%'DJIZ[L^D[80 I2A M89O&"R*"1"5'N0'#FL.VJ3M]EG9F$.3F-42)-A\"H&+O&3H3F8 MI$*7\8YN9)H\9A@J>W1.!T^ZK%.12=$\9@(2E?(8:?XTUGJ^2,G9/&8DB_/+ MC1XSGA> ZN!%7':R^U0_!A$BL0]2GP1!/+2"V/^34QNY MSYY&9%I,S@!*5EHDV1)5%'-$*0F)($?ZY..1_6=50XTI6\1"$?TSC1C#@D1& M8Y[F,/HYD MRN /D[:,?:=9(.!G-$D3&'AN%$&/A#X86O*)+[Q-I/KYA@5J7]]]O,;0(I,O MAI>F[K(03<&:G/HH$*:S)/X)$2=49BQM\TO+: M>*(P?QX:\B'2[V5U;(844 M B])4Y0"/R*IOS^WX\=>(%RVHM["Q$+2GQ<9)252!,J*B2GNQLF)$&WZ!>6( M#"%)42'/-E%1LN&DK*@S(GI57+K.F^;#S=_SFM\(\*'^5'Z]W;:7+RY2Y&$: M$Q_BC$09#EA6Y"5L'N=1/TQ@%LC< C>B&=-[2!P9OU2LQ\8ZB].BZ^^@/'U? MF'8^SXO-Q%1*;BHILVCDUK73'+T@1!J)M>.N-!V&5-H[G9@N-?5VD?(7IXOZ M/J^W#_R.$O2C;!8 ^0$.(0I=LO.",PE;DC(C2Y2(NC [CY2%_>NIJIPBX@4M&^( MJ\6GXI[UEMN\*=#7NFAO%7_:,JGN\G*S0!G";'KF$IRY;N(E"0K0T#8%1&C5 M16^+T^M*!TQ"6332>UENYF%VM 9=(E6;"@GSE%3_:L%8-:.2F6[+T MB$VQ##(CIS4#$.?W#LK$TZC'/)R9.BD29L=T215\I:732%S\_'&=+UL%0E_9 M__3M8"\"!'F4DB $81;#B*\W=^T BC,115#_=,.BL,?DM* DKG16X^J\/$Q# MDYQ"/&'HLE#HHDKBMFOCE"G=;BU/G=@%V"]9^X)TCF?&@@NNQ^&O=/41#4O> M[>04Q2A$+HZC-/&1ZR(2!V1HS_4#J5? U%N9;\%;8M%) YDCEKNU\ZAMM7O\ MQ>X3ZU/Z6+4C=]-@A\A*MP(SH]2HGU*2S ]1ZF:>@J$BM/W>=_JF7)BA MV$<0P(@2!$F*T;#F#=TX$3J=-:J!253ARN' AJ JL;*B3)O .M04C*D(Q6.R M5-:CE%F36)*:@CVU52DU%L66IDY8?6IU:BQ)%BQ0C3:ATMAI) 3W79E?E^L7 M6TMP&B9A &E((I*DK$T<#:VEP!/7W!%M&);=/3)EY1W#GX#X3D2=G/Z>8$U% M@L?0)Z'"$]&H)L3*=(II\6G;3\FQ!K8L4&0=5E1Z^Y"&!;MWY:9XNRWNF@4& M,6+I-@0!\B%)/.!%^V /"QT/8JFIN9;MN,8G1:DCJ4["7)'K-Z9X57; IX( MI=,MXNW)DEW'DV?9CFFZ+F-$5O-4.1+*+/NFFK=-LRM6BR2AO(G A8$;03=B M7PY+AA%&GM#-^"J?:UB;!C1.V<)Q_EQNG*8]\/T7B31(EBN!S-$@37)2LV>H M0V*0%8F$T" [:DF@*$MB.=]C\T[E>8HD6)#;J2*OQG@$* ,02)R]\T[5J),D_H<6+5SYY*"8L])(6Q+L.5A H:HDE1">E4#"DH MHB&F1JJB &-RRGCXP$OJJ$"(10JI@OXEE51F8=1LE_XHZF79%!_KH&T5"O& 74&W]_ATQC M4ZU%]C)[Y50'Q$-">7Y:Q*U,VVQ_"F9(Z)TZCP) M38'L'LI]Q*YS6#&>PHWVPP^DL<:B]#I18[+#- MD6JK(VDM32D/%5U!Z, MP_[X;M2FC"2!2GM8YK@;O:'%ESL'+K],S.6HW2YSG&K;^A+F5G4K[!$'XOMB M:M19D&=I,^7\CMD8?F1D'+%>MFHO#F/QXFNQ\'P$L4=PQ.-% %),DV'E)*;8 M%;J&<,SG3U-PX.0#+&?9XI*7'&GBQ%7;)&=*8NWL$3GI5'3)"[-)VD;IL3A] M4B+\Q-X+VJO*CCV2JVS!"TH[C@W)/+G;@5LM8I+ F+AAAB%@\]HL3ORAD21) M Y7,6/2CIZOCZA&-+&J5($TJ&S;!EW+^VX,Q2X]2@FN"IM$I[26Z9#/8_O,N MYZRR;-@CF2K@7\Y+U3@07:G[6%?+HE@U&;.B;W-HLEFP#!=3DKE!DE$4@11Y MWI#\)CZE0KMF6AHRO2/68W/J8EF4WYB&V M>TY;*H=\;(]LVD7/Q[4NB='HB!,PI0F7H H\ )"F$H2XE&/!D% Q0XMZ6C'L%IUT*Z<%MR5/:S[; MW:SX]2#W//W&#U_8![5W1F:$HBSSXC1S_3B,$NBE9&@9(+ K;,Y]?M1"O MG!:DDV]6SA[FE<-A*MTRJX5JX2QK4I:EDZVQ!)O*NRZQ=C[]TL:Y'0JGU:+G MR9AFMD8K'F^WOX,2HB2DF$ 41RCV(?0P3/J60Q2E6(OB2;1G@^(IW6*KA>R1 MFF>(9P.:-\O]M@*\J:B> NN6JYZ*1:*JI\R6J.KA7;GF)>_]K4(I?W 7>)X? M9 &;ZR:4Z>O0" PHD1$XR8\VK&4#&CF=DJ5'3)(,,B.G/@.0F2[ ?1B/Z8>2OR^58 (E7JB;6Q;G8:!,JC3U&)7E\W!8_/_'A M)JTVVSI?;A=3(E=@C*R=: MK?:M#MKZJ=@4W_-U=^2>Y;(@#% &8)P""@$FF4?A@"4A$11_@L44@LDRT+K# MQ4^Y$,:>>4<4K4>?7_QB!WND7D@Q@8W*3X?8])=@D_, M*+)W*O,V[@T+4G/S-E93]N_QR7W?<'M&.@LA3?TH0B'!/L!>X!+0MXI=[$M5 M,XYMRW"$&T:B^,43VDA4S^=-\:%%[)&H'\ M79TE4;EZW-['_(%'Z6:19#A)$"!A@F-^W#A(DF&F@ D,I5[@4FS"L#BE>7/K MW.?ERKFIZJ>+P,YZ>!%-3K=4V123JPF(E%.I9^HT8)I6F5[FY8P@C232#AT: M:T2EM7.-49VT:K:+)/(\/TQ<%WG410G%]"!OF&92.^8*'V]8;3X\T9?BQWVQ M$=XY&4.;BK1H9VRDK' \_LKR)US(?SP:]1<@F>(#&OI]D'D0H"B(/]S#2)(NDME2T-VY8?@:$3MY! M=.H!8Z]'\E,T_?RK*-7$U(_4L;T;>KC.'F_W&S/,ZF3I%)9!C9ZQ421UFG=6 M0K7SJ$5@2=DLJ]UF^RG?\EMR&$?9]ES4]5%JF00Q3;0*K MTOC4 KOJ,3K,#,%[Z,P1KT%937.N6UD'O X'W%X:OSQ73S^]MKY J*JVCO'- M*]#64>;):.MX'M6T]5V_V%06S3#O)KL"73?=KCW,W,3S0 3#-/$#F&:>ZPX0 M_)@*E6(::7C:.?.HN?)8BE44=$)V1ZFGI'&! ,_<0F" 4BB MV$.N-P BP$-C=UHUP3"LHKRD8?SFJR[*U?=E9V!;TY;M'OE!7*^QM+A M=[@!\^_IBA$MN=VKV7MV:/ 4A@IL$AOA5JL^LS#!(7SY7BV2@(8L3"1^E/J MNK$+P;"?E )/[E5KW6V;5V+/@!++D*M1?@WQ:E)S>4;+,3L,M(4Z>V!TK+@J M^.85*:J*=2HRJLRB$>UDW;%8H)"&&<0^< &3\6P+591#D^7CDIYZ!4JJ9Q]8[14@4D3:IJQP; /"'F M0)(PC+P84[!?VB44X,"4F HU;EY+ W-:*D:O?BG5SNPD2LI1VRND')TF'95R MS^N343GS1JBH H^Z173!UP\2 #+J0DC].,X.=:&$(6*9:+7-UWK%\V*C4J*Y MQR<\OK_P/^D+INXO53H;IE>O>&IEUK!HVBF5&B12V FO2QK%S5*41$G>M$CA M;YNAP*=8T1]+]JOHCO]KX8:A'_II%+*D-J(AJ.CO:5Z] =,?;**/ FA@=5S+UL(BI&Y,T]A(7T@#%'J1P6$R@"?3P MXEM17U?CZJ,NMR(SHH\!2>:>1HXI2G YI@Q*+XFC*IZ.Y-"&NJ8'Z1(F<2[M MD*W15@@5)LFR(BH]65[6?\O7NP(Q.=PV:+,Z*H7ZE2'8U<7JP^93L=S5-0/% M?N%]M:F'?^*\*9ON$:V,0/X:*<19$F592"AT21(#0!/?)R 3>K9^>E2&UR*Y M(4YKB=/#WM?(]%C;B[R/P:N]W3>A'\6$TDX7RDFK">\9T5YM9)]1Z^D=:H>^ MSV!W-?=04HPA^&'_Y?\J612KE[I554Y/3J?\>7*<8Z&]*[QSJ8EI2PJ M/]3,O*0D3DZZ3F6I$)%*K"RQ32KVVG1), PQ*Z^;;S?UNV[0R[?7/ M&L48>\ E- -^EJ8A2%$VM!@2(G?8?DP[AC6QQ>)(ELV/XDU2XPQ3IJIH5TX' MC#\@U#(XT^MG9W@2D:\1[%HF5F,L.25-H]D9(T1^WR+UW)"$F9OR!R%Q"HB7 MAD.+@,9J,U:%=B81(LGZ\U&\J0N1"'L6;NA"9H$R7 M$ 46"5&@)$2R[-HK1-*6" B1&CM3;@F_V[_K2.,LP:GO0NQ!S_7]&!/08P1^ M$$^^+2R.;+(EL2NGLZ==H#FR:-AT7#G5YMR68VO7B =I)W;X=/O'9GRMKM*3 MN=G:3>9W N_ISN-YRR+(M+8;V'!6]8#0RVQ_S^LZWVSW./GM=NN*PUI@&/L1 M:\B/62[NTS!*8G]H#=*8"+^]-J(-PY$CK>[NF%0TVVKYA_.]@[DOERREGJP= M0^1Y'9^20SE%[D%=.4>;) =@$Y$G\GM00K/KG_>73?EJLQK)DD+CW@AP%F0!!&.?$IP@N.VG3CP8XB$I@'J MGVY8D _/739'J!1>#I>C3$" C;,E)[V'EPP_3TF4POOJQ@@;^[BZ$'%R#ZL? M?^0I81W%BP62.@[_2^^ICV!"[/7A\A\[]OG;AX-:[^\C#4(WS)(P9-DTDVZ" M,B^C;7-1&F?LVT)/W([X?',*L4*S=%33D"]^5+\V&)F\1\+&"$4>2F KHM<1#&.0]@#2#(,I+:8-#9K>L=) M3FY,\"JV'#H3I7+B?032:5$Z.8?IM#B='JCS.X?JM%@G7L$4)_',\J0!3]BQ M]FC"L,IX+Y83Q+>;9757?,E_O"#!"4@@2^%XSD:H3SS"6FP/6!(/A#05+1$> MTX2YH=FAMU]3UG MEG>GS.(@BGP7PB""$8@!C * AM8"$DFE$JIM&,X;]K"K)2(YB$X85YRB [W$IG2%595 R^S%'GG+B(\R;V9SG$3,B MZ8X:E7:HS5@C3B4Y8SA1UYK^2!1@>N;Y$;_AV:6>1TF<14-S%!.I8YS*C8D=*>20)M55[9,VXJ#Y*O BOWF[S;<&+KQB/ MZ_^]J\MF52YYIM67_V(Y)+LAQ95W'*L3G'X&8Z)7"!K'-+KYIHMD.>M%GS=)%5 M*TM28L5W+3\OBTU>EU6;F"41=FF:\%N+(]?U$,11UK<5^0A('>56:\&P, U8 ME*9BBIQ):))1NB252) IF;^&W3W!?+ M\J8L5GVBY6,20Q>[B+AN',]AZ8X]QI!I:#, M3,*BFM1($FA&>4[Q$MM:XUI9X[= M]'>JQYE'$:JZK6Z&2PU;ZR(T3K2__D[@\*\.9NW0)"V67-QK5V5'5)WHS4VQ MW);?BOW:]R\<7*'(61A9/L7.?'2R;>8ELU$M9RT'5@^VEGC M./F%"6P\ENNRQ7CE?.QHGU;KQ#D\(WT&'&&'$IHPK#+>B26.:I'BIJCK8L5W M!ML;$PYON%1-D^9U_7!3U=_S>M6_(_6Y6J\6KI>2)*0^Q2&&:4I"+QPV#9,T M\(5N%S38O&'='$"WLIFWL*^3T3WI;6%"3_K1 M U(,M/,(]57_>I[SV0J72!S6F]\U:L?X#+E([+"?$FDOA+0)/&#! 4'#!E:3 M]>8QH8Y]D;)_E]M'(#X53<$O$3\" V-,H)?&&FC6SR*A DYMC1D.?@-$A_<1IV$@^7U)J^^%!"@**H$]HDM$XR?PDZ-&B&%*I0TES M832]5_/COEANV4A=MD8YV\K9'9G5!J'K#NKA^7FGW#@;?F/)]GNQ_E8X=]5F M>RNHI7/S*5I.\PK<+5F/<[#(Z4SB;CPVJE7KP2RG;)R#85UD22(HB1R M(4J](,Q@!!,W]4,:13%.0U?J.9X1S1A6TL.%W/4>F]/TX.3D<@R78L(X$8UR M$GA@\ #+^7R)02,Z=YJ?,XJF@50[M$N'(97V#B>G1X?-:I:0%L-;,@\+&H4\ MRP2N&T8>3K,,N7!HS05$2HQ4VS"L1"V:J\-JPK1#YP0I9\;-6!KMCK:CT M=JXQP^53^?66S]B:[C6F]BY'@-@<+?-HZB*:0@\,;<8$NNJ#1K8EPT.GA<,C MT*XI]N42FT+R(-I(,L5"^'0\RD7QH[JQ3H=::&^JFS<,7+=7,:<@/2%*6)94 M";91G)1M.2M1XQ@27MVYS>L"L^96:75W7VR:[FP*?VSH:WM7 'XX_,K'_(%_ M"_$]^.,'YG9W]VUA]J>R^2.KB^+MAFE%T6QY ?<"8(0!)9#)K!_1A) L[M[5 M0!"36.ZFM?G1&A?,YH\W-PQ4>PQ%+J+9@VR^:#AL5?^M6K./X9.-%CEU(Y(1$!&483>D+G83?T .8KDSEC;@ MG6K#_]L>UHQA4=6G,P3&"=QI36C<=Y*#L:\]-K[LOJFBX\C.\Q/&Q[&,F(R0 M6KPE%2.O+R._ED'^I:COO$6<0#=+7)Q$H0=<&@**AZ">@C"5GRK. W.JB,C^ M]L[Y\T.1UXWD%05S^E B%-KO/OLB(+=QAK!GQ%67HMV\_<.B(#9\=K>$ -V!Q'LI" M])RF/>3,.=8LN;^EA7?/RN\,-O;-"_ MW>QW_!&_^:SK?V9 M(W;*S5^.[K(ZH)Y-).6)/5=S;,Y+=@BJ20.?UBB;YE)"?+L[)?E%6XLX3%T_ MQFD*8(+"A+HQP'T;21;'4E-QN4\V?6*"#=HUPS'Y\#M0<'YD*5!ES:!1P?Y\ M/"@S(-K5T>K_[IIM>Q#@2S7PBS)( NP$ 7I"D8>B#'BI* M_52J7'D6@(8'WI%-_#Z">K"*5SJW(Y)_EW^]Y"%UUT51'=G,/-X6RW>L=[1< M1O3$QWN#'*ZZ_876?^9&_87_^+7D3B:<="8&S-HG[ @E\U)0631&Y0+;85%L MC_G#S=]SOIK&K_E!7IPD&?&] =AA%"*LZ%-UX525PZ,:\EPJ#E40<]Q-LQS#794IGHFCKV1OFKD3C! M?A8BX*>^'Z0(TJ$Q'"$X?D/S8A.&AUIW342W.;4\PJ5C/_(R?6,V$;4RIV?G MSX8-.NE=-6$>[="#@">U5+PB"36P97;\?X:OF,Q,PYJH9I6 M;$Z2A%V23" 24$6+S;%UWQ; MK%1%5 L(H8&== /[&*_P^.Y1.D4'KU/1BB-TECN&>[.5NDG?M$]4E74Z9^A4 MV<$Y/=S6-RU@R9OA32FM"*M2JJO53;8JL%XC+ZJQ 4[5E1DME_S.X.9C_L"O MBF,HV'?J'5.M0^*V8+-YS_7=* ECW^57R(4>V(.!B=1#Y88@F-['[3$Z]QW( M*R?O,.Y?^&JU8%5\*];5/5]]O6J_,?S6H.9C15N/NU1%>W)/:1'MO>]ZV*UC M>N#.$?*YQ5N$72GQUNHN6\5;KY$7Q=L I_H+A1<@#<,(Q4G@Q3'V8A>&V.\! ML*P^A8MMQ:8!8H*ML5DID=XCE*IRNUA'8ZHH^#+G8JH[$]UR2JM0!&QKY:^6 MBE]A5]BAHB8,4Z[PE>1NI%IFY2;?+%\N3W%#/PW]$ (O\''JQBX%@VRG&&*@ MY5C%& #F5W.?'*NX&-LV.-5]\N$G;2K2V>&:1P $%$19&F$,(Y8J@^$X1QH2 M('6?S_C6#*\>/'X=M>PA/BO.XPN,N^MUN70^W-P4-7.8G-1J8%U,6:MYP@IC@@"^DCIZ7JS0[U;S\_CBWV0VYS4M)IJD<\[('=.>66LDWGE/:FDAJ M22"%76&'4IHP3#EAE.1.5#MYZ_S_\^?4ON5K?MSD4\%2TY+?:,)_@#:KQ]\X M^LV/+$>J5L_7:)?KW8J!IS^ZAX#YA2B4)53\ (H+ (BCD!(< YC&(7')8$2, MB"NCOY9!GT+#]R=,N)I?=9I>'(QJ-U;JO_4%GM//"AMV5LS?=&6QO[_%R.NNG#5#3>O9,D+.T MB]D1*&TEIWH5,C%AP%Y$-/(@3#"F7A0D($:'0FV""<"+^];,S]N\WDX0A2_B MD9'2I] E554DF#KYUKDNOI:;#9?'ZL;IVIPPQE[VX 0A4ZO;9HF KRB*F0I* MPD[\"6*,N*TZ0X8DP]-$ (("/Z+4#0',8@\F7@B\ 5/HA4$? >A&L,S;+!IY M_1^ &U)_?JOM9=W_3Z0BHA[\&51$V%:M*B+'L/AM5*N2G]W+U[P]?L\F7;<7 M;S;G=BOCT*,N"N(L#C"A8>1#DA+B>Y3X 7)=J0O:S" PO)/XOMJ\:;5 0V6& M(1>()8#SLR^7^!WP'F[_=0;(5W;59RAQ>T:AS?K*#F4V;..SVY7,,WI)B:_7 M][>++W6^:?+V%'5:-?NRYJRJ^0YJ\>'F<['>%=E:FY;3U M"*73PMR?U&! VQ*.POEPXQRPSL7XJEKN^"CMKCNQDOE'$&?PP). QKE@88KC MZX.4+#LOQ"5C!,\;BLR951GNF'*I_[NB:8KB\8OVP^F9AU_S+6_]X0L']:7X ML<5K7KE#L9^Y(,6N2X$;^P13FB8Q2'Q,L0MBJ5O\3+1O. SQ:Y:J3;LPP&;_ M+>+A#+)[&,?V[:Y6)2A_;JZ"A+"_AJ?V#PXR;=-^DH.Y)]HQ96TW5[.=W%>5,V'V[Z$XP,R\=J72X?NO\]-)YE(?!# M"#. ( U@#.,T[)X.B@B,421W"D93H\9/OK0XN;A^Y >Z^_Q)3EMU\2LFIS,0 M*Z>@>T8/$*^<#I[S>__?V113C+TS(JF9?CMT4;=1E=$N*[]MA39/5[=_V]1/ M5\*?%EZTZ!8)"$*/^ 3A,*.)YR9QAGI0-/03)). &H9B.A<=]K>%-[5G\8=X M'8(EKI O1'C1"U?.,7KGS._9HL7C?'!A9W$"Y]JAW5,9^\+>XF08W9:T-:(M@+59Y3:I./LD&>C M%@I=SZZ33:&]Q:.3E_U#%/MUCV=?6XS:.I=_G5PC8Q4X/4#V@1.JV PQ 420V0#H)TL', M0QX,EZU*M..R:BQ7.IE?O]3-=KE\X>%%5L\^='>ED^A\_"A]/(<\/*?]Y/M? M['<: <==-CE7.%^\$=U 5_D$TWMR05+JEG# \>*-B-<[7;0X 6K'B^KLG#M= M=,#O! X778RJF:Q\7P:X/Z7OO6S$0#D'JY"U8(5A.KL;F%Z=8U6J>C9@H\7A VF[,P#8VS.J+*W3NKD]#5 M9C;4QUHKY96'/DI]2I*(IGGB9\-AGLA$#+JQ86+'L=)UH'1RL31I4].QL1B# MZ=>06]7ANKU*76#I:IJ4&;?34"4K(SF9]F2#'?4R;+\=9!9LJK7\<=%=JCB= M9T!3$:$DQP(%.,%"P@G9 ",2 89(DW7CCO5*XCW(R_%>(H867[/-NYJVW91R MF.!=9'LZWAJ4T0OBZ&QRIJ&8[H;WJD";4QZ5SG'>EO]\+I=#ENHL3B+!8I)R MEOEIYE-IC'*6ASRC'.5W #FCZ;&W(( &5(X63%(3E 9VU$7@ ' M( [YT3OD4.=)[0SCY0#/G5-HTC"!LPA=Y)7Y2Z"C?6_+=?%F6SS6,S]&),T" MG,K'XXP&61:*WHI@""E=1=)]]G@:V&#R6E!:'SR +H@8NF%*6Q#'(TE'&=V0 MI:>.AU1Y#]7&ILYVAYB: >7H]U*+K])\A+_NX\I.-+'HPNVH1]_C$ MPI3Y0J[[O*F$WJ'T6IA32'$_8NY".&V7^6G$T);'I)27;L:8DL?XR_Q[^?C\ MN+]%_^O78O4P-'29!2S-XDAD./'ECR'.XC0?+ 895B^B8FC'L;SUZ+QZ!\^K M&WR[JBD ?\F4404'VO- M+=6#-W5;>?=%VZ:I6'K/:ZF#1R_OGPV=U3)9:X.B2)^CFW>[608=E[%23ETQ<2B_1Y&P:BJ*-_CB- MQ(@%M6MJS;=2/?07%JK-Q_++U^W[YVV]G:^;UAH?J]5*5)O?YIOE+">8XC07 M@Y-Q\3:5_]GII%HZYWJAJHC8<\W-RI-EX+]\X[ .Q];B![/6;0 M#2J;_"O$>K>B'KB7]7MB'7)Q[4;L:]YYRSU0Y8E>40CBE@NQ&"6HS#5Z*!D:A+R&6HW2>KA MW7G5P7=WLS#R&F>7MO)MT3T-1\_><(XW\.WRI.0*#M?P^?=BLRCK8CGSFXNI M&8I]&G&$8Q*)%/=&$A9$P6Q=?&D*@G]2]/O@%I2^KK3[NEZ!4?Z\!CRUSC=U M9B%[-=9SRY4^*1-8E S 5U9>#)/W6\S+37<2EB0X21B)>80R'_N^P%$X6,L" M/U&.; QL. YD>+TM']OJ_0VD*\? =LE3"$M&X@T6A>SJDNQ0W8U/'B"Z&(E$ MO6!"DTQ-L=V-7%EUX5Q-47XU1G%1AW59L>;QDS"(148$C6*2ASD6J<@'LRCF M MPQS]0@W-\'-\7[_^/MJY+]._'VE8<#]?9A/(&\(6FA-55MLUN 5[N+UXZ"7H M;_C:GP0-O^PFDV'HK=F;%)@GI\K5-?_..N<3\OKLC^V4+^B(054/<8!!3\"8 M<4KEP^-<^J343TBS^5O+(J[?0'- M X<1EOI@QK):'L1HU%I=?\9UMB]Q=,'1MD+M-)QL.T.I'+QZ,-W:221=_N]S MO6V6X)V'7\\P15D>RL='8>Q3$O!])D#& ?&J_A M6^LU5 _>HJN,6K>9DK_U9\RK78[2IEA47];EOZ3C+?^J?'WJ:E4N6T=-KM326RL7[;-'/B)$(.<%YEDC;(0KB M($"#23_W$^@NE)&Q$7:@>+?GI.=@_&X61E6BI_&IV1D*9&&$\:-^:Z#7[OVK;'[MNWXQ'YP'EV"TN5)B[\.7997X:GZ#E,;VZ*&"?,?!'V=42X812 MQ.7'+_]%,\RC.!"]D9B1'%0<#OAHQYNY^P\.5-!'ER>@2MFG2%>.@'4I+&O. MN:H_AH1-3$6 X,_)A0X'RKKP?%^7RW*^^?'K?%7TPD2_E_4L8XDO,A$F 14B M#?* (C+80U$*DPAM*Z[50L+9KA8F),MC3GV2 M!DE*L@0%N#>N#G6@H$ID@51%21J73R-MND:E&W6Z2M EF;+' M[D3TRN* CH7+-E?@>*J+WII.A-6ZK<'3J";#:9QD\N&)"&-"L,_#<+")8YII MA5=:EERGSG1[&'M0>CZ4&9G &,PYCS"] E/H-C([Q8Y*H&;$ZD1TRLY8SH5Q M%AA25:F,XALKFBP7,ZM]WPNPK5[ !J29&DLE8M7$-KF=BO=IF+)YYLF!;L>=%%@'#*.D$]Q2).(ALEP*$]% M0!$LG5/3B/,\3KI8/#\^K]H,S+QX*!?E%MK#5H\]-4D:@3:8%@V O '1C23H M-#$7M,>0R6F(CND@7C68M< )>/OX[:X_189PG)&4H"CU?1J$S,^3P1#.4*RU M9ZS^^/'2!CUBV;!3G-X4-6 &U&'GQ(<]PPBA-!">, M^BD+&8N280\ZR]-@V^VFO'_>-GGR M37NC#_*U79_?NG+7>N4%2Q9"BB$>8! Q0'-<5!*7OS+AZ;@^L/^!MH7G[ MB]M**_XX$P+0L[$G05_LO ZJUV'U.K!W7@?WSCLQ.2.720#R>4T6'@@_:B,6314V[;JP[XI5D1$A,(8^7'S0R2B/!GVQK+F3 ^VZ6W#HN.]J _/ M]ZMR >P3:IE3(YET2*<]<6Q!WGD29O<'IJ&(+ZF#ZZ F]9-6/]TQJ6F>$6.6 M_,I:QB8+Z7AU=^J:_:EWQ?;]@Z@V#T6Y?99_9N:+1*0LI@*1C.8)2]$NZTHZ MPCFH:9][-,Y/"B6RG^_GM?RL%]7C4[&NV^)/SOQ,&Q-DQ?,<>6Y<^*+#$'IW MM!U$H\-M^9.#@4Q"C]5YU_=9+<[II'7S*XC5_H*O,+U"01A&+2<#CA(4AI72X M(\1R#"O6Z7GW[.#\?8+$C] M*+U^F/V2Y1T,=.QL8;"(ORS06LNG0\2KM>2K K!R/TRB,(I+2+$OR M5""?!5DP6/,QQN &+YIVX"=ZX*J:!^=YQ7KY[W4HKDKO-#YNXU$H'HK#6#$X M%"=A$H5Q3$001VF28L;2G:&,, K]BC1,W/ #^GT=Y:H2.8U/Q60 UX]R85RH M?B"Y?"N^R27O6_%F+>.^MO])4^+V?XKE%QD8TH7\+;G@%75>UHM55Y(3G#!1..07B.%1Z<6WW19.$H1WX MVZ%4.RQZ^C>'KOWN4'OM?!'3I8U8?J" MKHXR@=-0X'&&6MW@ P%6K>EO7LFPI76R]O;\D(9Q'O- &HI9DJ(H"SM[,<4( M45#E&FTKCO6XV27_Z6U5UW^2W_ZB>FPW*[K-#6#]>>U<1U' IARKF[@KDC M[8::>):@"X)G3NHTU,S".(XKVUAB1GE#OZX+J85#0?8D#"*6XHP@@<*$19*4 MN#629HP&/NAT%OAHQXK3H0%NC0/)4=S(=L<+<-NY!7*SI@PO>;BTF:M'V#0D M0A?\\4:I"0+^WD28R0EAV':5$(6+.QMY0G/0 4^]2RX#@X[ M.-Z\!???.AH!Y@PB%2[ITE&,.V]@[+;2<<3+5071Y7%*0J(]AI-Z8L:(>IV9 M(5^!S>NO,NYJ_M/LF7V;K]I(;,OFF\T/Z?9T9S8DXRE.>9"'OL]\E."(!3T* MC@+L0P3'MFW'4G205;200*$5:2SSK"92MZ08)E\'[#88VZVF]H<#M#MQ&[NL M#8C$"UKG:CJFH8+.1O>J0HY+%E65\\.F>)J72_Z].?8N)(KWVZ_%YH5VSY)& MM"D.(I10E&9I+/QDL)R'!'2MP(8]QPK90_2*#F.W7UPU,+W%"S\.IIU6F%;3 MR[%)AFGDP&\/KZ6W!>@=.7_CZJ,":1?#-*P'0CE;^Q3\U>,Y I(E$:T:94C MHRCSAJ&E:DBI3-8TQ$,3^Z40$LB K=#QG1QP#P"E(4DHX:$(HCR(18@B.@#( M,AS8C!H!9L<-&.^\=;7^>7'EPW%.M9W T1'++F+&/=1IA8U[7 81H\8\3$/G M7 P,&"=J(E9/Q6;[XX-\:[?2?F/[J4EP>%=L9S26[AFF*4=1&B(126U. M.Y,,\=0'-18T,N0\*.RPM5]G,0"38E@ 1=",3=7X;R0BH8%?!^O.:X&U5/(] ME>\N4.DHXCM/T\50SP*[TY O.T-Y%=Q9XP<6U( L=A%/L93[F/$0F$_%=OWL^2$.1V6#/JV 4YP-DNG8=( M_^L_DL"/_]*7\(,IA3W2U;3D)GS#U.:8ZJ&*\HV2$509NR!5UDF?AIC9'U;E M^&75%L17F10T%2PC 6>!3_P:BMQA0G,!:#AK8<2Q% S3OJ<,&C,=,"%0,TD;B#ABY M#;3UL.Z\%MBM#M_.?5^-HOY:%%MO.=\6S>\,*2K5_:K\TEJJO;([T%JV M\]$OMDW5JF_%>EEM:N^AVGA?JFK9Q>9U5YU'_N*H;T%C5#Y:!FE_K,]^*-Y\ M=S7WSZHK43,/?]4[&1"^#ZR]NF*=NN6,Q@%"41$HD@29;X M"<*A( $=C,8^#B'R8VAJI"V_IVK35JJ67D(U /96;OH>F)Q8RDB"0B"U+?Q_+Y M@D4B' PQ$220M R-QX^2HC'$,=K*I,.;[O&$51R77:_GW M'IV[01"&C3PA1^3:3G/1O@Z"'E_,OM4!645>M&?8KUHFS[Z* @C'*& YXSG@K*P^&(-(S\1@G4 MG1D3.ZZW=?;0VD.8Q2$XF$H8L:FF&F,1"5.18PZ9$H?.>B&<(>B"SMB@=1JZ M8V4D)_HBV&%'59=^*1[O7^>RDI!3(D(_D>*7!E$4RZ!NL"5\!*K1J6?!L1:= M2ITO6H3 Y%)-_M0TR#UU,/7I\?SQUNGP)WFY(#IF/$Y#;@S'4-E\L[0[&76% MK+#/@B@E490DO-F"]@7/=F9B"KJ[ W[X"$Y.M?;J!M"=]Y_HS\CWGN:;/AE& MAIU=XZ*_>-+*'>K^Z7L9>?/G[==J4_ZK3WPA=TD8W^$4][\*$W3G!_'PI\NN M=VA;F^IY6V_E#\U6QGSK_=+FN6#_SFMR5/JDID4[X_W_]=.[)B'FJ6AR7XH5 M\+X0?$+572YG<[%K<=) 5]"\^KVYWWKV)3 MV=$Q< D^^)RIB9?KZ8+IUWZF;B]A)YBYH&(F/$Y#R(Q&\+I.GB$;ZFV73W;& MG$4YYUQ$/!()BI( ,394'6524#EHXL.&;3-L2:% M:@HS!GLPE3G?17CL+L GF;F@,J9<3D-IC$?QJE6N#5;4"^]MY^6Z6 []:.AB M\?SXO)IOBV5>/)2+.:-J6C0RF3!9&L!YNR96/QU2VP,A7#8']*I0CE$+.^#4>/\I1?WUV*_WWU698E9AC&A:WB3C/I7; X9RS/,TX(;6X*]RVG6"Q=#ZR9$J-G;.P\F>XN(_QC MF5O.,#Z3$">E!?[Q==B^;PJWC^( M>;EI-V;Z_GGKPQMCOQ3SIM7O\OWZ8]&D%DJ'))O79?VIK9.P:[P9!RG-1"I0 M*#*1IR247WZ+,0D"GE#0>?NXR%R?TS\_/LXW/YHK8 ]R-/TV\V.'O4N#N?_A MK9I;P3"!''G^U-1TNE,'D]YA',VT-2,9=I_[;J"-&A^J\S >KUI[NQ%Y[9"\ MS^V@O)NU'K8Z)9<SCHXDZMSF&8L$%$841Q+\$$#.0VR!/D4@;I=WA3H&*N>KE*> ME\<)3OCM5T:K:/%3GOE__S5/G8H1ESK@_%Q;X>K-=O;WHOSR M=5LLZ;=B,_]2=+GZLP0S$M X)T$6ITPDV*?23L3"$*5)ZBNUK-=_NN.U9 #E M]:C45@<#LBY+^C@\P73XF"+O]'G*4(HY2':4PB$B=^KTX^0PB4OJEMQ+%X MO')+O :9][G!!O0S]7E4\Q%'H1"F*WKL.;K7=YJ="ZZ7,:'3<)O,A_'J@I\5 M7DST)Z\>Y^5Z)F-^GW/I&/$HX"A!+-SY1WXJ4&RJ0(IF;J1!'3H+*J3*IKX. M.2#2CA)=XW T+>J -4(2.MT]0@Z$ 5%TN)&5Y,^EO4_Q*8HWJSE]UW4VX_S M[>"4^5DF:..$-9T+>#,M,J$ M93WM&HE@0RV[\QJ<7@/4&Y!Z#50[<9RQOIUG$:!W%J9BFOIG8V!7]- :=[KZ M^&%3+HJ_5:OYMBV&U]L.XT0$\"1S .TS8WZ:LF@ 0$*:TT>[ K&/9&Q!Y/\IB=;Y" M@'-R]61O)%Z-M6^WN.SHGI +>)Y$@ Q:F(EI:J&-@5T11&OH_9J-*_KY\>G MME\K;-6QR[/:"G(SBH$I/CW,5O@[H-X!TKO7:\2XX@^A\8*0.YF-:8BRFZ%5 M([S-]L3R4[%YG(DP9TC0P(](3+",5P@==G$P#5-0LUQC8V/M&+<]FGXJU]Z/ M8KZISQ<8E%.%PAWWV MP6 P& S_ZW]_NQ__\B6;S4?3R5]_A7\!O_Z238;3Z]'D]J^__O'Q-_71O'GS MZ__^CW_[7__CM]_^C_[P]A<['2[OL\GB%S/+!HOL^I>OH\7=+_^\SN9__G(S MF][_\L_I[,_1E\%OOZT:_9+_93R:_/GOZ8_/@WGVR[?YZ-_GP[OL?O!V.APL M\F_?+18/__[[[U^_?OW+M\^S\5^FL]O?$0#X]TVKG4^D?_U6//9;^M%O$/V& MX5^^S:]__25*.)GGWR[QD>+Q;Z^>_XKSIZ&4\O?\MYM'YZ-M#\;7PM__S]_? M?LSE_&TTF2\&DV'VZW_\VR^_K."83?:2S]EXG,VF#W?3 MR5^&T_O?TS._F^G]_6B1P)^KR;693A9135%=HVP>.Y._\VZ6W?SUU\_CA[N( M0Y)LA<+_+-%T\?TA^^NO\]']PSC"\'O%?DXG'Q?3X9__',QF@]5'UW]].QI\ M'HU'B^]ENES^+6WW_EWZ]V+T);/98C :EU+ Z6]M6[I/@\_CGD.IO,LS1NY]/QZ#K973T8)WOR\2[+%B7D*?N&-GO] M?C"+!NDN6XR&@W%U$;:^KF%Y/B[BG\FL7MV8NT$TJ?,W*]K<3HJO[HM.>>Q-X/YG1]/OY[&NKUO:E&*JX=LEKL>U<5X_:KZY"C3A;'A7=I8[[6T-2U/.]2C1M+Y^OHDKHOOL MT^#;X7YM>;21?I34\.X6]?7J[2A.1-SC7?1.#G5K;Z-:^Y8^L/I4\1EU'?&(!FPP?C)+E(3SY!?6)]/5['8P M&?TK_TB<[]X-%M$J7-WHY7PTR>8')2C9O+7^E@3^N+?4U_L/H]N[Z)?&N2[. M?%F^.'H;#?%A^WBP80M]+(EMV?8M]+C7W]S5I![QO_]Q M>7\_F'V_NMEX>VFME7O9;Z+#7=IEK^?MK4F[ZL21$:LJ[VQ-L@_9?#$;#?/E M;ZY'91FPOUF=_5N3 MZN,HFO";T3 /\PZGRWS?Y/UT/"JSZ7+<6]KN?6G,3WA9V[+4JY%:-/-T?U&N M9)EDMRET^'80)7W>TVWMQK/9LV9I8U.FC4W(VO)5%A]./NVR";7V76>%E%\.JZA MMLF8RW])UC(,/1$ M/H4>J<8,9(S#@PBHD#$.03+(/*4 MG&HV_&4ZN\YF?_TUMHV_N M,U"V:<#2$^\L1?$O6CM$O"4YR,(2+CCI;N3;Z!%\R0,Z;R:QL\N"-_^97=]& MWJQ7SD?;@2JO#0P3@['3RDE&0?PK4ZA RUF#+\,JU$^>:6#"?7]VL>WXUR_<7\AC5/F=@9Z-@ M%-212HAI;WD4%F%?2$HD\S_:$"^M^)=S?5T(/P[@HW@TGRV><"C^ZR5_XH\B M ,M)Q#A"E8;F?::^C>9;6+/KT4 5PIHPA0&R2%C,J2>%)(JX"^%*G2J=UHIH MD]SXD#TL9\.[P3Q3M[,L3]UYV6,[O1^,)CL(4[I]4%YI15'TG3U(HTLJK J9 M';7T,EA47>73YL$]D5!'3UIO)E^R>=3BW[/[S]ELST3U_,$ H8Y@:>2I"MRUSL77FW>&L'&P3E%!$ 2VXD4@!H*S MI 1 M( PN@T$->"UU0]LI?78Z+R5:!>OCW&R09Q@+HXC'#+)"3@5I%0KU:!ZJ4=]E M&'02MFUQ:'6.YZ"_\O2QX+!%4%CEXU0:IU6=#.M:$A;'7)6IZEQ8;*'LOIFI %;B[+?2=GQ> #,*X$4HXP[JY@U6A5S,@-"EHH8G?DL;"[19#:$$DP<\1R*TWLN>9%GPV%5:B ?P JU(9LI_[&V]$D>[/( M[H_V63<-@Z9"18O'*%:(60DIY!ON4ZA+[56=.8\:<%Q/Q?=DVU+LCZSREW?9 MD^=/!2E=ZAP&# /. (]_+48.UPKR'\"7.$%1T[H K:QL]^UA-'MVAF*7PA^? M#!Y8[XR'6!&J-:,22%GTD7OH?@ ?HB:EGPQJIW.&^Y;-AJ-Y]GXV&F:;7\[7 MOYW#8Z>20^\+B%,#./26:!FG5$X4*S".\ZJKLJX]EQGF=,*U"7VGM+Q:+E*9 MI%1^ZE@&/FD:L$,PCD,-(*;$.0,P+X(''#M89?>0_-AD.QWED^>YK?U8)35? MW7P:W6?J)F*/R<_!KMS WSR_/]&\Q;CO;!.P)4(1AHYB@' A&I"YD M-)[K"DQCQS+M2S;[/#TOKM4-<(V.NTOI::D$XZ=L=E_>BW_6+" #M$% *D^$ M%0IA[D31^RA5E;QJ_F,8HGH1KLH/=9]-KO.MV4C.VYUSV/:G T2*:6@U3U3& MU&@GB\E9. VJI+Z('XH-U8"MP4BLO/N#T9S-@T%8R80%Q,>_;8:!3W.KA?6< 01MI0"R3AU%MC5D09L*/2E MPDX-K0V&=]GUQG'*G, Y^9W1M3'8>D095H H025W&YR M(576%CW:!*B?-B_7%BTIH%\VH4P=Y![;"*J9Y0A1R(2AWA@9;?+*'$-BE"K% M_?,X@4.U8UP0Z S'GF+/E7:%I,+8"SE54;_BRY_ .0[A\\QRU1QB#[2/(&&/ MXG#U>+U'#BGBH-21]OZSJ$YEE\YR/0[:\\UR58YA(5!*K_$8*&]."^8B[,V%LP2HZ$I!@^+XXK] #DL%>E1#=%S3WJ, MTS9%3 %MHJ!*>.OD1EI*U(6<]VK;CSD5WVKY =.B%]-7>0H?IN.QG\Z^#F8[ M8^A'O")8@A66<:GN-76661M9NY:*$UXIM^1<)J435/QJO[\1M"\A=\E9:R2D M1@O+5(366.\+B1V@K:ZN'G:4#JQWI=X$'8[-93H.]2YV]2 R7&O H6(.8$Z8 MEWC=0V$0JW) O?QL=:CDX]D0HQ:0ZZ/!I@1Y:3YL6@0AHN]G"'<,:(@A])@5 M42RA$:RRENY19FU'C#@5YDN8B0A%W&OB%>/$4HN]]+:0&'!7Q3\^.HOV86L) MWK,A5T.85S9 \:NKC:@G?=A0OH3C?.Q[(G": >,=T!PH;23 Q1$)*!AT]@=8 MXS6OF;!*15EXC9:: 4%X1JP8O!($[5W<:YS]L%'$>KI5$L1J.32)![C)#)"$&5PY)' MVZ\F<[#;I5>=F)^S >/ 4T>PU2**3 'B"(%"4FC;=>5;\+CZ8;Z. [V]S)OC M;NQNL9#^DXNI_6@2.S0:C-]/Y_EECR7JYY=I'K '"N*&&(&ZPYE&!5H5QK M"T&I:$M5\K1& M9-N:'U:=-,M9@JLT75X\'QRT@F-@A#18.0Z8-W0MFQ5.=Y:7^1 GA]EH\3V? M6)JAT*E:WDJ6:KBV%LT9S._2_0WQ/VGG_LM@G)=O7Y@X?WV/<]6N$.%1[8,1 MSC KO/30L;@$Q?Q1=DU$9Y:H-4Z=3(:7T9P&X&Z+:H^W)58EW9%O"D0[B:5# MEL+HR .!F4%K/!Q E8XG]3 $5"_CFL6ZO6-+V<-@=.V^I9LOLRC%U>(NFSU# M:@_?2K0.(@&L<"K0\"%<_V)WX7V7]KH Q MQ=8"[2"WD#LI@;)K6;R+T+6YY[%X[J(4N5!2:W;[/!/%MM_]W\ M$2UKPF96'7BV^+I[]CK MQ??WXW3X;G*=QL%#BKF\VTNE?^-5U60DI%R^T2@=Y0P[OY83*2PZNWFC77J=K/V7\V%M M2)^<"AF[,%MFUW%EF<5WI#6ES;YDXVGNL^W*>]S;*% ,=)8*A)9B9G3R*^C MK@8S3JODH=6TSH=GP)':@6[1Z*0^OX9BO\G9WB8HY#S1 E!O 8"$1JA8(2-V ME9SNOJ_MFS$XM>#<3;QHLH<5 MLAL@4JWX=N=K'^5C!R(!$5XC"2&.PGC#/"VD,AY5R4^L*0!P3K:H,L =&Z%2 MVR,'VP9$"<<.8>FM=U@RQ&P17"71^:M"JAZ& AI?H]4->-4S1IM$7CN:#\?3 M^7)K]?,#+2(:%@CKO%"*6R.-4%X7?2;:58D7]>B08^,DJ1?F#J:M4$%9 K+0HYF-=5;IOI^S9^FT&@(W%N+8UR>G\_RD^1) C,=)+,8389 M[N?/GE8!>H HLP8C9XV37CE:Q"(H@Y7X5.F2CT<^T;/E4WVXM\6O5;6D\KLB M6Y\/A#I%/(4B#AJ)&%O5GES)YB&HDH9[]'4>W2WLF^%4'8BW::W6E4H/YG>_ M>#1@:!"3A#$A7%IQ0N_T1B*NJKA%?8]&5U3Q%B-4 =D6,V=7&BE%ERU/!P1E M\NZP45$\I8"!N AS,6'0A14]JYCZS<3,W@812]T M7P!Z>XL0UX;.>>92A4@F$#"FR" W<6QT=V]C"[-4O>2I!^#V4F,7@]$DNW:# MV22Z8W,U'"[OE^-T"-5F-Z/A:']*[*'&@2F$#** 8D]('AY%1:"+&5(IZ-/W M/+-Z:54[UFTQ[+77MX=1KQ\.$2+"G=/$&T$ ]@;((L+.(*A4A;SOL>AZ&509 MV[[DIU7(2PO1]AINC;%6.T)42C58)_09'@USE2W[XR_/N]R 41W@]Z<"P_L< MW[ML,1H^^E8768X!: ^8)I0#RI5$V"JS4CU75&!?*@FA\=5S5,?5+!?G.O?- M2URV6J)UL( CSKA$"FD6HR M6;5MCZ%%Z MR&V[1\_Z<5[H5)8U@G@W?#O"^]K?,!@-.2:$MMF<88J[7TG*)=9530Y4V M8\^>7Q61[I)7!SVOW8T"QAP# 8CU(HX@Y[$CKI#2X4K1R>/C29?'IY-0[I)+ MY;RN RT#B&L5"AR4Q" KH%?:FT)>JD055HF?K*H =:ZRYL=5%FIAY->A\E<;7A5P;FU[=/EY/KH>#6;? M/PXV]\D?N+)Y9YN@331AVE.!E/<26:3BI+F6$3!Y89?6G:K@ESRI"<[6*//8 MRW>#^_C73[/!9!Y'2E38P=N:#S<.5!!MN5.02"1D.BL9I]N5U (!UEFR84,D MJJ[]EWRJ&^*VB+4^,'+P@MYGSP7'',6*IB03J(74'GM0R ($ZJQT=4-TJ5&Y MVV\O. G6]K)YUB9W-4>;Z?W#=)*G]!^8LO:U"P9++G2$1GC*"<'045K(BKFJ M0J$>)JO6-6W5"&E;]'G1U8.SU=;G S+:&JTPI)1Z:PP7KC#,@E-?):FPCQ:G M'CUOO3&^&K(=[&T=G)M>/1N,!8@2:0S$6G%.+.3%^)(F3N^7Q9:*>MV]4W42 MFAWGP1]DR]YVP2+IO5&4 M8VH< %!AJ@135!0!"^7C*J+-C(PF+X]KACFU@-JZ/_RVN.VSC!.\>3AH@+DF MDL3U)(0*40.M**3"&E2Y9["']0[J]GQ/Q;$M=KR9#&>I.H?-5O_=%J__L/?V MW1/?%"@R<:D)+8(@#CS#XK!A!1Z$7VP@\ 1"3-L$^ORR"XDC'%./J(R&-YT* M<5 7\AF&JB3DU'#7;@OGCQLC1,ETP^,4<"ZGNK P2@GOB%%0&FH,$X7IUU96 MVO0ZVK6^:%I5QKXM1KW+%A&3Z7WV=CK?YT0]>RY@YR%!!$/I$)#(:^1L(0N' MNM6;=%M.46V+054 ;]4G@%> M@7G/VP=&/ .4 \C37YAG5A1K+9V">Y>55-TQ\2IAWPN3]WBYVRK7(J$4G8RK MFXC8339:+&>G6\,R[P[0"R\-5QX0K:Q(=P\4#G IYB3YD$5PYZ-%]C&;?1D-LQ4@'[+A M]':2O^50E:^F/QT\0)(QPPER4=64*J6*K61C<:4U>:6L\PL:%CW3X?F%(Q6C MC!&IM!96>@ -TJB0#V)C+JO+4 M80R.?UF(]&:1C8I!!KR1$$36KY$1DL J&1U'[X*UD=%1#TU>!Y*;Q;W?6Q6" M&("$-H8RJ8AT0-#U1IZ17@C2)H>:CY(TJ>R]&Q3'P=S)NC%Y[9/A:)P]Z_FG M:7TFKHG/!0\]\1)K@"F%Z8)T@M9K"Z,,,E6,8 _3(5LD< ^TU=8XV%Q&\RCS MU6N#(+G64B-/5%H1(6P40>&L1>T:X6C;3%-YM%70Y' M>1??32O2 M47?IR!M4UK'G$JYE^9<$RR F0BHEE(#2.^Q!,1HU-;;*OO#1]0-W,;6Q+85> M,;4QI75'W?>S[&$P2I]L+ )%/<0RZ\ M=-Y!KH'%!3JFK:.GS].]NMPEJ\ZB@T1M0"W=D58-A]/E)%64_YY.P$0I7E]4 M?A1IR[PP1%<( @2X) (!Y>(,!.D&'2:K5#;OH9_:"4L;T$.+TX@F0FZJK)J.3]EN]PJ.=H.BS2BD8UJN*P36L^6SYV4! M$&0((BSZ64@;(,"FL((QFNDJ90..-IJ7MN53'^YML3%*,,RRZ[F/N*VC6^Y; M-AN.YGO-XKYF@4$)=.[1"R*]!]+!QW'G*Z7-]C!JV2057M7\K WU+OB5K)]M ![(AI=4#?O\FU MEDDU$&Z \10A2%ST>S6#L)@_K,:55B!GZO,UP<;&%-):GFCL??K_E!SV93!. ML;/'7/'TB[BN>OZ#)T^N,F)?+\V&XV6J].R^#?.BR1^BF^-N;K*]_F*['0D> M4$H%)\YJ09D1Q );:$,HV^[EN^T.CT;='9-9)5ML.E4NOV5;BT"85D@8+P&###.H 1;Y14$B+M,I+^6X-B/C M9D]GO3=>9F[9V29X:@$BD&K@ "0I6:WS5^;C87:UZU3"Z7[,43**=3'5ID743; 1W=QK6\\8=52BC5=#][8W=QU4^\>L%N MBURO<#AF%@U($*$]E=$YH\9[ZQF%:YDPD:K=>H3M1G+K)U!5>%NG3*E3H5N> M#M'*8D^@-UHKP*&VAOBU7*G48JO))BW3IC'_ZV1XS_LLG",8":4-(\Y#BCFQ MSA2R(F+:J2C?04'*6DE4)\3M91M_R59=7:'Q9A(]B&ROE[ZK2?#8<,^P^S3XELW=MXA0U.YH,IA]SZOOOYO&WTX6$?5Q;HA+$+&QKP:&N142QBE M2JJ5)907/@.5Q%2)8!Y?%O6\Y];^J*G=X1 E6;N@.JYI;D:'J?RJ12!<2"84 M9LH#(* E3*!"/FLK;1R6WY1O,K"MXN[5L%FC<:DY'"Q<9UZWQ,HPZ$N.N^+/&X @&K5L$ M)P!4S JBK>>*<2E-8?KC=UQ(A292*W M#=-Y,4[GV? OM],OOU]GHS1$9?I+&IGRR!^6];* MKD>#)0L\&XS=Q M-'W[_[-M-QKL?#;X9(BB6?(..<"A -&.%&(X)JM4%NB1K6Z#']60;8@@A2&XC4JM/1F=:RW>.E9TJ'"H VS(+WQ2DP&Y=, M!^CP[-E@@!***RXHT8)1;UUT.-9B$(NK[#14VN4_1UY40;8A@JC8K^O4-S\> M;(N1O7HF "*U05%R[J$4Q#--_:;;U%I;/)@LM^MV-HB2."EYA@Q@QU24%EA82%2^D\K&]EG3I+Z\&V4,A_O M!^.Q7LY'DVSK!O:.)X,E!EDB$?!<" @(ULQMYD<(JFPR5KI@\_PH4@779JW) MM_P 8WY:FXR)(:0,\4@@)KI[04 A%JH,.B2D9\I1V0\V-'!5@;Y46> M^9<.0'_)HL\\,,M90FHO0[8W"5)1JPUGA"J)M))0KH1RQ+*(595US/'W-YXW M66I!N"':K#OC1_/A8/Q?V6"V?\V[Z_' !53& 010)#]A5'E5+,X@YK;2=9\_ M3/BT)G2;#:&N^O@A>YC.THF@M*F\W._';F\2K)0. >L!T]P;@$%*)EP+Q:2I M='??CQ91K0/A1FGC1^-L9B*7;Z>S_1[+LR<#A;'+2.2G.1"-GCK.,Q1R$53\ MGRHD^6'BK-6!;=:DO+P8>W\:6KF&P1FM(7<>(.RY%D9IB-8"(LDKU7^$/TPD MMG:<&X[;/TZ=/OYDU[2TX^F@*/).&LEP7/=S!BU!M! %651E?01_F%AM/>"V MPI/5NKX\4YX\'XAC+AV4-T89BK@U:+-=A02LEO[UPX1LZX*WK9R=S1'FOV># M^7*VJLEU0K).S6?=;81O/$T=*E.F:E^S *1E<2%*J676\;BVD&"5$2HA!!IV M>%W]MFY_BFCK\?Y*_GO;!0>8T(8:8@T4J1!XJA]?R*O(A5T@7H_J=YWKKP'@ M3@>RFL^7]P_YD=M4Y-UFB\%H?%G#&TNJ+*:8:^:5!UQA;7*SJ@5P4I:B>\/2 MKFZ?BU/-DUN^UEJZOII\2 4<9^GXQ.3ZW70R*_Z9T:9PEP0BWR!-E3@PBZCJ8=X.XN&=*Z?$]/+Y[/% MDU$0__5R!,0?A0^I^KWZ-MKFAS[[?4!0:>,=U,QX0H435$4@F>8 1!'8A=6. M[8?ZI]45T3AY_IZEXU_[Z+-Z(C"J)%%$DW0?(V$:8"E6_8; P4OQ>$[4U4M- MGX19D[K^^V@RNE_>[]7VLV>"Q)808('UFDLH\[LT4M_C^EL)ABXDK_UDC4WK MP:U1G0^^'=;YTV<"U-%[UQ@ "RF"&B&.9>R[ 4H:KBK51>G1SDHM.J^ 6Y,Z M?W&X=Z_NMSX;!#:1J3S2-?+7I!/IRB=9* 41%MCN]6"]YD =^+5U]O#)>O7- MY&&9I\[O\!L/-0D0,FU1[Y)?T_-^/)MO6]@%9[(FW4FJOA4?"(E? BX@'%W:.OP6>U0%S5Q1+ M9133!6MVE&Z,G5R?9-1VOR2XB(#3%&#CC;84,JE4@0(BYD(<^Q;)5AO6;3&N M(5?V[6B2Y=5DV]\OV7PZ8.XM89X![XCED"FW3B.(B"M3J;)P#]G=RT5)SW3< MUJ@J2M&G6S)30.!IEMM+D[%GA!SSFN!)"D#C:,8E])K361_8^RF;W9_(V-0TW35C@%<(QI4IB6X](ZHP)%A1624)NX?N M[5FR] 0]=9IKL_GA?XZR6>S)W?=+3+?AGEF#65P5.Z&0UB:I(4]^0HA%[9QW MNDT;N34K3\9;AD0<,=I+[CVQC@%;X&BIKY28W6,#5(E2#3AUIRBC]361_O[: MMKQ-=S0>V"8I]X*@F;'1DP;,82>L)$APN98><^0N+&3= 6MV\;9.M;1.R@-3 MWZ$ME*/>$Y13A'*)XZK/6@LU)7J#!8N^ZH52M":"[.)? ]"W3L-\ 3//08$' M0Y)[6@6A-:3 .D^1-X90$QW-M9S$6F8NE&+UCLKN!+X]5I>'?)*WP2K]:M L'0(\J A,0[!+215!5R M0B^K;-#U.:K<.J].P_N<]DW:VB1Y#!; MV/V*HP/M'1X).^J\KV.#6T('6WAZH$7TE07BL;M(Q$D .<+E^N:_V&<6O><+ M]>[:U?>T"5UT&M/-A]UE!7#3_3@4&F\H((Y$O*/OO;HZ J%4PJ"[ .['X5UV MO1QG5S?'\O?11)8Y/EWK=P)'4D5[[ 'UVL=5.!4(%G@ZH2[LTIQZJ#7MCT+. MR5';E19Q5,V )K\?(@&B0T*L)P (YZ$FQ*^QQTI*?Z&.79V#H8^*:FL.?G(A M>&=S[J8/CTHM,>7N:96*NPM!L4?.&PZY@WC-!&Z= N6NX6E-UC*V9%^SX E5 MT%E*($[+8BBD X6T6O@J)J"'\V$M>M]U>WEU>#L8N%TG/=0_?B65<<6-HVW$ MUB$+K2#,6NB@A92XPYQQ*BCC MF*I"1FSYA7FQM6A[V@2R;;FC'Y>?YUGT"R8+]R6;E#ESN:-%D#AEDVO')>?8 M,(45L=8BKQ%2C%W:OEEE+;]<^M2":H>L.;C1O[--(!!RJ9UVD&@M-+1,HK6, M$3%U84?9*FOZ,'-.PK4C[AS<^]KZ?* 8>^RDD!8DCP=*#722S8JXT%+HPG*5 M:M#Q?M:X:J!=3N*'-P?MK5)-"($D2<6L6 @W'-)3PO)'3:7EC.654U'V3-2:BV M-CE%%64IU!:U./[_EK/1_'HT3$H[/$WM;QFT)AA@!2@@D$&F#!:PD)=A="&U MR>I3^\OYJE9X6Z53VD#\.,PF@]EH>FAMM>WY(+D&<<'II20-?=KV3A2 MM,K*JH<9/K6OK&K M#6^K+OXQV3^D U'-Z/L^O"Z:E>;@+05#&B@+ !""."0 MIX6,U+H+B\!6U/.KK8EEU=8&@2+E@*-88P$H\8PB0];2 M"8?(I7&FNI9W\*82K&V1YK6I?5LB!7!/JR A8I8K:+6. !H.N"RFX>0_7L@5 MX4U-5?4AVQ:#W,U-EM_^MW'X4H41,YTL1I/E:')[]9#-:K#N@N3V[?3^=P, M9K/O-]/9U\'L>J[NI\LXP4\?07N9^GG2RP* QDKBD--$,V,L@:18E4B#*T43 MSR(R=#JM6@.]/GK%OYCX[]'B6<<^1.VEHP,G4*SL"P,3VC)HA&=>18"994H4 M$DLCJUBOLUC(U4VSAH _F6KO9]-AEEW/?<3BXR#E,;[J\BY2E6@:?(0(,:P< M$L R;WD<-(44R/,J(:2S<*XJTJ=^B%N/9J=R;I-YIK-)=C,JE<;RO$4@.@(4 MIVXD)(Z#P3.'"\]4C Z'825[?# MP61A[E))\3>3/U*JZ#3^^%\Y_]?]G[^)YG,PGT[B.N;[^SAYC^)Z9F5(KVY6 M3:*VKP\3L*$O!LCB*MHIAJR3W@GID<1K?%546)7-F!Y=3=@D<_NAF;82$M^. M_GLYBA["]^>?+Y6'N&.6W[RR5&+AH28!$T"\) 2D='!DE8?>K1(YH[]"NLP* M3CD"BTB3T6!LI\O/"_5YNES\;1K=^KA<'&:S2:E#-J5?$AA7BD-#&0 *1!NJ M!6%K)*37M+/@=Z?>S8DM_1".RM#]S3\XC;&;_ $"-3X0H: M%[)($BP<=\;&?RD+L2U5Y_+8GN_*[MWR5.""><.)=$9#J:,MMM&]7?7/ >NJ MA&1[%#*K3TW3NJ \OQ1>88BS.'XE_K^)4B(M12$?T4I<(E6.U&S)M-WCD#S/ MM%T$(2%4 ^"1(8(2%Z>I0D;OV(5EM%36=.FTW>-P/:^T7<)07!8CS00%A$B# MH=C(AAB[_%3O8W5<*FWW.%3/+6U74A0A,BRN=JGGD&D9)5M)YPW&54IV]&AS MILY9J18@SS%55PA--,":6F<=58X)B3<2*G4A%X+6I>:RJ;K'H7K^J;J< N<1 MY5AA0;V&#FR6"MY1>6$W%U17^Y&INL?!>_)FW,:6OMV3T[3CR0 Y(%(C+*/) MQ3H5HZ9^(SL Z#)V:NN8<^I!L"VC80;SNTC-]!\7N_QE,$[5G=1J WDTN0(-ILT#?;(I6=^D_#'5 M5LG+KWR\R\8W5S=1#;$KN\S*_E8!&:DY\QH+&/]*L>;2%GU'&E?9R>JM6WLZ M+^I'M#T_93K\\\U\OLRN[3+U\WWL[?3ZXUW$;?XN^YK_:O^AD#(O"&GN3(%[ MX1P%D#'I-"JDE[Q2..;H*>M+-OL\[3FC&H6W-7+EO5SU/K]8,G8^_]D^/NUJ M$R17@$ND-"*I>!K#&*A"1@= E?COT0E&9T6AFA"M)?$L=2-E"ES=F.G]_722 M\_M=MG-OJTS;0!1#7%+"N!><">ZAPYN)UNDJQJ5\WM!Y358-X'HR/_Z81*B_ MICES7;1HPXS!^SV@F,+;*1%Q$(85VE2Z.Z5%2 M3JWLJ!_6MJ:<]X/O>4G\^$-+1GR% GBI5' (F*Y*R2%\0<5R",NCSRM 7T)!S:2 MB(AC))2B1B&"$2Q6E)! 4<4AEC\*M1H"N[>'-"2#T$"#K,;1[%(CR$8*&,UP ME=@?N%#.U(]K6UF*T8=?[9\DN_ER[=UZR5,WF$VB#=]TI$2]TUU- H\K$0:! MY(A2@95S%J[+5G/)<;F+,MJ1LDP6\LXV 5)%>9S($&:*&R$!TX6<"@-0Y0+H M'F[V55?WR^/$-0';XH!-0W4U:#1L#3 MU!#7Q@_+E=ZO;EX1[T#!XWH_%(SC1FEAM+0..8^ K! 5#-W88ELU8FU\Z:/ M#K315J2DHFCZ^_87',BB:_"K 2$*$*>0D^C*$4DPTWR-,\?075B-YZY(.NVK M0KL=..\&]X?3U0\U#43%_S%*8P>IEV MHW!$7UB=M?I4_G+Y41/ M;9'H0Q8=I]%PD5WG/3Y(H*W/!R^)@@PXRZ'5%# KJ"UDLYZTFCK4Y#Y]X_2I M ]ZVJ+.^2/,@99X]%[!S#KBXX&:< TX-1;1P.H3AM,K.6H\261LG2A50SV2Y M\;9$Z<>Z/A$@= 0A+RDDC%GG/51BC:!,R9R7D?QX60N)4[5W)OQ?[40U1_[5 M^X-2P%,9@<)$,D\IM'Z#'0#DPI;0[5.N7LZ?I+2V8ME7L]O!9/2O%0TFU^\& MB^4LVAB]G$?8YMU%KI_VRTPG\^EX=%UT\OT3@:]N_&@RF Q'@_&F>'>9:ZUK M>7](6Y2&>T.P T S03A870^LF!<$=!@3+Q19JGCNZX>#TQ):994P#"ICH7;2 M%I)%M_;"3$S+;)C6#']/C$77NUWG83.\\(PY2XA17F+FTI4CJSU-#(4&I79] M2J:IO%NFI<;533KQ'V>PP6RT]9#(SF<#M)!0[;'$7'/DK)9:K/N*!%.='4+K MLQ4HK=]IO>BW900^C&[O4O&^^9-+Q;/!O,-;ME>?+S& GS\8K%22>N.A)"8E M(0H)5QN/V@,JNKR+]VVTIEGVF%"9][M,CLK^AH$ZQ*6F! EE*)181W)N)";V MPF;U4]4];1#3SD=IUY/TJ8,58&I5BEDP ZP"!A.]NDS%84REZ=#57O$C[Z[- MYL/9*-]".)1+LJ=5X'&)&#DJ(5:.0FRM8+Z0%3MX81>3GJKHK<.T#D!;.P43 M!VTV6WQ_/QY,%G& ID/J#\F9T-]+%. KT3IXZY3W4!@/4%R.2 ;7I<@3E@I> M6(91+0QX>3ZF=I0[9U>IDGTE6@>F)'$ZW8/ E4",0'&@9:/3EL>80,0XT$B[Z]&@M+U767=@N8)-$JA?IMIBU?=)_ M6V(C^D#+H)@0+#.*^0AX4 HXA5 7IFBMP3("ZEL7;ONMH4YJT';KFEYWM=/V>P^5>"8 M' Y?'&H<@"+.0I8JNC!CD3; DXU!E:)*_N;9&)C3"=48T*=7B]S1D^FF)P7_ M/V23[.M@O*H2M;NFY(GO"XH2K#QEPE#'J+8>.E;(*Y_>'7L1"7N-6*J6L._2 ME*T[GJ0ZTHX]:1D\870N6W3 E51R_FK 6;5CG(O>%=4 MU$M7VT?G;ICM3>P^]E7!2 B8U5 #PC5"(*)01-/2F;,JJ1@]JH;9)N^JH]P- M[]Z.!I]'XSRGO)C%[;),J8YC7A.8!Q)"RADQ$L5EL(< %$@@X:I$KWI47[-1 MOM6*<)&Q$&[WB;$0NB?#IZ[0J41_?%"1V).I (FX0=4 1HO5 MDZ'19;ZLE6A_V'FR"GI)R?CAPZE_1[PK*.*(9QI1$.>QJ B!3!%6LECC*D:S MA\O?_M'R!"7TD9A^NJP\JS]Y5:!I]DB82$(X%-K1C7=M'=55ZI3V<.W<.UJ> MH(.^L;(&-H;DM4A*O0.,.22$?XQXV@A*%>-X_$IZNAB,?QP6'HE]+]CWQ^1Z M'2C(KMVW87STX*G]D]X7 "&((,-)G"BX(PK@QY&)O&[G1@NYXN4DNQW$_GWZ M 8QD3?KH-A;T_>BPS_<@HK-LC8 2,(>5@,RQPC]QDL$J>R1'7X#11D6G5JA6 M#]B=G_K*\_C.[] 7QMY$,#G!6A$:76^I_>ILG=-*EDNYZV"*^7LZ&%_^7U">365^N% M)==1JQ)$+:=$4FZ SY4LG4>0E5I"-H/88SG"3?G<;/9E-,P>.7L4 \I?O5#C M]P+2# (/-7-"P3B"'66BP)<#5F6[IZ9+UE%/S5YI9NZ\M*$[/;:UM%]=$+,I M$?1V+',W#%7IDWII6/^'3S[ MO[==@!)0"37 AD3P() .\Y6L'@ *+ZSJ?"U:+\>DD_!MBTN;NQ8GUS;[DHVG M^@Y6[@ M:R(YK8752K]$12.KB M^%!&X'5964:0,QVN6_H?12S-P9U1Q':U=^+4.Y\MGK __NLE\^./PH?4XQVQ MP6>_#\0S[ZGW5F#L0;3&UK.BS]IV-V$V[?JUINMI==0;9\K.]?"+)X+$)B[W MI2$268D(YEP44E--594D[1ZQY41=O=3T29@UJ>N_Q]7U_?)^K[:?/1,<)'$] M#P$'1B)FH9 ;V:-O2"YD]_YDC4WKP:U1G0^^'=;YTV<",S#.HP0[' 7GP'-& M\$9Z5:XX>O^/K=6B\PJXM;7P3@4XTWV3APJ /WDL>"68(0I1+:G1A#*N92%) M^O.'B VU[2#4H(FV.76X\/>S!R,D'E'&B'-0&0XDDK"0AFF(+JSHY6F*W,&& MDQ \N?B@?@R-I,*]B^]O)JD"QNA+EOHSWSF9E&\<()-($">%4!81 QRRM)#$ M<7UAMT&=JL9IP[B>S) W?PYFH\&V?KQ/1OK3%"*??9XM![/OT8B0_8PYZ64! M4^Z4';X$Y]ESD?8>JOPN+B.= MU5PQ;PM9,"T7TFZ")C^$$UQ%%6W1ZG1L'J6;7)?VI9OX7!"$&*BKE?T+TB6DS46\Q&P[27F_9%RZ3FO7X^4,VQB?,!)XI2 M+Y4WN)AS!!;^PI9]W=+C=09?986\)MOY>,V]4,8E^% '@=R%X]L2N6W57QZB M+8?,*:J(I@AXHA@H-G^%-[2*4W]T]:#6-\Z[]]=:UV#O>9__\8]H?D>3VU5Z MU;Y*TW5^)E !E,50,H*%H98A#. :2>DEZFS3[G$DD,[L?8T\K&L(5%?AR3&7 MT_M\>SO+JP!M[II/C\W5E\%HG R)G\[^%E^R+>.LG0^'. \C*J1.^_7."T<5 MT&L$%=6FRE4BY^CGU,_[7NJQ_9&PW@-6D\ER,([^W"Q5 6E[5)S2B:"!0M 3 MS&"<^Z02A"I7(&NUKY)KV,,XZ-F-D!9TVGLGZOAQU/0G W$16H8CSD!2Q 7@ M^3&/%<)87]@5'^?H3]6KP5Z=)'LWG7R)CF*V\AGGGU*!T*>_3RG2[Z:+_\H6 MCV<[JIXI.^6;04C/*09(">0MUYPC7D28-!65SM]6NI#D<0E"+W#(]$6?9S]F M5LNP:#'6/TK/[5N^M]N1X*@TSGG$9*H019R$M)CEM<&JRAQ4Z?J5GZ.K,R7W M:LA]&GS3V22[&2U\5.!QYSSK^4 @7BC&L"2.8 #3V4)>).-JH7V5Y?_1]6M_ M#I%&E=?[5'C$.SSZ6&!4;H?@U-FI">Q!T3ZM20*1_$N MDPO'JO'XT\/'X=K[Q>W;=I+/K:,$:2JE PY [YW:. Q*QC\N+->P\TFN=97U MGNB;=:6*R\G[U3S=-O1QK(N*I$B'L/ MO3'>R(UU,H)7NA[L,A/=>S755%!E3[;*5OMC:KB(DBR^_]P@V[Y7@75IJ\\;9-Q*!5@RSX(8#=,E6NM*T23^H]T;'\XI=EB: ?LVR(X#O^\; M9,X#KCR55'OJ.:=&T6)80N,OK<[2:8K*@$8ZL<[P(BJA=Z ;JL:K=4[2I9H3/N?BNE,!*[5.-$BQ5"F,Q M6DBJ%$(5N-3#0&0=7&H#YQ-GJ)JO%$*QIRCZ@%%16*"!1$74H+T1%WMN%+H.,R:U/7Q5PI! M;8PEE'M"773:*#3:%GVWR*D+T_>Q&MMYI=!QN#6J\Z.O%#+YB1F-K22 282M M,*CH.T6@U8NR>Z[S"KCU?M_C;3OI6) 903TCC-H(DG52L\*Z8LQHE4OJ^KCC MUWE(I765]9[HKP\1?IB.QWXZ2[]L\,3<]@\&3##2VD(.M8^F*!V/6E<\(L1A M#[J:)8D4WXD"@' MJT0SCAX@#_EQ_8^+P6S1SQWOFNC9W&@Y2:GG,E BSC?9:+&,;"M*.S0X5+9\ M+5 "HV/+ 6:*B&@+@>?KVL0D_JI2;;?RSKQ<#99)?C+X^M5\PGZ.FI;T>R[C MIML)QM&T#:60858);Y''JM OU8!4N:ONZ"7):H)QD]>CIG]>6#]'357]GLN8 M>5*%H?$Q\^I;P9OH7?-T?S:$4'B'&=Q@JG"E*SUZ%#2Z@(5*5=757+0]_^E< M+1=WT:S]*[O^8Q)UGB<;KOJ;[[FM^YR]GXV&V9XTO4:^$Q!TWD.DE?7 ,(>$ M=$5DD&DHJF1JU'2W(+P@GO=!AYUSO&EN!VW2-7I>>2N2XXBD8QL\C(95HJXU MK*$;O(6I8WHU0?(CE5DSNO7RJPOL8/!R.IH,I3)B!22'.':1%,3\6S MJPR''GDOO>=^=RK] 2R^Y=8A2CRGBC%!%-JD@7.A894B')47M3\8S1O77G,F MOOSBHA[+?N+W0I1*8VZ8 -1BSX2BF]U\SIRN$O:\S/-P-;KIK:OO7"(T3R)1 M+PH\/Y,^!'7>LQ'6 LV[&9%'TJ W MP_"$I5M3X['FK@3-"8E+2H,I2?64B&6B2.N-_HFZD-382QR2W3*A-V/S8J9( MQ1G6FGLIB0<>("L-*/!7'E0YMO2#[=%W/C0[8<2YC,@G2^2.1F3)'@2HF!4" M&L>L8PP0[E@1<)7I.LH*([+2/8<]&X#=+PB;4>BY#"AU?9W?V3@8/]95*5/Z MI]'OID/*2!D2;9CWRCN$!%Y?YQ5_YEB5Z:RF&Q O*<>@CSKM?<7(@]/QARR= MMX\_-]-)CL!R,$X5 =&A4=5N;X)P-+KK@!,ED80JU6<+RN M\I.MZ?U(]\V:C%V,K70]Q@4&5?H[' MYO7>DT*7'[*(]"@5[RP%$H6F5]T$.?I2W2-5;Q\CAU];KB);0&(&F] M@%)SHX5V<".)LQ=2\*=#!NRM>'D4^'VO> E<1 -:[XTU"E(+D5V?,T'2$'2A M%0V/4^3^BI?'(5A7Q#!)IX_]=)B..5>:> M&I=U0=O[X.W;=HH12>T$%9038#RU@%FPL=H*>WMI2]'.9[O65=9[HK^;3E9+ MZF)H1Y]VF6N@O?I$Q_8A2,DD1XAB22@'R=8H5NA 8M^9DW@>B:&E&5S7X&E8 MOY1R)1#R#$/I"TNLB0!53OI7_53M?MVV3YO&.39;<$_\CFVT=+LQ\,0EBB)(%"(>*T1I"X(L2JL255+M$N MGW[YO*S8I_YNW34^1GJE[3.>?7KG_SGHE+?$:&FY5-0#6>3@(4VQJK*R.OH< MZSFE.9_SK%25!;T??Z\E7MQELT]W@S4B\XC-E]SRO)DL9J/)?#3,;\YL..Q1 M0[<"XHA"$JED(Y>B T"UL86F!%55]CAJ\B#[G,?9>B2D?96W[SP>E/&)O1EM M/_JTN;NV=D>SSLX%R[E1UDBK*&!2VX@^7FO"*&>K.*67=VRV5>K7XJ9VR)7S MGU+SI>ZNHXWY+VU<1.T;Z+WK8W ,$VHP5-I&%EJH'2Q\-F,UKS+>:YIL^^<8 M=S'LSYTYYS_Z_['6:)]'_Y%]#,0QJC3@&#+&A).>V"(H85**39LG@'N<-GZ9 M [Y9LOQTTIMSO+PG1! &. (80HJ@0K[0A*"5KC>J'-'Z.73/ERF]/Z]U$!MU M>SO+MS*>:[/LV>0N^A0T=1!1#9AESAJ(G&-%8JOEQ%0I^_\#U$:O%.\Z WV? MQSRZD;F4(]RK_@6J-5?(&)FLN6::4U3DA5B!?:MGF5L->?6;_9U-IO5QI8=C M=YVNT] M'*BENQ:$Q!C$%8=/>^S61OX4UX0A:^(RJH,F'N,$ <^G0Q M R:<8TD!W"1RNG1_PH4&EWX.VH:9=4_#XG4M6I[?,?C<>7+VODX',3_0S.1HYAH(F-JL-" D.* MQ8L3@E?9X*GI,"COWTYXZ6.J[97[NLIHY]T]P"O43!0(]""ULS'WOT>T;U1I'5']5?#A M947/R?6+G_PQ&2TJ#X):/QN8XT8SR0E3FO-H6" R!=+"XRHW\=64=G'APZ-+ M=;8_<-S]PWCZ/ *"=%)I!YYB3 MT5*N$)?1;J-2(8-6I#Q8/GW+XT%0X[31$D:>8JPD,A!9B[BE2@) +ZT@=64E M[Q^HIV#:FO_YHJOQXP-(,:*B1>)K^;24^-)N_*FDX@-\ M.0W2#BESL$KYSC:!6 \0ID):P2R"W' GUS(:)T25$X9G0)NC-7V8.2?AVA%W M=I8XW_M\T,QK;+ &*@H3 8)EJE1OJ-) M@ 1KJP3VAED?9W4*0&&?K<$O[WH_^Z3P!J>H4S%MC34I&OAF/E]FUW8Y&TUN M5R&./"@R?Y=]S7^UET.E7A"8I11:*J-'Z)U'F$BD5M(;;<2E71E4G00O6=4$ MRJUF+LU7O<\O\XV=SW]V*(MH6YL@# 3$.@R$QDA;+"5W*QD=T195283OOVVJ M@4DU 7MR^OC[V7289==S'V5-W1A,AJM(\/UZ6^]=MBW04+IMT 9XR2T$U$JF MF1:,FY4<7BMJJIQHZF,ICKH(TA3 )Q/ECTG$_.MLM(CF+FT:3)MGYW\:1$TX"C[^8@E0Y0BAST,.*T\N* [!2C+72%LPYT*1^?-N:BXK] MI*N;S92:.)YOZ>R9CO8U"TAQ N/L2JT""BE,'%NM21ETP*,JV>'T@IG4 +;M M!>S7%[!^'-U.1C>CX6"R4,-\&"3?;#H>#4<=)F2^[DJ)"/[N1L%*#J(W(+&6 M5CM@ .&KK#$E(H&@Z3"&OP__4GMPI5X0$ONDM90P@1"UE"LB"P0TT!=V6V = M5'CI=C:!<[^&>]>[=G6/>D\E(A(Z08$B&C AH#*(.,Z%%HJ5^]8O[(5P5#G&-Q $C&@!+<:.RM M011Z"^(_8)75Q7E9@M+TV!;*: [QMAS)53'\E!ST,)TM4LCP8W9[_S339@O; M=C<*4BJGHG%ERD!,/.-,@@).0T!GM=K/AE>U8=L6@ZX>LMD@0? V&T2X1X// MHTC_[WOHLZ-%<)P@B6UTN F'VGBO "ODBXOT*MSI8<2C >[4 VPWQ/F0#K1= MW?PQS]1\OC5T5JI=D%0RJE+<&#H#E#,,T@UV<=%^6?&0QDE4#=ZVJ/0DLK<* M##\Y*KF'2?N:!2$50Y+ZN&3'WE-E&(V#AF*C&<$,7E@XI $BU8ANOU9(%Q<8 M 1*DU%0*'()>2.:]6Z^&N>56=Q@8T8/Y:'YU\Z+OWU=_E@F,E'M!*HM+$6$L M,I$YS 03^56@.0),J%9/A,9EP^=I=\.]-!FF+2#=V@0RF-^EP'_\3UK,?1F, MD\?]QV2V.6^T_8F5=/NFF$HOCM,M)M BJS3Q3D(@A2^4X:)/IWZ8Y=2IK&P5 M_VYKJ*S.D491WDR&4831E^S]># Y3-$3WA:$(B8=$Z+$8DBE<(+0 A=@ M'KU4.U-[V3SL)V]9/_'<_CE(A4L6F[7DX9GWR#<$;U4Z](8M(=("C@S7MI!) M&G5A&]@U$JE9H-NR99'GT_OLT^!;>9]N5Y-@HD5.=X]%VTR$4M02AS;#P\$J MV7E'+]G.U"K5A&U;[/D0E16_E29PFWW)QM.'%"IUWY(]S0[.?"5:!^"L AAX M3B4ED#!%X,;D(EBI: :[://4',AMD>MM-I]G61X&FY>W3GM:A3AN'(U>)%1$ M,"6M@+I8_'CM>968$O\AR%0?N*UML&5?G^ PFT[B7X=Y';CYL;&,8U\5E/0, M"(O3J1&!?42&F@(1YE&5\P_BAZ!;PXB7"&NN?Y'^2(4D_N/?_A]02P$"% ,4 M " =@*M0VBIP54B_ !A: H $0 @ $ 8FQP:"TR M,#(P,#,S,2YX;6Q02P$"% ,4 " =@*M0YL//UY8, #I@ $0 M @ %WOP 8FQP:"TR,#(P,#,S,2YX&UL4$L! A0#% @ '8"K4$K0V:(A+P H58" !4 M ( !MML &)L<&@M,C R,# S,S%?9&5F+GAM;%!+ 0(4 Q0 ( !V JU!P M8Z\9EWX !C6!@ 5 " 0H+ 0!B;'!H+3(P,C P,S,Q7VQA M8BYX;6Q02P$"% ,4 " =@*M0G&UL4$L%!@ & 8 B@$ ,77 $ 0 $! end XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R32.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation - Summary of Fair Value of Options Issued (Details) - Bellerophon Equity Incentive Plans
3 Months Ended

Mar. 31, 2019

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Risk-free rate 2.51%

Expected volatility 82.95%

Expected term (years) 6 years

Dividend yield 0.00%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=blph_BellerophonEquityIncentivePlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R36.htm IDEA: XBRL DOCUMENT v3.20.1

Income Taxes (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended

Apr. 30, 2020

Jan. 31, 2019

Feb. 28, 2018

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2020

Valuation Allowance [Line Items]

Effective tax rate (as a percent) 0.00% 0.00%

Income tax benefit $ 0 $ 1,801,000

Expected change to unrecognized tax benefit liability in next twelve months $ 0

Scenario, Forecast

Valuation Allowance [Line Items]

Effective tax rate (as a percent) 0.00%

New Jersey

Valuation Allowance [Line Items]

Deferred tax assets, amount sold $ 20,000,000 $ 21,200,000

Deferred tax assets, research, amount sold 200,000

Proceeds from sale of deferred tax assets 1,700,000 $ 2,000,000

Income tax benefit $ 1,800,000

Subsequent Event | New Jersey

Valuation Allowance [Line Items]

Deferred tax assets, amount sold $ 21,200,000

Deferred tax assets, research, amount sold 200,000

Proceeds from sale of deferred tax assets $ 2,000,000

X

- Definition
Deferred Tax Assets, Operating Loss Carryforwards, Amount Sold
+ References
No definition available.
+ Details

Name: blph_DeferredTaxAssetsOperatingLossCarryforwardsAmountSold

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Deferred Tax Assets, Tax Credit Carryforwards, Research, Amount Sold
+ References
No definition available.
+ Details

Name: blph_DeferredTaxAssetsTaxCreditCarryforwardsResearchAmountSold

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds From Sale Of Deferred Tax Assets
+ References
No definition available.
+ Details

Name: blph_ProceedsFromSaleOfDeferredTaxAssets

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ValuationAllowanceLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R19.htm IDEA: XBRL DOCUMENT v3.20.1

Right of Use Assets and Leases (Tables)
3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Components of Lease Expense
Information related to the Company's right-of-use asset and related lease liability were as follows ($ amounts in thousands):

Three months ended March 31,

2020

2019
Cash paid for operating lease liability

$
187

$
161

Operating lease expenses

177

153

Weighted average remaining lease term

3 years

4 years

Weighted average discount rate

4.94
%

4.98
%

Maturities of the lease liability as of March 31, 2020 were as follows :

2020

$
570

2021

770

2022

783

2023

205

2,328

Less imputed interest

(170
)

Total operating lease liability

2,158

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Net Income (Loss) Per Share
3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net (Loss) Income Per Share
Net Loss Per Share

Basic net loss per share is calculated by dividing net (loss) income by the weighted average number of shares outstanding during the period, as applicable. Diluted net loss per share is calculated by dividing net (loss) income, adjusted to reflect the impact of dilutive warrants, by the weighted average number of shares outstanding, adjusted to reflect potentially dilutive securities using the treasury stock method, except when the effect would be anti-dilutive.

The Company reported a net loss for the three months ended March 31, 2020 and 2019, therefore diluted net loss per share is the same as the basic net loss per share.

As of March 31, 2020, the Company had 666,444 options to purchase shares, 6,666 restricted shares and 2,028,626 warrants to purchase shares outstanding that have been excluded from the computation of diluted weighted average shares outstanding, because such securities had an anti-dilutive impact due to the loss reported.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.1

Common Stock Warrants and Warrant Liability
3 Months Ended

Mar. 31, 2020

Common Stock Warrant Liability [Abstract]

Common Stock Warrants and Warrant Liability
Common Stock Warrants and Warrant Liability

On November 29, 2016, the Company issued 1,142,838 warrants that were immediately exercisable and will expire 5 years from issuance at an exercise price of $12.00 per share (the “2016 Warrants”). On June 28, 2019, the Company entered into a warrant amendment (the “Warrant Amendment”) with certain holders (the “Holders”) of 839,899 of the 2016 Warrants to purchase shares. Pursuant to the Warrant Amendment, the Company and the Holders agreed to eliminate provisions that had previously precluded equity classification treatment on the Company’s consolidated balance sheets. In consideration of such amendment, the 2016 Warrants were extended by two (2) additional years (until November 29, 2023). The difference in fair market value of the warrants before and after the amendment, of $0.7 million, was recorded in the consolidated statement of operations as a warrant amendment charge. The fair market value of the amended warrants was reclassified from common stock warrant liability to stockholders' equity. The balance of the 2016 Warrants that were not amended could require cash settlement under certain circumstances, and therefore continue to be classified as liabilities and to be recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of March 31, 2020, 661,310 of the 2016 Warrants were outstanding, of which 585,139 were equity classified and 76,171 were liability classified. During the three months ended March 31, 2020, 254,760 of the 2016 warrants were exercised for net proceeds of $3.1 million.

On May 15, 2017, the Company issued to an investor a warrant to purchase 66,666 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $22.50 per share. In addition, the Company issued to the placement agent warrants to purchase 4,000 shares that were immediately exercisable and will expire five years from issuance at an exercise price of $28.125 per share. As the warrants, under certain situations, could require cash settlement, the warrants were classified as liabilities and recorded at estimated fair value using a Black-Scholes-Merton pricing model. As of March 31, 2020, all of these warrants were outstanding.

On September 29, 2017, the Company issued warrants to purchase 1,296,650 shares that became exercisable commencing six months from their issuance and will expire five years from the initial exercise date at an exercise price of $18.63 per share. As the warrants could not require cash settlement, the warrants were classified as equity. As of March 31, 2020, all of these warrants were outstanding.

The following table summarizes warrant activity for the three months ended March 31, 2020 (fair value amount in thousands):

Equity Classified

Liability Classified

Warrants

Warrants

Estimated Fair Value
Warrants outstanding as of December 31, 2019

2,136,549

146,837

$
274

Exercises

(254,760
)

—

Change in fair value of common stock warrant liability recognized in consolidated statement of operations

—

—

894

Warrants outstanding as of March 31, 2020

1,881,789

146,837

$
1,168

The following table summarizes warrant activity for the three months ended March 31, 2019 (fair value amount in thousands):

Equity Classified

Liability Classified

Warrants

Warrants

Estimated Fair Value
Warrants outstanding as of December 31, 2018

1,296,650

986,736

$
6,965

Change in fair value of common stock warrant liability recognized in consolidated statement of operations

—

—

(1,616
)
Warrants outstanding as of March 31, 2019

1,296,650

986,736

$
5,349

See Note 6 for determination of the fair value of the common stock warrant liability.

X

- Definition
Common Stock Warrant Liability [Abstract]
+ References
No definition available.
+ Details

Name: blph_CommonStockWarrantLiabilityAbstract

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation - Summary of Option Activity (Details) - $ / shares
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Bellerophon 2015 and 2014 Equity Incentive Plans

Options

Options outstanding as of beginning of period (in shares) 663,501

Forfeited (in shares) (325)

Options outstanding as of end of period (in shares) 663,176 663,501

Options vested and exercisable (in shares) 295,768

Weighted Average Price

Options outstanding as of beginning of period, Weighted Average Price (in dollars per share) $ 24.15

Forfeited, Weighted Average Price (in dollars per share) 32.41

Options outstanding as of end of period, Weighted Average Price (in dollars per share) 24.15 $ 24.15

Options vested and exercisable, Weighted Average Price (in dollars per share) $ 39.48

Weighted Average Remaining Contractual Life (in years)

Options outstanding 8 years 8 years 3 months 18 days

Options vested and exercisable 7 years 1 month 6 days

Bellerophon 2015 and 2014 Equity Incentive Plans | Minimum

Range of Exercise Price

Options outstanding as of beginning of period, Exercise Price (in dollars per share) $ 7.35

Options forfeited, Exercise Price, (in dollars per share) 7.35

Options outstanding as of end of period, Exercise Price (in dollars per share) 7.35 $ 7.35

Options vested and exercisable, Exercise Price (in dollars per share) 7.35

Bellerophon 2015 and 2014 Equity Incentive Plans | Maximum

Range of Exercise Price

Options outstanding as of beginning of period, Exercise Price (in dollars per share) 199.20

Options forfeited, Exercise Price, (in dollars per share) 199.20

Options outstanding as of end of period, Exercise Price (in dollars per share) 199.20 $ 199.20

Options vested and exercisable, Exercise Price (in dollars per share) $ 199.20

Ikaria Equity Incentive Plans

Options

Options outstanding as of beginning of period (in shares) 3,463

Forfeited (in shares) (195)

Options outstanding as of end of period (in shares) 3,268 3,463

Options vested and exercisable (in shares) 3,268

Weighted Average Price

Options outstanding as of beginning of period, Weighted Average Price (in dollars per share) $ 124.21

Forfeited, Weighted Average Price (in dollars per share) 118.55

Options outstanding as of end of period, Weighted Average Price (in dollars per share) 124.54 $ 124.21

Options vested and exercisable, Weighted Average Price (in dollars per share) $ 124.54

Weighted Average Remaining Contractual Life (in years)

Options vested and exercisable 2 years 1 month 6 days 2 years 3 months 18 days

Ikaria Equity Incentive Plans | Minimum

Range of Exercise Price

Options outstanding as of beginning of period, Exercise Price (in dollars per share) $ 116.55

Options forfeited, Exercise Price, (in dollars per share) 116.55

Options outstanding as of end of period, Exercise Price (in dollars per share) 116.55 $ 116.55

Options vested and exercisable, Exercise Price (in dollars per share) 116.55

Ikaria Equity Incentive Plans | Maximum

Range of Exercise Price

Options outstanding as of beginning of period, Exercise Price (in dollars per share) 223.65

Options forfeited, Exercise Price, (in dollars per share) 124.05

Options outstanding as of end of period, Exercise Price (in dollars per share) 223.65 $ 223.65

Options vested and exercisable, Exercise Price (in dollars per share) $ 223.65

X

- Definition
Exercise price at which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
No definition available.
+ Details

Name: blph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableExercisePrice

Namespace Prefix: blph_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: blph_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodExercisePrice

Namespace Prefix: blph_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The exercise price for purposes of disclosing shares potentially issuable under outstanding stock option awards.
+ References
No definition available.
+ Details

Name: blph_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice

Namespace Prefix: blph_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: blph_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceAbstract

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=blph_Bellerophon2015And2014EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=blph_IkariaEquityIncentivePlansPriorTo12February2014Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 25 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Net (Loss) Income Per Share - Additional Information (Details)
3 Months Ended

Mar. 31, 2020

shares

Stock Option

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 666,444

Restricted Stock

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 6,666

Warrant

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 2,028,626

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 26 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 27 R14.htm IDEA: XBRL DOCUMENT v3.20.1

Income Taxes
3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes

Excluding the impact of the sale of state net operating losses and research and development credits during the first quarter of 2019, the effective tax rate for each of the three months ended March 31, 2020 and 2019 was 0.0% which was lower than the federal statutory rate primarily due to the losses incurred and the full valuation allowance on deferred tax assets.

The Company’s estimated tax rate for 2020 excluding any benefits from any sales of net operating losses or research and development, or R&D, tax credits is expected to be zero because the Company expects to generate additional losses and currently has a full valuation allowance. The valuation allowance is required until the Company has sufficient positive evidence of taxable income necessary to support realization of its deferred tax assets. In addition, the Company may be subject to certain limitations in its annual utilization of NOL carry forwards to offset future taxable income (and of tax credit carry forwards to offset future tax expense) pursuant to Section 382 of the Internal Revenue Code, which could result in tax attributes expiring unused.

In May 2020, the Company has sold $21.2 million of state NOLs and $0.2 million of Research and Development credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program for net proceeds of $2.0 million. In January 2019, the Company sold $20.0 million of state NOLs for net proceeds of $1.7 million under the State of New Jersey's Technology Business Tax Certificate Transfer Program, which resulted in the reversal of the valuation allowance and a tax benefit of $1.8 million for the three months ended March 31, 2019. Subject to state approval, the Company plans to sell additional NOLs and credits under the same program in the future. The proceeds from such sales are recorded as Income tax benefit when sales occur or proceeds are received.

As of March 31, 2020, there were no material uncertain tax positions. There are no tax positions for which a material change in any unrecognized tax benefit liability is reasonably possible in the next 12 months.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Right of Use Assets and Leases
3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Right of Use Assets and Leases
Right of Use Assets and Leases

The Company has two operating leases in Warren, NJ, one for the use of an office and research facility and a second for the use of a laboratory. The office and research facility lease is for a term of four years with a term date of March 31, 2023, with the Company's right to extend the original term for one period of five years. The laboratory lease is for a term of three years and nine months with a term date of April 30, 2023, with the Company's right to extend the original term for one period of 90 days. Operating lease expense is recognized on a straight-line basis over the respective lease term.

The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended March 31, 2020 and 2019 were de minimis.

Information related to the Company's right-of-use asset and related lease liability were as follows ($ amounts in thousands):

Three months ended March 31,

2020

2019
Cash paid for operating lease liability

$
187

$
161

Operating lease expenses

177

153

Weighted average remaining lease term

3 years

4 years

Weighted average discount rate

4.94
%

4.98
%

Maturities of the lease liability as of March 31, 2020 were as follows :

2020

$
570

2021

770

2022

783

2023

205

2,328

Less imputed interest

(170
)

Total operating lease liability

2,158

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Policies)
3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission, or the SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America, or U.S. GAAP, can be condensed or omitted. The Company operates in one reportable segment and solely within the United States. Accordingly, no segment or geographic information has been presented.

The Company is responsible for the unaudited condensed consolidated financial statements. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive income (loss) and its cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three months ended March 31, 2020 for the Company are not necessarily indicative of the results expected for the full year.

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of costs and expenses during the reporting period, including right of use asset and operating lease liability, accrued expenses, accrued research and development expenses, stock-based compensation, common stock warrant liabilities and income taxes. Actual results could differ from those estimates.

On February 5, 2020, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of the Company's outstanding shares of common stock which became effective on February 7, 2020. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance under the Company’s equity incentive plans and employee stock purchase plan were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans and warrants were proportionately adjusted for the reverse stock split. There was no change to the Company’s authorized number of shares or to its par value per share. The reverse stock split reduced the number of shares of the Company’s common stock that were outstanding at February 10, 2020 from 69,053,548 to 4,603,460, after the cancellation of fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the reverse stock split received a de minimis cash payment in lieu of such fractional shares. These condensed consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly.

Cash and Cash Equivalents
Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity date of three months or less to be cash equivalents. All investments with maturities of greater than three months from date of purchase are classified as available-for-sale marketable securities.

Stock-Based Compensation
Stock-Based Compensation

The Company accounts for its stock-based compensation in accordance with applicable accounting guidance which establishes accounting for share-based awards, including stock options and restricted stock, exchanged for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company recognizes stock-based compensation expense in operations based on the fair value of the award on the date of the grant. The resulting compensation expense, less estimated forfeitures, is recognized on a straight-line basis over the requisite service period or sooner if the awards immediately vest. The Company determines the fair value of stock options issued using a Black-Scholes-Merton option pricing model. Certain assumptions used in the model include expected volatility, dividend yield, risk-free interest rate, estimated forfeitures and expected term. For restricted stock, the fair value is the closing market price per share on the grant date. See Note 7 - Stock-Based Compensation for a description of these assumptions.

Common Stock Warrants and Warrant Liability
Common Stock Warrants and Warrant Liability

The Company accounts for common stock warrants issued as freestanding instruments in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company classifies warrant liabilities on the consolidated balance sheet based on the warrants' terms as long-term liabilities, which are revalued at each balance sheet date subsequent to the initial issuance. Changes in the fair value of the warrants are reflected in the consolidated statement of operations as “Change in fair value of common stock warrant liability.” The Company uses the Black-Scholes-Merton pricing model to value the related warrant liability. Certain assumptions used in the model include expected volatility, dividend yield and risk-free interest rate. See Note 6 - Fair Value Measurements for a description of these assumptions.

Income Taxes
Income Taxes

The Company uses the asset and liability approach to account for income taxes as required by applicable accounting guidance, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount expected to be realized, on a more likely than not basis. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.

Research and Development Expense
Research and Development Expense

Research and development costs are expensed as incurred. These expenses include the costs of the Company’s proprietary research and development efforts, as well as costs incurred in connection with certain licensing arrangements. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties upon or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. The Company also expenses the cost of purchased technology and equipment in the period of purchase if it believes that the technology or equipment has not demonstrated technological feasibility and it does not have an alternative future use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and are recognized as research and development expense as the related goods are delivered or the related services are performed.

(g) Leases

A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of operations in the same line item as expenses arising from fixed lease payments.

Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.

The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended March 31, 2020 and 2019 were de minimis.


Leases
Leases

A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of operations in the same line item as expenses arising from fixed lease payments.

Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.

The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended March 31, 2020 and 2019 were de minimis.

New Accounting Pronouncements
Recently Issued Accounting Pronouncements

Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which eliminates, adds and modifies certain disclosure requirements for fair value measurements. The standard requires the disclosure of the range and weighted average used to develop significant unobservable inputs and how weighted average is calculated for recurring and nonrecurring Level 3 fair value measurements. The amendment is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted ASU 2018-13’s during the quarter ended March 31, 2020 by including disclosure on the range of inputs used to calculate the Company's Level 3 fair value measurements.

X

- Definition
Common Stock Warrant Liability [Policy Text Block]
+ References
No definition available.
+ Details

Name: blph_CommonStockWarrantLiabilityPolicyTextBlock

Namespace Prefix: blph_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586
+ Details

Name: us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R26.htm IDEA: XBRL DOCUMENT v3.20.1

Right of Use Assets and Leases (Details)
$ in Thousands
3 Months Ended

Mar. 31, 2020

USD ($)

lease

period

Mar. 31, 2019

USD ($)

Lessee, Lease, Description [Line Items]

Number of operating leases | lease 2

Cash paid for operating lease liability $ 187 $ 161

Operating lease expenses $ 177 $ 153

Weighted average remaining lease term 3 years 4 years

Weighted average discount rate 4.94% 4.98%

Operating leases

2020 $ 570

2021 770

2022 783

2023 205

Total lease payments 2,328

Less imputed interest (170)

Total operating lease liability $ 2,158

Building

Lessee, Lease, Description [Line Items]

Term of contract 4 years

Number of renewal periods | period 1

Renewal term 5 years

Property, Plant and Equipment

Lessee, Lease, Description [Line Items]

Number of renewal periods | period 1

Renewal term 90 days

X

- Definition
Lessee, Operating Lease, Term of Contract, Number Of Renewal Periods
+ References
No definition available.
+ Details

Name: blph_LesseeOperatingLeaseTermofContractNumberOfRenewalPeriods

Namespace Prefix: blph_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number Of Operating Leases
+ References
No definition available.
+ Details

Name: blph_NumberOfOperatingLeases

Namespace Prefix: blph_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeaseDescriptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation (Tables)
3 Months Ended

Mar. 31, 2020

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Assumptions used in estimating the fair value of options issued
The following are the weighted average assumptions used in estimating the fair values of options issued during the three months ended March 31, 2019:

Three Months Ended March 31, 2019
Valuation assumptions:

Risk-free rate
2.51
%
Expected volatility
82.95
%
Expected term (years)
6.0

Dividend yield
—

Summary of option activity
The following table summarizes the stock-based compensation expense by the unaudited condensed consolidated statement of operations line items for the three months ended March 31, 2020 and 2019 (in thousands):

Three Months Ended March 31,

2020

2019
Research and development

$
79

$
311

General and administrative

389

697

Total expense

$
468

$
1,008

A summary of option activity under the 2015 and 2014 Plans for the three months ended March 31, 2020 is presented below:

Bellerophon 2015 and 2014 Equity Incentive Plans

Options

Range of
Exercise
Price

Weighted
Average
Price

Weighted Average
Remaining
Contractual
Life (in years)
Options outstanding as of December 31, 2019
663,501

$
7.35

-
199.20

$
24.15

8.3

Forfeited
(325
)

7.35

-
199.20

32.41

—

Options outstanding as of March 31, 2020
663,176

$
7.35

-
199.20

$
24.15

8.0

Options vested and exercisable as of March 31, 2020
295,768

$
7.35

-
199.20

$
39.48

7.1

Summary of restricted stock activity
A summary of restricted stock activity under the 2015 Plan for the three months ended March 31, 2020 is presented below:

Bellerophon 2015 Equity Incentive Plan

Shares

Weighted
Average
Fair Value

Aggregate
Grant Date
Fair Value
(in millions)

Weighted Average
Remaining
Contractual
Life (in years)
Restricted stock outstanding as of December 31, 2019

—

$
—

$
—

—

Granted

23,332

6.00

0.1

Vested

(16,666
)

6.00

—

Restricted stock outstanding as of March 31, 2020

6,666

$
6.00

$
—

0.7

Summary of stock-based compensation expense by the condensed consolidated statement of operations line item
A summary of option activity under Ikaria incentive plans assumed in 2014 for the three months ended March 31, 2020, is presented below:

Ikaria Equity Incentive Plans

Options

Range of
Exercise
Price

Weighted
Average
Price

Weighted Average
Remaining
Contractual
Life (in years)
Options outstanding as of December 31, 2019

3,463

$
116.55

-
223.65

$
124.21

2.3

Forfeited

(195
)

116.55
-
124.05

118.55

—

Options outstanding as of March 31, 2020

3,268

$
116.55

-
223.65

$
124.54

2.1

Options vested and exercisable as of March 31, 2020

3,268

$
116.55

-
223.65

$
124.54

2.1

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Cash flows from operating activities:

Net loss $ (4,970) $ (795)

Adjustments to reconcile net loss to net cash used in operating activities:

Change in fair value of common stock warrant liability 894 (1,616)

Stock based compensation 468 1,008

Depreciation 46 88

Changes in operating assets and liabilities:

Prepaid expenses and other current assets 56 (298)

Accounts payable, accrued research and development, and accrued expenses (830) (727)

Net cash used in operating activities (4,336) (2,340)

Cash flows from financing activities:

Proceeds received from exercise of warrants 3,057 0

Proceeds from issuance of common stock in Public Offering 0 6,374

Net cash provided by (used in) financing activities 3,057 6,374

Net change in cash, cash equivalents and restricted cash (1,279) 4,034

Cash, cash equivalents and restricted cash at beginning of period 10,277 17,046

Cash, cash equivalents and restricted cash at end of period 8,998 21,080

Non-cash financing activities:

Unpaid expenses related to offerings $ 0 $ 138

X

- Definition
Transaction Costs Payable For Issue Of Securities
+ References
No definition available.
+ Details

Name: blph_TransactionCostsPayableForIssueOfSecurities

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_DepreciationNonproduction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 33 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Current assets:

Cash and cash equivalents $ 8,595 $ 9,874

Restricted cash 103 103

Prepaid expenses and other current assets 349 405

Total current assets 9,047 10,382

Restricted cash, non-current 300 300

Right of use assets, net 1,961 2,110

Property and equipment, net 270 316

Total assets 11,578 13,108

Current liabilities:

Accounts payable 2,220 3,106

Accrued research and development 1,785 2,117

Accrued expenses 2,101 1,703

Current portion of operating lease liabilities 669 658

Total current liabilities 6,775 7,584

Long term operating lease liabilities 1,489 1,659

Common stock warrant liabilities 1,168 274

Total liabilities 9,432 9,517

Commitments and contingencies

Stockholders’ equity:

Common stock, $0.01 par value per share; 200,000,000 shares authorized and 4,857,393 and 4,580,127 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively 49 46

Preferred stock, $0.01 par value per share; 5,000,000 shares authorized, zero shares issued and outstanding at March 31, 2020 and December 31, 2019 0 0

Additional paid-in capital 196,830 193,308

Accumulated deficit (194,733) (189,763)

Total stockholders’ equity 2,146 3,591

Total liabilities and stockholders’ equity $ 11,578 $ 13,108

X

- Definition
Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.
+ References
No definition available.
+ Details

Name: blph_AccruedResearchAndDevelopment

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Warrant, Fair Value Disclosure
+ References
No definition available.
+ Details

Name: blph_WarrantFairValueDisclosure

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765
+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_MembersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 305
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 34 R16.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies

Legal Proceedings

The Company periodically becomes subject to legal proceedings and claims arising in connection with its business. The ultimate legal and financial liability of the Company in respect to all proceedings, claims and lawsuits, pending or threatened, cannot be estimated with any certainty.

As of the date of this report, the Company is not aware of any proceeding, claim or litigation, pending or threatened, that could, individually or in the aggregate, have a material adverse effect on the Company’s business, operating results, financial condition and/or liquidity.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R12.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value Measurements
3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements
Fair Value Measurements

Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value.  Level inputs are as follows:

•
Level 1 — Values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date.

•
Level 2 — Values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.

•
Level 3 — Values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset.

The following table summarizes fair value measurements by level at March 31, 2020 for liabilities measured at fair value on a recurring basis (in thousands):

Level 1

Level 2

Level 3

Total
Common stock warrant liability

—

—

1,168

1,168

The following table summarizes fair value measurements by level at December 31, 2019 for liabilities measured at fair value on a recurring basis (in thousands):

Level 1

Level 2

Level 3

Total
Common stock warrant liabilities

—

—

274

274

The Company uses a Black-Scholes-Merton option pricing model to value its liability classified common stock warrants. The significant unobservable inputs used in calculating the fair value of common stock warrants represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. Any significant changes in the inputs may result in significantly higher or lower fair value measurements.

The following are the weighted average and the range of assumptions used in estimating the fair value of warrants outstanding (weighted average calculated based on the number of outstanding warrants on each issuance) as of March 31, 2020 and December 31, 2019:

March 31, 2020

December 31, 2019
Valuation assumptions:
Range

Weighted Average

Range

Weighted Average
Risk-free interest rate
0.21
%
-
0.27
%

0.24
%

1.57
%
-
1.61
%

1.59
%
Expected volatility
149.76
%
-
187.49
%

169.86
%

104.74
%
-
109.05
%

107.00
%
Expected term (in years)
1.7

-
2.6

2.1

1.9

-
2.9

2.4

Dividend yield
—
%
-
—
%

—
%

—
%
-
—
%

—
%

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 135 261 1 false 33 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bellerophon.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.bellerophon.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.bellerophon.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.bellerophon.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004000 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity Sheet http://www.bellerophon.com/role/CondensedConsolidatedStatementOfChangesInStockholdersEquity Condensed Consolidated Statement of Changes in Stockholders' Equity Statements 5 false false R6.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.bellerophon.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Organization and Nature of the Business Sheet http://www.bellerophon.com/role/OrganizationAndNatureOfBusiness Organization and Nature of the Business Notes 7 false false R8.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.bellerophon.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Liquidity Sheet http://www.bellerophon.com/role/Liquidity Liquidity Notes 9 false false R10.htm 2104100 - Disclosure - Right of Use Assets and Leases Sheet http://www.bellerophon.com/role/RightOfUseAssetsAndLeases Right of Use Assets and Leases Notes 10 false false R11.htm 2106100 - Disclosure - Common Stock Warrants and Warrant Liability Sheet http://www.bellerophon.com/role/CommonStockWarrantsAndWarrantLiability Common Stock Warrants and Warrant Liability Notes 11 false false R12.htm 2107100 - Disclosure - Fair Value Measurements Sheet http://www.bellerophon.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2108100 - Disclosure - Stock-Based Compensation Sheet http://www.bellerophon.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 2109100 - Disclosure - Income Taxes Sheet http://www.bellerophon.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 2110100 - Disclosure - Net Income (Loss) Per Share Sheet http://www.bellerophon.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 15 false false R16.htm 2111100 - Disclosure - Commitments and Contingencies Sheet http://www.bellerophon.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 2117100 - Disclosure - Subsequent Events Sheet http://www.bellerophon.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.bellerophon.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.bellerophon.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 2304301 - Disclosure - Right of Use Assets and Leases (Tables) Sheet http://www.bellerophon.com/role/RightOfUseAssetsAndLeasesTables Right of Use Assets and Leases (Tables) Tables http://www.bellerophon.com/role/RightOfUseAssetsAndLeases 19 false false R20.htm 2306301 - Disclosure - Common Stock Warrants and Warrant Liability (Tables) Sheet http://www.bellerophon.com/role/CommonStockWarrantsAndWarrantLiabilityTables Common Stock Warrants and Warrant Liability (Tables) Tables http://www.bellerophon.com/role/CommonStockWarrantsAndWarrantLiability 20 false false R21.htm 2307301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.bellerophon.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.bellerophon.com/role/FairValueMeasurements 21 false false R22.htm 2308301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.bellerophon.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.bellerophon.com/role/StockBasedCompensation 22 false false R23.htm 2401401 - Disclosure - Organization and Nature of the Business (Details) Sheet http://www.bellerophon.com/role/OrganizationAndNatureOfBusinessDetails Organization and Nature of the Business (Details) Details http://www.bellerophon.com/role/OrganizationAndNatureOfBusiness 23 false false R24.htm 2402402 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.bellerophon.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.bellerophon.com/role/SummaryOfSignificantAccountingPoliciesPolicies 24 false false R25.htm 2403401 - Disclosure - Liquidity (Details) Sheet http://www.bellerophon.com/role/LiquidityDetails Liquidity (Details) Details http://www.bellerophon.com/role/Liquidity 25 false false R26.htm 2404402 - Disclosure - Right of Use Assets and Leases (Details) Sheet http://www.bellerophon.com/role/RightOfUseAssetsAndLeasesDetails Right of Use Assets and Leases (Details) Details http://www.bellerophon.com/role/RightOfUseAssetsAndLeasesTables 26 false false R27.htm 2406402 - Disclosure - Common Stock Warrants and Warrant Liability - Narrative (Details) Sheet http://www.bellerophon.com/role/CommonStockWarrantsAndWarrantLiabilityNarrativeDetails Common Stock Warrants and Warrant Liability - Narrative (Details) Details 27 false false R28.htm 2406403 - Disclosure - Common Stock Warrants and Warrant Liability - Warrant Activity (Details) Sheet http://www.bellerophon.com/role/CommonStockWarrantsAndWarrantLiabilityWarrantActivityDetails Common Stock Warrants and Warrant Liability - Warrant Activity (Details) Details 28 false false R29.htm 2407402 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details) Sheet http://www.bellerophon.com/role/FairValueMeasurementsFairValueHierarchyDetails Fair Value Measurements - Fair Value Hierarchy (Details) Details 29 false false R30.htm 2407403 - Disclosure - Fair Value Measurements - Assumptions Used (Details) Sheet http://www.bellerophon.com/role/FairValueMeasurementsAssumptionsUsedDetails Fair Value Measurements - Assumptions Used (Details) Details 30 false false R31.htm 2408402 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.bellerophon.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 31 false false R32.htm 2408403 - Disclosure - Stock-Based Compensation - Summary of Fair Value of Options Issued (Details) Sheet http://www.bellerophon.com/role/StockBasedCompensationSummaryOfFairValueOfOptionsIssuedDetails Stock-Based Compensation - Summary of Fair Value of Options Issued (Details) Details 32 false false R33.htm 2408404 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Details) Sheet http://www.bellerophon.com/role/StockBasedCompensationSummaryOfOptionActivityDetails Stock-Based Compensation - Summary of Option Activity (Details) Details 33 false false R34.htm 2408405 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Sheet http://www.bellerophon.com/role/StockBasedCompensationSummaryOfRestrictedStockActivityDetails Stock-Based Compensation - Summary of Restricted Stock Activity (Details) Details 34 false false R35.htm 2408406 - Disclosure - Stock-Based Compensation - Allocation of Recognized Period Costs (Details) Sheet http://www.bellerophon.com/role/StockBasedCompensationAllocationOfRecognizedPeriodCostsDetails Stock-Based Compensation - Allocation of Recognized Period Costs (Details) Details 35 false false R36.htm 2409401 - Disclosure - Income Taxes (Details) Sheet http://www.bellerophon.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bellerophon.com/role/IncomeTaxes 36 false false R37.htm 2410403 - Disclosure - Net (Loss) Income Per Share - Additional Information (Details) Sheet http://www.bellerophon.com/role/NetLossIncomePerShareAdditionalInformationDetails Net (Loss) Income Per Share - Additional Information (Details) Details http://www.bellerophon.com/role/NetIncomeLossPerShare 37 false false R38.htm 2417401 - Disclosure - Subsequent Events (Details) Sheet http://www.bellerophon.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.bellerophon.com/role/SubsequentEvents 38 false false All Reports Book All Reports blph-20200331.xml blph-20200331.xsd blph-20200331_cal.xml blph-20200331_def.xml blph-20200331_lab.xml blph-20200331_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2018-01-31 true true XML 37 R31.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation - Narrative (Details) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

May 14, 2019

May 04, 2017

Stock-Based Compensation

Number of shares available for grant (in shares) 333,333

Maximum annual increase number of shares available for grant (in shares) 200,000

Number of shares available for grant (in shares) 454,362 833,333 333,333

Weighted average grant-date fair value of options issued (in usd per share) $ 9.30

Options, outstanding, intrinsic value $ 400,000

Bellerophon Equity Incentive Plans

Stock-Based Compensation

Unrecognized compensation expense $ 2,700,000

Weighted-average period unrecognized compensation expense is to be recognized 2 years 4 months 24 days

Tax benefit recognized related to stock-based compensation expense $ 0 $ 0

Ikaria Equity Incentive Plans

Stock-Based Compensation

Options, outstanding, intrinsic value 0

Options, exercisable, intrinsic value $ 0

Minimum

Stock-Based Compensation

Vesting period 1 year

Maximum

Stock-Based Compensation

Vesting period 4 years

X

- Definition
ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateNumberOfSharesAvailableForGrant
+ References
No definition available.
+ Details

Name: blph_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateNumberOfSharesAvailableForGrant

Namespace Prefix: blph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Maximum Annual Increase Number Of Shares Available For Grant
+ References
No definition available.
+ Details

Name: blph_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseNumberOfSharesAvailableForGrant

Namespace Prefix: blph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=blph_BellerophonEquityIncentivePlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=blph_IkariaEquityIncentivePlansPriorTo12February2014Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R35.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation - Allocation of Recognized Period Costs (Details) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Stock-based compensation expense by condensed consolidated statement of operations and comprehensive loss line item

Allocated share-based compensation expense $ 468 $ 1,008

Research and development

Stock-based compensation expense by condensed consolidated statement of operations and comprehensive loss line item

Allocated share-based compensation expense 79 311

General and administrative

Stock-based compensation expense by condensed consolidated statement of operations and comprehensive loss line item

Allocated share-based compensation expense $ 389 $ 697

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.1

Common Stock Warrants and Warrant Liability - Warrant Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2018

Class of Warrant or Right, Outstanding [Roll Forward]

Exercises (in shares) (254,760)

Warrant, outstanding (in shares) 661,310

Estimated Fair Value

Beginning balance, Warrants outstanding $ 274 $ 6,965

Change in fair value of common stock warrant liability recognized in consolidated statement of operations 894 (1,616)

Ending balance, Warrants outstanding $ 1,168 $ 5,349 $ 6,965

Equity Classified

Class of Warrant or Right, Outstanding [Roll Forward]

Warrant, outstanding (in shares) 2,136,549 1,296,650

Exercises (in shares) (254,760)

Warrant, outstanding (in shares) 1,881,789 1,296,650 1,296,650

Liability Classified

Class of Warrant or Right, Outstanding [Roll Forward]

Warrant, outstanding (in shares) 146,837 986,736

Exercises (in shares) 0

Warrant, outstanding (in shares) 146,837 986,736 986,736

X

- Definition
Class of Warrant or Right, Outstanding [Roll Forward]
+ References
No definition available.
+ Details

Name: blph_ClassofWarrantorRightOutstandingRollForward

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants Exercised
+ References
No definition available.
+ Details

Name: blph_WarrantsExercised

Namespace Prefix: blph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants and Rights Outstanding, Fair Value [Roll Forward]
+ References
No definition available.
+ Details

Name: blph_WarrantsandRightsOutstandingFairValueRollForward

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_EquityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_LiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R24.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies (Details)
$ in Thousands
3 Months Ended

Feb. 07, 2020

Mar. 31, 2020

USD ($)

integer

shares

Feb. 10, 2020

shares

Feb. 09, 2020

shares

Dec. 31, 2019

USD ($)

shares

Accounting Policies [Abstract]

Stockholders' Equity Note, Stock Split, Conversion Ratio 0.0667

Number of reportable segments | integer 1

Lease, liability $ 2,158

Right of use assets, net $ 1,961 $ 2,110

Common stock, shares outstanding (in shares) | shares 4,857,393 4,603,460 69,053,548 4,580,127

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

XML 41 R20.htm IDEA: XBRL DOCUMENT v3.20.1

Common Stock Warrants and Warrant Liability (Tables)
3 Months Ended

Mar. 31, 2020

Common Stock Warrant Liability [Abstract]

Schedule of warrant activity
The following table summarizes warrant activity for the three months ended March 31, 2020 (fair value amount in thousands):

Equity Classified

Liability Classified

Warrants

Warrants

Estimated Fair Value
Warrants outstanding as of December 31, 2019

2,136,549

146,837

$
274

Exercises

(254,760
)

—

Change in fair value of common stock warrant liability recognized in consolidated statement of operations

—

—

894

Warrants outstanding as of March 31, 2020

1,881,789

146,837

$
1,168

The following table summarizes warrant activity for the three months ended March 31, 2019 (fair value amount in thousands):

Equity Classified

Liability Classified

Warrants

Warrants

Estimated Fair Value
Warrants outstanding as of December 31, 2018

1,296,650

986,736

$
6,965

Change in fair value of common stock warrant liability recognized in consolidated statement of operations

—

—

(1,616
)
Warrants outstanding as of March 31, 2019

1,296,650

986,736

$
5,349

X

- Definition
Common Stock Warrant Liability [Abstract]
+ References
No definition available.
+ Details

Name: blph_CommonStockWarrantLiabilityAbstract

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R4.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Operating expenses:

Research and development $ 2,238 $ 2,305

General and administrative 1,872 2,037

Total operating expenses 4,110 4,342

Loss from operations (4,110) (4,342)

Change in fair value of common stock warrant liability (894) 1,616

Interest and other income, net 34 130

Pre-tax loss (4,970) (2,596)

Income tax benefit 0 1,801

Net loss $ (4,970) $ (795)

Weighted average shares outstanding:

Basic (in shares) 4,615,046 4,346,109

Diluted (in shares) 4,615,046 4,346,109

Net loss per share:

Basic (in usd per share) $ (1.08) $ (0.18)

Diluted (in usd per share) $ (1.08) $ (0.18)

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 43 R8.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies
3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
Summary of Significant Accounting Policies

(a) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission, or the SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America, or U.S. GAAP, can be condensed or omitted. The Company operates in one reportable segment and solely within the United States. Accordingly, no segment or geographic information has been presented.

The Company is responsible for the unaudited condensed consolidated financial statements. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive income (loss) and its cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three months ended March 31, 2020 for the Company are not necessarily indicative of the results expected for the full year.

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of costs and expenses during the reporting period, including right of use asset and operating lease liability, accrued expenses, accrued research and development expenses, stock-based compensation, common stock warrant liabilities and income taxes. Actual results could differ from those estimates.

On February 5, 2020, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of the Company's outstanding shares of common stock which became effective on February 7, 2020. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance under the Company’s equity incentive plans and employee stock purchase plan were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans and warrants were proportionately adjusted for the reverse stock split. There was no change to the Company’s authorized number of shares or to its par value per share. The reverse stock split reduced the number of shares of the Company’s common stock that were outstanding at February 10, 2020 from 69,053,548 to 4,603,460, after the cancellation of fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the reverse stock split received a de minimis cash payment in lieu of such fractional shares. These condensed consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly.

(b) Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity date of three months or less to be cash equivalents. All investments with maturities of greater than three months from date of purchase are classified as available-for-sale marketable securities.

(c) Stock-Based Compensation

The Company accounts for its stock-based compensation in accordance with applicable accounting guidance which establishes accounting for share-based awards, including stock options and restricted stock, exchanged for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company recognizes stock-based compensation expense in operations based on the fair value of the award on the date of the grant. The resulting compensation expense, less estimated forfeitures, is recognized on a straight-line basis over the requisite service period or sooner if the awards immediately vest. The Company determines the fair value of stock options issued using a Black-Scholes-Merton option pricing model. Certain assumptions used in the model include expected volatility, dividend yield, risk-free interest rate, estimated forfeitures and expected term. For restricted stock, the fair value is the closing market price per share on the grant date. See Note 7 - Stock-Based Compensation for a description of these assumptions.

(d) Common Stock Warrants and Warrant Liability

The Company accounts for common stock warrants issued as freestanding instruments in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company classifies warrant liabilities on the consolidated balance sheet based on the warrants' terms as long-term liabilities, which are revalued at each balance sheet date subsequent to the initial issuance. Changes in the fair value of the warrants are reflected in the consolidated statement of operations as “Change in fair value of common stock warrant liability.” The Company uses the Black-Scholes-Merton pricing model to value the related warrant liability. Certain assumptions used in the model include expected volatility, dividend yield and risk-free interest rate. See Note 6 - Fair Value Measurements for a description of these assumptions.

(e) Income Taxes

The Company uses the asset and liability approach to account for income taxes as required by applicable accounting guidance, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount expected to be realized, on a more likely than not basis. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.

(f) Research and Development Expense

Research and development costs are expensed as incurred. These expenses include the costs of the Company’s proprietary research and development efforts, as well as costs incurred in connection with certain licensing arrangements. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties upon or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. The Company also expenses the cost of purchased technology and equipment in the period of purchase if it believes that the technology or equipment has not demonstrated technological feasibility and it does not have an alternative future use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and are recognized as research and development expense as the related goods are delivered or the related services are performed.

(g) Leases

A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of operations in the same line item as expenses arising from fixed lease payments.

Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.

The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended March 31, 2020 and 2019 were de minimis.


(g) Recently Issued Accounting Pronouncements

Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which eliminates, adds and modifies certain disclosure requirements for fair value measurements. The standard requires the disclosure of the range and weighted average used to develop significant unobservable inputs and how weighted average is calculated for recurring and nonrecurring Level 3 fair value measurements. The amendment is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted ASU 2018-13’s during the quarter ended March 31, 2020 by including disclosure on the range of inputs used to calculate the Company's Level 3 fair value measurements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R25.htm IDEA: XBRL DOCUMENT v3.20.1

Liquidity (Details) - USD ($)
1 Months Ended

Apr. 01, 2020

Jan. 25, 2019

Apr. 30, 2020

Jan. 31, 2019

Feb. 28, 2018

Mar. 31, 2020

Dec. 31, 2019

Jul. 06, 2018

Sep. 29, 2017

May 15, 2017

Liquidity [Line Items]

Cash and cash equivalents $ 8,595,000 $ 9,874,000

Maximum securities shelf offering $ 100,000,000

Stock issued during period (in shares) 666,666

Price to the public (in dollars per share) $ 10.5 $ 18.63 $ 22.50

Proceeds from issuance of common stock, net $ 6,200,000

Underwriting discounts And commissions 500,000

Payments of stock issuance costs $ 300,000

New Jersey

Liquidity [Line Items]

Deferred tax assets, amount sold $ 20,000,000 $ 21,200,000

Deferred tax assets, research, amount sold 200,000

Proceeds from sale of deferred tax assets $ 1,700,000 $ 2,000,000

Subsequent Event

Liquidity [Line Items]

Stock issued during period (in shares) 1,275,000

Price to the public (in dollars per share) $ 12.00

Proceeds from issuance of common stock, net $ 14,100,000

Underwriting discounts And commissions 1,100,000

Payments of stock issuance costs $ 100,000

Subsequent Event | New Jersey

Liquidity [Line Items]

Deferred tax assets, amount sold $ 21,200,000

Deferred tax assets, research, amount sold 200,000

Proceeds from sale of deferred tax assets $ 2,000,000

X

- Definition
Deferred Tax Assets, Operating Loss Carryforwards, Amount Sold
+ References
No definition available.
+ Details

Name: blph_DeferredTaxAssetsOperatingLossCarryforwardsAmountSold

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Deferred Tax Assets, Tax Credit Carryforwards, Research, Amount Sold
+ References
No definition available.
+ Details

Name: blph_DeferredTaxAssetsTaxCreditCarryforwardsResearchAmountSold

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
[Line Items] for Liquidity [Table]
+ References
No definition available.
+ Details

Name: blph_LiquidityLineItems

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum amount of securities to be issued under shelf offering.
+ References
No definition available.
+ Details

Name: blph_MaximumSecuritiesShelfOffering

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Proceeds From Issuance Of Common Stock, Net
+ References
No definition available.
+ Details

Name: blph_ProceedsFromIssuanceOfCommonStockNet

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds From Sale Of Deferred Tax Assets
+ References
No definition available.
+ Details

Name: blph_ProceedsFromSaleOfDeferredTaxAssets

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Underwriting discounts and commissions that were deducted from the gross proceeds of the offering.
+ References
No definition available.
+ Details

Name: blph_UnderwritingDiscountsAndCommissions

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value Measurements (Tables)
3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Summary of fair value measurements by level
The following table summarizes fair value measurements by level at March 31, 2020 for liabilities measured at fair value on a recurring basis (in thousands):

Level 1

Level 2

Level 3

Total
Common stock warrant liability

—

—

1,168

1,168

The following table summarizes fair value measurements by level at December 31, 2019 for liabilities measured at fair value on a recurring basis (in thousands):

Level 1

Level 2

Level 3

Total
Common stock warrant liabilities

—

—

274

274

Fair value inputs
The following are the weighted average and the range of assumptions used in estimating the fair value of warrants outstanding (weighted average calculated based on the number of outstanding warrants on each issuance) as of March 31, 2020 and December 31, 2019:

March 31, 2020

December 31, 2019
Valuation assumptions:
Range

Weighted Average

Range

Weighted Average
Risk-free interest rate
0.21
%
-
0.27
%

0.24
%

1.57
%
-
1.61
%

1.59
%
Expected volatility
149.76
%
-
187.49
%

169.86
%

104.74
%
-
109.05
%

107.00
%
Expected term (in years)
1.7

-
2.6

2.1

1.9

-
2.9

2.4

Dividend yield
—
%
-
—
%

—
%

—
%
-
—
%

—
%

X

- Definition
Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R29.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value Measurements - Fair Value Hierarchy (Details) - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Common stock warrant liabilities $ 1,168 $ 274

Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Common stock warrant liabilities 0 0

Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Common stock warrant liabilities 0 0

Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Common stock warrant liabilities $ 1,168 $ 274

X

- Definition
Warrant, Fair Value Disclosure
+ References
No definition available.
+ Details

Name: blph_WarrantFairValueDisclosure

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R9.htm IDEA: XBRL DOCUMENT v3.20.1

Liquidity
3 Months Ended

Mar. 31, 2020

Liquidity

Liquidity
Liquidity

In the course of its development activities, the Company has sustained operating losses and expects such losses to continue over the next several years. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development and clinical trials of, and seeks regulatory approval for, its product candidates. The Company's primary uses of capital are, and it expects will continue to be, compensation and related expenses, third-party clinical research and development services, contract manufacturing services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.

The Company had cash and cash equivalents of $8.6 million as of March 31, 2020. The Company's existing cash and cash equivalents as of March 31, 2020 will be used primarily to fund the Phase 3 trial of INOpulse for PH-ILD, to complete the dose escalation study for PH-Sarc. and to treat COVID-19 patients under the emergency expanded access.

On June 25, 2018, the Company filed a shelf registration statement on Form S-3 with the SEC, which became effective on July 6, 2018. The shelf registration allows the Company to issue, from time to time at prices and on terms to be determined prior to the time of any such offering, up to $100 million of any combination of common stock, preferred stock, debt securities, warrants and rights, either individually or in units.

On January 25, 2019, the Company completed the sale of 666,666 shares of its common stock at a public offering price of $10.50 per share, resulting in net proceeds of $6.2 million, after deducting placement fees of $0.5 million and other offering costs of $0.3 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3.

On April 1, 2020, the Company completed the sale of 1,275,000 shares of its common stock in a registered direct offering at an offering price of $12.00 per share, resulting in net proceeds of approximately $14.1 million, after deducting agent fees of $1.1 million and offering costs of $0.1 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3.

Taking into consideration the cash proceeds from the April 1, 2020 registered direct offering, the Company evaluated whether there are any remaining conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q.

Based on such evaluation and the Company's current plans, which are subject to change as discussed below, management believes that the Company's existing cash and cash equivalents as of March 31, 2020, proceeds received from the April 1, 2020 registered direct offering and proceeds received in May 2020 and expected to become available upon the future sale of state net operating losses, or NOLs, and research and development (“R&D”) tax credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program, will be sufficient to satisfy its operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q.

In April 2020, the Company submitted an Investigational New Drug Application (“IND”) to study the iNO delivery system for the treatment of patients infected with COVID-19. The IND was accepted by the U.S. Food and Drug Administration (the "FDA") in May 2020, which allows the Company to initiate the Phase 3 study. The Company is currently reviewing its clinical plans for this program and, in parallel, the Company submitted an application for federal funding, through the Biomedical Advanced Research and Development Authority (“BARDA”) and the National Institutes of Health (“NIH”), to support the study. If the Company decides to incur additional costs related to the COVID-19 trial in the next 12 months in advance of receiving federal or other funding, its operating cash needs are likely to increase and its existing cash and cash equivalents as of March 31, 2020 may not be sufficient to satisfy its operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q.

The State of New Jersey's Technology Business Tax Certificate Transfer Program enables qualified, unprofitable New Jersey based technology or biotechnology companies to sell a percentage of NOL and R&D tax credits to unrelated profitable corporations, subject to meeting certain eligibility criteria. Based on consideration of various factors, including application processing time and past trend of benefits made available under the program, the Company believes that it is probable that its plans to sell its NOLs can be effectively implemented to address its short term financial needs. The Company has sold $21.2 million of state NOLs and $0.2 million of Research and Development credit under the State of New Jersey’s Technology Business Tax Certificate Transfer Program in May 2020 for net proceeds of $2.0 million and has sold $20.0 million of state NOLs for net proceeds of $1.7 million in January 2019. Subject to state approval and program availability, the Company plans to sell additional NOLs and credits under the same program in the future. The proceeds from such sales are recorded as income tax benefit when sales occur or proceeds are received.

The Company’s estimates and assumptions may prove to be wrong, and the Company may exhaust its capital resources sooner than expected. The process of testing product candidates in clinical trials is costly, and the timing of progress in clinical trials is uncertain. Because the Company’s product candidates are in clinical development and the outcome of these efforts is uncertain, the Company may not be able to accurately estimate the actual amounts that will be necessary to successfully complete the development and commercialization, if approved, of its product candidates or whether, or when, the Company may achieve profitability.

Until such time, if ever, as the Company can generate substantial product revenues, it expects to finance its cash needs through a combination of equity and debt offerings, sales of state NOLs and R&D credits subject to program availability and approval, existing working capital, funding from federal programs subject to approval, and funding from potential future collaboration arrangements. To the extent that the Company raises additional capital through the future sale of equity or debt, the ownership interest of its existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences or rights such as anti-dilution rights that adversely affect the rights of its existing stockholders. If the Company raises additional funds through strategic partnerships in the future, it may have to relinquish valuable rights to its technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to it. If the Company is unable to raise additional funds through equity or debt financings when needed, is unable to sell its state NOLs and R&D credits or obtain federal funding for the IND to study the iNO delivery system for the treatment of patients infected with COVID-19, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself.

X

- References
No definition available.
+ Details

Name: blph_LiquidityDisclosureAbstract

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R5.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($)
$ in Thousands

Total

Common Stock

Additional Paid in Capital

Accumulated Deficit

Warrant

Warrant

Common Stock

Warrant

Additional Paid in Capital

Balance at beginning of period (in shares) at Dec. 31, 2018 3,911,857

Balance at beginning of period at Dec. 31, 2018 $ 3,856 $ 39 $ 180,313 $ (176,496)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (795)

Public offering (in shares) 666,666

Public offering 6,236 $ 7 6,229

Stock-based compensation (in shares) 15,151

Stock-based compensation 1,008 $ 0 1,008

Balance at end of period (in shares) at Mar. 31, 2019 4,593,674

Balance at end of period at Mar. 31, 2019 $ 10,305 $ 46 187,550 (177,291)

Balance at beginning of period (in shares) at Dec. 31, 2019 4,580,127 4,580,127

Balance at beginning of period at Dec. 31, 2019 $ 3,591 $ 46 193,308 (189,763)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (4,970) (4,970)

Reverse Stock Split Adjustment (in shares) (826)

Public offering (in shares) 254,760

Public offering $ 3,057 $ 3 $ 3,054

Stock-based compensation (in shares) 23,332

Stock-based compensation $ 468 $ 0 468

Balance at end of period (in shares) at Mar. 31, 2020 4,857,393 4,857,393

Balance at end of period at Mar. 31, 2020 $ 2,146 $ 49 $ 196,830 $ (194,733)

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Reduction in the number of shares during the period as a result of a reverse stock split.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 49 R1.htm IDEA: XBRL DOCUMENT v3.20.1

Document and Entity Information - shares
3 Months Ended

Mar. 31, 2020

May 08, 2020

Document and Entity Information

Entity Registrant Name Bellerophon Therapeutics, Inc.

Entity Central Index Key 0001600132

Document Type 10-Q

Document Period End Date Mar. 31, 2020

Amendment Flag false

Entity Emerging Growth Company true

Entity Small Business true

Entity Ex Transition Period true

Entity Shell Company false

Entity Interactive Data Current Yes

Current Fiscal Year End Date --12-31

Entity Current Reporting Status Yes

Entity Filer Category Non-accelerated Filer

Entity Common Stock, Shares Outstanding 6,132,393

Document Fiscal Year Focus 2020

Document Fiscal Period Focus Q1

X

- References
No definition available.
+ Details

Name: blph_DocumentAndEntityInformationAbstract

Namespace Prefix: blph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

XML 50 R17.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events
3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events
Subsequent Events

On April 1, 2020, the Company completed the sale of 1,275,000 shares of its common stock in a registered direct offering at an offering price of $12.00 per share, resulting in net proceeds of approximately $14.1 million, after deducting agent fees of $1.1 million and offering costs of $0.1 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R13.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation
3 Months Ended

Mar. 31, 2020

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation
Stock-Based Compensation

Bellerophon 2015 and 2014 Equity Incentive Plans

During 2014, the Company adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which provided for the grant of options. Following the effectiveness of the Company's registration statement filed in connection with its IPO, no options may be granted under the 2014 Plan. The awards granted under the 2014 Plan generally have a vesting period of between one to four years.

During 2015, the Company adopted the 2015 Equity Incentive Plan, or the 2015 Plan, which provides for the grant of options, restricted stock and other forms of equity compensation. On May 4, 2017, the Company’s stockholders approved an amendment to the 2015 Plan to increase the aggregate number of shares available for the grant of awards to 333,333 and to increase the maximum number of shares available under the annual increase to 200,000 shares. On May 14, 2019, the Company's stockholders approved an additional amendment to the 2015 Plan to increase the aggregate number of shares reserved for issuance under the 2015 Plan from 333,333 to 833,333. As of March 31, 2020, the Company had 454,362 shares available for grant under the 2015 Plan.

As of March 31, 2020, there was approximately $2.7 million of total unrecognized compensation expense related to unvested stock awards. This expense is expected to be recognized over a weighted-average period of 2.4 years.

No tax benefit was recognized during the three months ended March 31, 2020 and 2019 related to stock-based compensation expense since the Company incurred operating losses and has established a full valuation allowance to offset all the potential tax benefits associated with its deferred tax assets.

Options

The weighted average grant-date fair value of options issued during the three months ended March 31, 2019 was $9.30. No options were granted in the three months ended March 31, 2020. The following are the weighted average assumptions used in estimating the fair values of options issued during the three months ended March 31, 2019:

Three Months Ended March 31, 2019
Valuation assumptions:

Risk-free rate
2.51
%
Expected volatility
82.95
%
Expected term (years)
6.0

Dividend yield
—

A summary of option activity under the 2015 and 2014 Plans for the three months ended March 31, 2020 is presented below:

Bellerophon 2015 and 2014 Equity Incentive Plans

Options

Range of
Exercise
Price

Weighted
Average
Price

Weighted Average
Remaining
Contractual
Life (in years)
Options outstanding as of December 31, 2019
663,501

$
7.35

-
199.20

$
24.15

8.3

Forfeited
(325
)

7.35

-
199.20

32.41

—

Options outstanding as of March 31, 2020
663,176

$
7.35

-
199.20

$
24.15

8.0

Options vested and exercisable as of March 31, 2020
295,768

$
7.35

-
199.20

$
39.48

7.1

The intrinsic value of options outstanding, vested and exercisable as of March 31, 2020 was $0.4 million.

Restricted Stock

All restricted stock awards granted under the 2015 Plan during the three months ended March 31, 2020 were in relation to director compensation and vested in full by December 31, 2020 subject to certain terms and conditions.

A summary of restricted stock activity under the 2015 Plan for the three months ended March 31, 2020 is presented below:

Bellerophon 2015 Equity Incentive Plan

Shares

Weighted
Average
Fair Value

Aggregate
Grant Date
Fair Value
(in millions)

Weighted Average
Remaining
Contractual
Life (in years)
Restricted stock outstanding as of December 31, 2019

—

$
—

$
—

—

Granted

23,332

6.00

0.1

Vested

(16,666
)

6.00

—

Restricted stock outstanding as of March 31, 2020

6,666

$
6.00

$
—

0.7

Ikaria Equity Incentive Plans prior to February 12, 2014

Options

A summary of option activity under Ikaria incentive plans assumed in 2014 for the three months ended March 31, 2020, is presented below:

Ikaria Equity Incentive Plans

Options

Range of
Exercise
Price

Weighted
Average
Price

Weighted Average
Remaining
Contractual
Life (in years)
Options outstanding as of December 31, 2019

3,463

$
116.55

-
223.65

$
124.21

2.3

Forfeited

(195
)

116.55
-
124.05

118.55

—

Options outstanding as of March 31, 2020

3,268

$
116.55

-
223.65

$
124.54

2.1

Options vested and exercisable as of March 31, 2020

3,268

$
116.55

-
223.65

$
124.54

2.1

The intrinsic value of options outstanding, vested and exercisable as of March 31, 2020 was zero.

Stock-Based Compensation Expense, Net of Estimated Forfeitures

The following table summarizes the stock-based compensation expense by the unaudited condensed consolidated statement of operations line items for the three months ended March 31, 2020 and 2019 (in thousands):

Three Months Ended March 31,

2020

2019
Research and development

$
79

$
311

General and administrative

389

697

Total expense

$
468

$
1,008

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-URI http://asc.fasb.org/subtopic&trid=2208855
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Millions

Apr. 01, 2020

Jan. 25, 2019

Sep. 29, 2017

May 15, 2017

Subsequent Event [Line Items]

Public offering (in shares) 666,666

Shares Issued, Price Per Share $ 10.5 $ 18.63 $ 22.50

Proceeds from issuance of common stock, net $ 6.2

Underwriting discounts And commissions 0.5

Payments of stock issuance costs $ 0.3

Subsequent Event

Subsequent Event [Line Items]

Public offering (in shares) 1,275,000

Shares Issued, Price Per Share $ 12.00

Proceeds from issuance of common stock, net $ 14.1

Underwriting discounts And commissions 1.1

Payments of stock issuance costs $ 0.1

X

- Definition
Proceeds From Issuance Of Common Stock, Net
+ References
No definition available.
+ Details

Name: blph_ProceedsFromIssuanceOfCommonStockNet

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Underwriting discounts and commissions that were deducted from the gross proceeds of the offering.
+ References
No definition available.
+ Details

Name: blph_UnderwritingDiscountsAndCommissions

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R30.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value Measurements - Assumptions Used (Details)

Mar. 31, 2020

Dec. 31, 2019

Minimum

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Expected term (in years) 1 year 8 months 12 days 1 year 10 months 24 days

Minimum | Risk-free interest rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 0.0021 0.0157

Minimum | Expected volatility

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 1.4976 1.0474

Minimum | Dividend yield

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 0 0

Maximum

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Expected term (in years) 2 years 7 months 6 days 2 years 10 months 24 days

Maximum | Risk-free interest rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 0.0027 0.0161

Maximum | Expected volatility

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 1.8749 1.0905

Maximum | Dividend yield

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 0 0

Weighted Average

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Expected term (in years) 2 years 1 month 6 days 2 years 4 months 24 days

Weighted Average | Risk-free interest rate

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 0.0024 0.0159

Weighted Average | Expected volatility

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 1.6986 1.0700

Weighted Average | Dividend yield

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Valuation assumptions 0 0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_WeightedAverageMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R34.htm IDEA: XBRL DOCUMENT v3.20.1

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Bellerophon 2015 Equity Incentive Plan
$ / shares in Units, $ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

$ / shares

shares

Shares

Restricted stock outstanding, beginning of period (in shares) | shares 0

Restricted stock granted (in shares) | shares 23,332

Restricted stock forfeited (in shares) | shares (16,666)

Restricted stock outstanding, end of period (in shares) | shares 6,666

Weighted Average Fair Value

Beginning of period, weighted average fair value (in usd per share) | $ / shares $ 0.00

Restricted stock granted, weighted average fair value (in usd per share) | $ / shares 6.00

Restricted stock forfeited, weighted average fair value (in usd per share) | $ / shares 6.00

End of period, weighted average fair value (in usd per share) | $ / shares $ 6.00

Aggregate Grant Date Fair Value

Restricted stock beginning of period, aggregate grant date fair value | $ $ 0.0

Restricted stock granted, aggregate grant date fair value | $ 0.1

Restricted stock forfeited, aggregate grant date fair value | $ 0.0

Restricted stock end of period, aggregate grant date fair value | $ $ 0.0

Weighted Average Remaining Contractual Life (in years)

Restricted stock, weighted average remaining contractual life (in years) 8 months 12 days

X

- Definition
Aggregate grant date fair value of restricted shares granted
+ References
No definition available.
+ Details

Name: blph_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedinPeriodAggregateGrantDateFairValue

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate grant date fair value of outstanding restricted shares.
+ References
No definition available.
+ Details

Name: blph_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandinginPeriodAggregateGrantDateFairValue

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The weighted average fair value of vested and nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
No definition available.
+ Details

Name: blph_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandinginPeriodWeightedAverageFairValue

Namespace Prefix: blph_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested in Period, Aggregate Grant Date Fair Value
+ References
No definition available.
+ Details

Name: blph_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedinPeriodAggregateGrantDateFairValue

Namespace Prefix: blph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Vested
+ References
No definition available.
+ Details

Name: blph_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsVested

Namespace Prefix: blph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of non-option equity instruments granted to participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=blph_Bellerophon2015EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Stock-Based Compensation - Summary of Fair Value of Options Issued (Details) - Bellerophon Equity Incentive Plans	3 Months Ended
	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free rate	2.51%
Expected volatility	82.95%
Expected term (years)	6 years
Dividend yield	0.00%

Income Taxes (Details) - USD ($)	1 Months Ended			3 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($)	Apr. 30, 2020	Jan. 31, 2019	Feb. 28, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2020
Valuation Allowance [Line Items]
Effective tax rate (as a percent)				0.00%	0.00%
Income tax benefit				$ 0	$ 1,801,000
Expected change to unrecognized tax benefit liability in next twelve months				$ 0
Scenario, Forecast
Valuation Allowance [Line Items]
Effective tax rate (as a percent)						0.00%
New Jersey
Valuation Allowance [Line Items]
Deferred tax assets, amount sold		$ 20,000,000	$ 21,200,000
Deferred tax assets, research, amount sold			200,000
Proceeds from sale of deferred tax assets		1,700,000	$ 2,000,000
Income tax benefit		$ 1,800,000
Subsequent Event \| New Jersey
Valuation Allowance [Line Items]
Deferred tax assets, amount sold	$ 21,200,000
Deferred tax assets, research, amount sold	200,000
Proceeds from sale of deferred tax assets	$ 2,000,000

Net Income (Loss) Per Share	3 Months Ended
Net Income (Loss) Per Share	Mar. 31, 2020
Earnings Per Share [Abstract]
Net (Loss) Income Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing net (loss) income by the weighted average number of shares outstanding during the period, as applicable. Diluted net loss per share is calculated by dividing net (loss) income, adjusted to reflect the impact of dilutive warrants, by the weighted average number of shares outstanding, adjusted to reflect potentially dilutive securities using the treasury stock method, except when the effect would be anti-dilutive. The Company reported a net loss for the three months ended March 31, 2020 and 2019, therefore diluted net loss per share is the same as the basic net loss per share. As of March 31, 2020, the Company had 666,444 options to purchase shares, 6,666 restricted shares and 2,028,626 warrants to purchase shares outstanding that have been excluded from the computation of diluted weighted average shares outstanding, because such securities had an anti-dilutive impact due to the loss reported.

Net (Loss) Income Per Share - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020 shares
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	666,444
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,666
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,028,626

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Excluding the impact of the sale of state net operating losses and research and development credits during the first quarter of 2019, the effective tax rate for each of the three months ended March 31, 2020 and 2019 was 0.0% which was lower than the federal statutory rate primarily due to the losses incurred and the full valuation allowance on deferred tax assets. The Company’s estimated tax rate for 2020 excluding any benefits from any sales of net operating losses or research and development, or R&D, tax credits is expected to be zero because the Company expects to generate additional losses and currently has a full valuation allowance. The valuation allowance is required until the Company has sufficient positive evidence of taxable income necessary to support realization of its deferred tax assets. In addition, the Company may be subject to certain limitations in its annual utilization of NOL carry forwards to offset future taxable income (and of tax credit carry forwards to offset future tax expense) pursuant to Section 382 of the Internal Revenue Code, which could result in tax attributes expiring unused. In May 2020, the Company has sold $21.2 million of state NOLs and $0.2 million of Research and Development credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program for net proceeds of $2.0 million. In January 2019, the Company sold $20.0 million of state NOLs for net proceeds of $1.7 million under the State of New Jersey's Technology Business Tax Certificate Transfer Program, which resulted in the reversal of the valuation allowance and a tax benefit of $1.8 million for the three months ended March 31, 2019. Subject to state approval, the Company plans to sell additional NOLs and credits under the same program in the future. The proceeds from such sales are recorded as Income tax benefit when sales occur or proceeds are received. As of March 31, 2020, there were no material uncertain tax positions. There are no tax positions for which a material change in any unrecognized tax benefit liability is reasonably possible in the next 12 months.

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission, or the SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America, or U.S. GAAP, can be condensed or omitted. The Company operates in one reportable segment and solely within the United States. Accordingly, no segment or geographic information has been presented. The Company is responsible for the unaudited condensed consolidated financial statements. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive income (loss) and its cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three months ended March 31, 2020 for the Company are not necessarily indicative of the results expected for the full year. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of costs and expenses during the reporting period, including right of use asset and operating lease liability, accrued expenses, accrued research and development expenses, stock-based compensation, common stock warrant liabilities and income taxes. Actual results could differ from those estimates. On February 5, 2020, the Company filed a certificate of amendment to its amended and restated Certificate of Incorporation to effect a 1-for-15 reverse stock split of the Company's outstanding shares of common stock which became effective on February 7, 2020. The shares of common stock underlying the Company's outstanding options and warrants were also proportionately adjusted for the reverse stock split. In addition, the number of shares of common stock available for issuance under the Company’s equity incentive plans and employee stock purchase plan were proportionately adjusted for the reverse stock split. Further, the per share exercise prices for options granted under such plans and warrants were proportionately adjusted for the reverse stock split. There was no change to the Company’s authorized number of shares or to its par value per share. The reverse stock split reduced the number of shares of the Company’s common stock that were outstanding at February 10, 2020 from 69,053,548 to 4,603,460, after the cancellation of fractional shares. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise held fractional shares of the Company’s common stock as a result of the reverse stock split received a de minimis cash payment in lieu of such fractional shares. These condensed consolidated financial statements give retroactive effect to such reverse stock split and all share and per share amounts have been adjusted accordingly.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity date of three months or less to be cash equivalents. All investments with maturities of greater than three months from date of purchase are classified as available-for-sale marketable securities.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for its stock-based compensation in accordance with applicable accounting guidance which establishes accounting for share-based awards, including stock options and restricted stock, exchanged for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company recognizes stock-based compensation expense in operations based on the fair value of the award on the date of the grant. The resulting compensation expense, less estimated forfeitures, is recognized on a straight-line basis over the requisite service period or sooner if the awards immediately vest. The Company determines the fair value of stock options issued using a Black-Scholes-Merton option pricing model. Certain assumptions used in the model include expected volatility, dividend yield, risk-free interest rate, estimated forfeitures and expected term. For restricted stock, the fair value is the closing market price per share on the grant date. See Note 7 - Stock-Based Compensation for a description of these assumptions.
Common Stock Warrants and Warrant Liability	Common Stock Warrants and Warrant Liability The Company accounts for common stock warrants issued as freestanding instruments in accordance with applicable accounting guidance as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company classifies warrant liabilities on the consolidated balance sheet based on the warrants' terms as long-term liabilities, which are revalued at each balance sheet date subsequent to the initial issuance. Changes in the fair value of the warrants are reflected in the consolidated statement of operations as “Change in fair value of common stock warrant liability.” The Company uses the Black-Scholes-Merton pricing model to value the related warrant liability. Certain assumptions used in the model include expected volatility, dividend yield and risk-free interest rate. See Note 6 - Fair Value Measurements for a description of these assumptions.
Income Taxes	Income Taxes The Company uses the asset and liability approach to account for income taxes as required by applicable accounting guidance, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount expected to be realized, on a more likely than not basis. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
Research and Development Expense	Research and Development Expense Research and development costs are expensed as incurred. These expenses include the costs of the Company’s proprietary research and development efforts, as well as costs incurred in connection with certain licensing arrangements. Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties upon or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. The Company also expenses the cost of purchased technology and equipment in the period of purchase if it believes that the technology or equipment has not demonstrated technological feasibility and it does not have an alternative future use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and are recognized as research and development expense as the related goods are delivered or the related services are performed. (g) Leases A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of operations in the same line item as expenses arising from fixed lease payments. Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended March 31, 2020 and 2019 were de minimis.
Leases	Leases A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of operations in the same line item as expenses arising from fixed lease payments. Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. The Company does not recognize right of use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheet. Short-term lease costs are recorded in our consolidated statements of operations in the period in which the obligation for those payments was incurred. Short-term lease costs for the three months ended March 31, 2020 and 2019 were de minimis.
New Accounting Pronouncements	Recently Issued Accounting Pronouncements Adopted In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which eliminates, adds and modifies certain disclosure requirements for fair value measurements. The standard requires the disclosure of the range and weighted average used to develop significant unobservable inputs and how weighted average is calculated for recurring and nonrecurring Level 3 fair value measurements. The amendment is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted ASU 2018-13’s during the quarter ended March 31, 2020 by including disclosure on the range of inputs used to calculate the Company's Level 3 fair value measurements.

Right of Use Assets and Leases (Details) $ in Thousands	3 Months Ended
Right of Use Assets and Leases (Details) $ in Thousands	Mar. 31, 2020 USD ($) lease period	Mar. 31, 2019 USD ($)
Lessee, Lease, Description [Line Items]
Number of operating leases \| lease	2
Cash paid for operating lease liability	$ 187	$ 161
Operating lease expenses	$ 177	$ 153
Weighted average remaining lease term	3 years	4 years
Weighted average discount rate	4.94%	4.98%
Operating leases
2020	$ 570
2021	770
2022	783
2023	205
Total lease payments	2,328
Less imputed interest	(170)
Total operating lease liability	$ 2,158
Building
Lessee, Lease, Description [Line Items]
Term of contract	4 years
Number of renewal periods \| period	1
Renewal term	5 years
Property, Plant and Equipment
Lessee, Lease, Description [Line Items]
Number of renewal periods \| period	1
Renewal term	90 days

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (4,970)	$ (795)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of common stock warrant liability	894	(1,616)
Stock based compensation	468	1,008
Depreciation	46	88
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	56	(298)
Accounts payable, accrued research and development, and accrued expenses	(830)	(727)
Net cash used in operating activities	(4,336)	(2,340)
Cash flows from financing activities:
Proceeds received from exercise of warrants	3,057	0
Proceeds from issuance of common stock in Public Offering	0	6,374
Net cash provided by (used in) financing activities	3,057	6,374
Net change in cash, cash equivalents and restricted cash	(1,279)	4,034
Cash, cash equivalents and restricted cash at beginning of period	10,277	17,046
Cash, cash equivalents and restricted cash at end of period	8,998	21,080
Non-cash financing activities:
Unpaid expenses related to offerings	$ 0	$ 138

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 8,595	$ 9,874
Restricted cash	103	103
Prepaid expenses and other current assets	349	405
Total current assets	9,047	10,382
Restricted cash, non-current	300	300
Right of use assets, net	1,961	2,110
Property and equipment, net	270	316
Total assets	11,578	13,108
Current liabilities:
Accounts payable	2,220	3,106
Accrued research and development	1,785	2,117
Accrued expenses	2,101	1,703
Current portion of operating lease liabilities	669	658
Total current liabilities	6,775	7,584
Long term operating lease liabilities	1,489	1,659
Common stock warrant liabilities	1,168	274
Total liabilities	9,432	9,517
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value per share; 200,000,000 shares authorized and 4,857,393 and 4,580,127 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	49	46
Preferred stock, $0.01 par value per share; 5,000,000 shares authorized, zero shares issued and outstanding at March 31, 2020 and December 31, 2019	0	0
Additional paid-in capital	196,830	193,308
Accumulated deficit	(194,733)	(189,763)
Total stockholders’ equity	2,146	3,591
Total liabilities and stockholders’ equity	$ 11,578	$ 13,108

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings The Company periodically becomes subject to legal proceedings and claims arising in connection with its business. The ultimate legal and financial liability of the Company in respect to all proceedings, claims and lawsuits, pending or threatened, cannot be estimated with any certainty. As of the date of this report, the Company is not aware of any proceeding, claim or litigation, pending or threatened, that could, individually or in the aggregate, have a material adverse effect on the Company’s business, operating results, financial condition and/or liquidity.

Stock-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	May 14, 2019	May 04, 2017
Stock-Based Compensation
Number of shares available for grant (in shares)				333,333
Maximum annual increase number of shares available for grant (in shares)				200,000
Number of shares available for grant (in shares)	454,362		833,333	333,333
Weighted average grant-date fair value of options issued (in usd per share)		$ 9.30
Options, outstanding, intrinsic value	$ 400,000
Bellerophon Equity Incentive Plans
Stock-Based Compensation
Unrecognized compensation expense	$ 2,700,000
Weighted-average period unrecognized compensation expense is to be recognized	2 years 4 months 24 days
Tax benefit recognized related to stock-based compensation expense	$ 0	$ 0
Ikaria Equity Incentive Plans
Stock-Based Compensation
Options, outstanding, intrinsic value	0
Options, exercisable, intrinsic value	$ 0
Minimum
Stock-Based Compensation
Vesting period	1 year
Maximum
Stock-Based Compensation
Vesting period	4 years

Stock-Based Compensation - Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation expense by condensed consolidated statement of operations and comprehensive loss line item
Allocated share-based compensation expense	$ 468	$ 1,008
Research and development
Stock-based compensation expense by condensed consolidated statement of operations and comprehensive loss line item
Allocated share-based compensation expense	79	311
General and administrative
Stock-based compensation expense by condensed consolidated statement of operations and comprehensive loss line item
Allocated share-based compensation expense	$ 389	$ 697

Summary of Significant Accounting Policies (Details) $ in Thousands		3 Months Ended
	Feb. 07, 2020	Mar. 31, 2020 USD ($) integer shares	Feb. 10, 2020 shares	Feb. 09, 2020 shares	Dec. 31, 2019 USD ($) shares
Accounting Policies [Abstract]
Stockholders' Equity Note, Stock Split, Conversion Ratio	0.0667
Number of reportable segments \| integer		1
Lease, liability		$ 2,158
Right of use assets, net		$ 1,961			$ 2,110
Common stock, shares outstanding (in shares) \| shares		4,857,393	4,603,460	69,053,548	4,580,127

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
Research and development	$ 2,238	$ 2,305
General and administrative	1,872	2,037
Total operating expenses	4,110	4,342
Loss from operations	(4,110)	(4,342)
Change in fair value of common stock warrant liability	(894)	1,616
Interest and other income, net	34	130
Pre-tax loss	(4,970)	(2,596)
Income tax benefit	0	1,801
Net loss	$ (4,970)	$ (795)
Weighted average shares outstanding:
Basic (in shares)	4,615,046	4,346,109
Diluted (in shares)	4,615,046	4,346,109
Net loss per share:
Basic (in usd per share)	$ (1.08)	$ (0.18)
Diluted (in usd per share)	$ (1.08)	$ (0.18)

Liquidity (Details) - USD ($)			1 Months Ended
Liquidity (Details) - USD ($)	Apr. 01, 2020	Jan. 25, 2019	Apr. 30, 2020	Jan. 31, 2019	Feb. 28, 2018	Mar. 31, 2020	Dec. 31, 2019	Jul. 06, 2018	Sep. 29, 2017	May 15, 2017
Liquidity [Line Items]
Cash and cash equivalents						$ 8,595,000	$ 9,874,000
Maximum securities shelf offering								$ 100,000,000
Stock issued during period (in shares)		666,666
Price to the public (in dollars per share)		$ 10.5							$ 18.63	$ 22.50
Proceeds from issuance of common stock, net		$ 6,200,000
Underwriting discounts And commissions		500,000
Payments of stock issuance costs		$ 300,000
New Jersey
Liquidity [Line Items]
Deferred tax assets, amount sold				$ 20,000,000	$ 21,200,000
Deferred tax assets, research, amount sold					200,000
Proceeds from sale of deferred tax assets				$ 1,700,000	$ 2,000,000
Subsequent Event
Liquidity [Line Items]
Stock issued during period (in shares)	1,275,000
Price to the public (in dollars per share)	$ 12.00
Proceeds from issuance of common stock, net	$ 14,100,000
Underwriting discounts And commissions	1,100,000
Payments of stock issuance costs	$ 100,000
Subsequent Event \| New Jersey
Liquidity [Line Items]
Deferred tax assets, amount sold			$ 21,200,000
Deferred tax assets, research, amount sold			200,000
Proceeds from sale of deferred tax assets			$ 2,000,000

Fair Value Measurements - Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liabilities	$ 1,168	$ 274
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liabilities	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock warrant liabilities	$ 1,168	$ 274

Liquidity	3 Months Ended
Liquidity	Mar. 31, 2020
Liquidity
Liquidity	Liquidity In the course of its development activities, the Company has sustained operating losses and expects such losses to continue over the next several years. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development and clinical trials of, and seeks regulatory approval for, its product candidates. The Company's primary uses of capital are, and it expects will continue to be, compensation and related expenses, third-party clinical research and development services, contract manufacturing services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs. The Company had cash and cash equivalents of $8.6 million as of March 31, 2020. The Company's existing cash and cash equivalents as of March 31, 2020 will be used primarily to fund the Phase 3 trial of INOpulse for PH-ILD, to complete the dose escalation study for PH-Sarc. and to treat COVID-19 patients under the emergency expanded access. On June 25, 2018, the Company filed a shelf registration statement on Form S-3 with the SEC, which became effective on July 6, 2018. The shelf registration allows the Company to issue, from time to time at prices and on terms to be determined prior to the time of any such offering, up to $100 million of any combination of common stock, preferred stock, debt securities, warrants and rights, either individually or in units. On January 25, 2019, the Company completed the sale of 666,666 shares of its common stock at a public offering price of $10.50 per share, resulting in net proceeds of $6.2 million, after deducting placement fees of $0.5 million and other offering costs of $0.3 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3. On April 1, 2020, the Company completed the sale of 1,275,000 shares of its common stock in a registered direct offering at an offering price of $12.00 per share, resulting in net proceeds of approximately $14.1 million, after deducting agent fees of $1.1 million and offering costs of $0.1 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3. Taking into consideration the cash proceeds from the April 1, 2020 registered direct offering, the Company evaluated whether there are any remaining conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. Based on such evaluation and the Company's current plans, which are subject to change as discussed below, management believes that the Company's existing cash and cash equivalents as of March 31, 2020, proceeds received from the April 1, 2020 registered direct offering and proceeds received in May 2020 and expected to become available upon the future sale of state net operating losses, or NOLs, and research and development (“R&D”) tax credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program, will be sufficient to satisfy its operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q. In April 2020, the Company submitted an Investigational New Drug Application (“IND”) to study the iNO delivery system for the treatment of patients infected with COVID-19. The IND was accepted by the U.S. Food and Drug Administration (the "FDA") in May 2020, which allows the Company to initiate the Phase 3 study. The Company is currently reviewing its clinical plans for this program and, in parallel, the Company submitted an application for federal funding, through the Biomedical Advanced Research and Development Authority (“BARDA”) and the National Institutes of Health (“NIH”), to support the study. If the Company decides to incur additional costs related to the COVID-19 trial in the next 12 months in advance of receiving federal or other funding, its operating cash needs are likely to increase and its existing cash and cash equivalents as of March 31, 2020 may not be sufficient to satisfy its operating cash needs for at least one year after the filing of this Quarterly Report on Form 10-Q. The State of New Jersey's Technology Business Tax Certificate Transfer Program enables qualified, unprofitable New Jersey based technology or biotechnology companies to sell a percentage of NOL and R&D tax credits to unrelated profitable corporations, subject to meeting certain eligibility criteria. Based on consideration of various factors, including application processing time and past trend of benefits made available under the program, the Company believes that it is probable that its plans to sell its NOLs can be effectively implemented to address its short term financial needs. The Company has sold $21.2 million of state NOLs and $0.2 million of Research and Development credit under the State of New Jersey’s Technology Business Tax Certificate Transfer Program in May 2020 for net proceeds of $2.0 million and has sold $20.0 million of state NOLs for net proceeds of $1.7 million in January 2019. Subject to state approval and program availability, the Company plans to sell additional NOLs and credits under the same program in the future. The proceeds from such sales are recorded as income tax benefit when sales occur or proceeds are received. The Company’s estimates and assumptions may prove to be wrong, and the Company may exhaust its capital resources sooner than expected. The process of testing product candidates in clinical trials is costly, and the timing of progress in clinical trials is uncertain. Because the Company’s product candidates are in clinical development and the outcome of these efforts is uncertain, the Company may not be able to accurately estimate the actual amounts that will be necessary to successfully complete the development and commercialization, if approved, of its product candidates or whether, or when, the Company may achieve profitability. Until such time, if ever, as the Company can generate substantial product revenues, it expects to finance its cash needs through a combination of equity and debt offerings, sales of state NOLs and R&D credits subject to program availability and approval, existing working capital, funding from federal programs subject to approval, and funding from potential future collaboration arrangements. To the extent that the Company raises additional capital through the future sale of equity or debt, the ownership interest of its existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences or rights such as anti-dilution rights that adversely affect the rights of its existing stockholders. If the Company raises additional funds through strategic partnerships in the future, it may have to relinquish valuable rights to its technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to it. If the Company is unable to raise additional funds through equity or debt financings when needed, is unable to sell its state NOLs and R&D credits or obtain federal funding for the IND to study the iNO delivery system for the treatment of patients infected with COVID-19, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself.

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Deficit	Warrant	Warrant Common Stock	Warrant Additional Paid in Capital
Balance at beginning of period (in shares) at Dec. 31, 2018		3,911,857
Balance at beginning of period at Dec. 31, 2018	$ 3,856	$ 39	$ 180,313	$ (176,496)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(795)
Public offering (in shares)		666,666
Public offering	6,236	$ 7	6,229
Stock-based compensation (in shares)		15,151
Stock-based compensation	1,008	$ 0	1,008
Balance at end of period (in shares) at Mar. 31, 2019		4,593,674
Balance at end of period at Mar. 31, 2019	$ 10,305	$ 46	187,550	(177,291)
Balance at beginning of period (in shares) at Dec. 31, 2019	4,580,127	4,580,127
Balance at beginning of period at Dec. 31, 2019	$ 3,591	$ 46	193,308	(189,763)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,970)			(4,970)
Reverse Stock Split Adjustment (in shares)						(826)
Public offering (in shares)						254,760
Public offering					$ 3,057	$ 3	$ 3,054
Stock-based compensation (in shares)		23,332
Stock-based compensation	$ 468	$ 0	468
Balance at end of period (in shares) at Mar. 31, 2020	4,857,393	4,857,393
Balance at end of period at Mar. 31, 2020	$ 2,146	$ 49	$ 196,830	$ (194,733)

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 08, 2020
Document and Entity Information
Entity Registrant Name	Bellerophon Therapeutics, Inc.
Entity Central Index Key	0001600132
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		6,132,393
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 1, 2020, the Company completed the sale of 1,275,000 shares of its common stock in a registered direct offering at an offering price of $12.00 per share, resulting in net proceeds of approximately $14.1 million, after deducting agent fees of $1.1 million and offering costs of $0.1 million. Such shares were sold pursuant to the Company's effective shelf registration statement on Form S-3.

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Apr. 01, 2020	Jan. 25, 2019	Sep. 29, 2017	May 15, 2017
Subsequent Event [Line Items]
Public offering (in shares)		666,666
Shares Issued, Price Per Share		$ 10.5	$ 18.63	$ 22.50
Proceeds from issuance of common stock, net		$ 6.2
Underwriting discounts And commissions		0.5
Payments of stock issuance costs		$ 0.3
Subsequent Event
Subsequent Event [Line Items]
Public offering (in shares)	1,275,000
Shares Issued, Price Per Share	$ 12.00
Proceeds from issuance of common stock, net	$ 14.1
Underwriting discounts And commissions	1.1
Payments of stock issuance costs	$ 0.1

Fair Value Measurements - Assumptions Used (Details)	Mar. 31, 2020	Dec. 31, 2019
Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	1 year 8 months 12 days	1 year 10 months 24 days
Minimum \| Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	0.0021	0.0157
Minimum \| Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	1.4976	1.0474
Minimum \| Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	0	0
Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	2 years 7 months 6 days	2 years 10 months 24 days
Maximum \| Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	0.0027	0.0161
Maximum \| Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	1.8749	1.0905
Maximum \| Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	0	0
Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (in years)	2 years 1 month 6 days	2 years 4 months 24 days
Weighted Average \| Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	0.0024	0.0159
Weighted Average \| Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	1.6986	1.0700
Weighted Average \| Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Valuation assumptions	0	0

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Bellerophon 2015 Equity Incentive Plan $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Shares
Restricted stock outstanding, beginning of period (in shares) \| shares	0
Restricted stock granted (in shares) \| shares	23,332
Restricted stock forfeited (in shares) \| shares	(16,666)
Restricted stock outstanding, end of period (in shares) \| shares	6,666
Weighted Average Fair Value
Beginning of period, weighted average fair value (in usd per share) \| $ / shares	$ 0.00
Restricted stock granted, weighted average fair value (in usd per share) \| $ / shares	6.00
Restricted stock forfeited, weighted average fair value (in usd per share) \| $ / shares	6.00
End of period, weighted average fair value (in usd per share) \| $ / shares	$ 6.00
Aggregate Grant Date Fair Value
Restricted stock beginning of period, aggregate grant date fair value \| $	$ 0.0
Restricted stock granted, aggregate grant date fair value \| $	0.1
Restricted stock forfeited, aggregate grant date fair value \| $	0.0
Restricted stock end of period, aggregate grant date fair value \| $	$ 0.0
Weighted Average Remaining Contractual Life (in years)
Restricted stock, weighted average remaining contractual life (in years)	8 months 12 days